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High consumption of wholegrains is associated with lower risk of cardiovascular disease. Studies suggested 
that regular consumption of oats lowers blood cholesterol and improves post-prandial glycaemic control. 
Some of these benefits were shown to be partly mediated by β-glucan soluble fiber. However, oats are also 
a source of bioactive phenolics, including the most abundant ferulic acid and avenanthramides. Circulating 
phenolic acids from other foods/beverages such as blueberries and champagne were shown to exert health 
benefits via enhancing nitric oxide bioavailability to the vascular endothelium, research to date has not yet 
established whether oat phenolics may also contribute to cardiovascular health benefits of oats. Therefore, 
this thesis investigates the potential beneficial effects of oat phenolics on human cardiovascular system. 
Composition and content of a variety of commercial oat products were analyzed and average amounts 
delivered to the consumer in a portion was estimated as follows: 15.79-25.05 mg /40 g for oat products and 
16.7 mg /11 g for oat bran concentrate. While the compositions and concentrations of the components in 
the different products were broadly similar, most abundant phenolic acid was shown to be ferulic acid. The 
findings suggested that commercial oat products are a source of phenolic acids and avenanthramides and 
these data informed following clinical work about human dietary intake levels of these compounds in oats.  
A 2-arm, randomized, crossover, single-blind acute clinical trial was conducted with 16 pre and stage 1 
hypertensive men. Consumption of 90.2g of oats containing 50mg of phenolics resulted in a small non-
significant improvement in flow mediated dilatation (FMD) at 1h and significant changes in both 
endothelium dependent and independent microvascular function relative to control at 2h. Inter-individual 
variability in phenolic absorption observed and changes in microvascular function at 2h were positively 
correlated with the blood concentration of phenolic acid metabolites including ferulic acid glucuronides 
and sulfates. However, no other changes in blood pressure (BP) and NADPH oxidase activity were observed 
between treatments.  
In a 3-arm, randomized , crossover, double-blind chronic trial , 28 pre and stage 1 hypertensive subjects 
consumed  either a high (68.1 mg of phenolics) or moderate (38.9 mg of phenolics) phenolic acid and 
avenanthramide containing oat diet, or fibre matched control diet. 24-hour SBP, night time SBP and DBP 
decreased significantly and FMD response improved non-significantly following the consumption of high 
phenolic oats. There was also small non-significant improvements in endothelial dependent and 
independent microvascular reactivity and non-significant reductions in total and LDL-cholesterol following 
the consumption of high and moderate phenolics but no change observed in the numbers of circulating 
extracellular vesicles. These data suggest that consumption of oat phenolics may improve cardiovascular 
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Cardiovascular disease (CVD) is the number one cause of mortality globally, accounting for 31% of all 
deaths (1). Of these deaths, coronary heart disease (CHD) and stroke are the most common forms and 
over three quarters of deaths take place in low and middle-income countries(1). CVD accounts for 45% 
and 25% of all deaths in Europe and the UK, respectively (2, 3). Although there are now treatments 
and rehabilitation available and the most recent published Global Burden of Disease figures showed a 
significant decline in the mortality rates, more than 4 million people still die from CVD in Europe every 
year (2, 4). Early detection and management of the disease through modifiable risk factors is 
fundamental and the focus should be on reduction of these risk factors by encouraging health lifestyle 
choices(1). 
CVD have complex multifactorial aetiology underlying a number of non-modifiable and modifiable risk 
factors(5). Non-modifiable risk factors include age, ethnicity, gender, genetic predispositions and 
family history of premature CVD, whilst modifiable risk factors  are poor socioeconomic status, high 
blood pressure, high body mass index (BMI) ,elevated blood lipid levels, hyperglycaemia , physical 
inactivity, smoking and poor diet (6-9). Among the modifiable risk factors, diet is one of the main 
contributors to the development of CVD and, therefore, improving dietary behaviour can be a strong 
preventative strategy against the disease (10). Current dietary recommendations in the UK provided 
by Scientific Advisory Committee on Nutrition(SACN) (11) states  based on latest scientific evidence 
that, diet rich in fruits, vegetables, wholegrains and oily fish and low in saturated fat, trans-fat, 
carbohydrates and salt can help to maintain cardiovascular health (12-18). In 2016, SACN also 
concluded that increased intake of fibre, specifically wholegrain and cereal fibre was strongly 
associated with lower risk of cardio-metabolic disease(11). Additionally, higher intake of oat bran and 
β-glucans were reported to lower blood pressure, total cholesterol (TC), LDL–cholesterol (LDL-C) and 
triacylglycerol concentrations (TAG) (11). As a result, SACN increased the recommended intake values 
for fibre from 23g to 30g and stated that mean intakes of the population are well below the 
recommendation (14 g/day in adults aged 19–64 years, 13.4 g/day in adults aged 65+ years)(19). The 
European Food Safety Authority (EFSA) also approved the health claim, which states that the 
consumption of β-glucan at least 3g/d can reduce the blood cholesterol concentrations of healthy, and 
mildly hypercholesteraemic adults (20). In addition to fibre, wholegrains provide a range of nutrients 
including vitamins, minerals and bioactive polyphenols (21). Observational and human intervention 
studies have shown evidence for cardiovascular health benefits of consumption of fruits, vegetables 
and wholegrains, which may be due in part to their high content of polyphenols (22). Although the fate 
of these compounds after ingestion and their mechanisms of action are not completely understood, 
2 
 
there is a growing body of evidence suggesting their protective role against cardiovascular disease risk 
factors (22-24).  Oats are extensively studied for their cardiovascular health benefits mostly due to 
their high β-glucan content, but they also contain substantial amounts of phenolic acids, which are a 
sub-class of polyphenols, including the most abundant ferulic acid and structurally similar 
avenanthramides (25, 26). There are  limited number of in vitro and human studies showing cardio 
protective effects of these compounds either in oats or in other plant sources(27-31). However, further 
human studies are necessary to explore the role of oat phenolics (phenolic acids and avenanthramides) 
on cardiovascular health.  
This literature review will mainly focus on the aetiology of CVD and its risk factors, how endothelium 
maintains vascular health, impact of wholegrain consumption on CVD risk factors and the potential of 
plant polyphenols in particularly phenolic acids in the prevention or management of the disease. 
1.2 Cardiovascular Disease 
 
CVD represents a group of pathophysiological conditions of heart and/or blood vessels such as 
coronary heart disease, stroke, hypertension, congestive heart failure and myocardial infraction, all 
majorly caused by atherosclerosis(32). Atherosclerosis develops slowly over many years and its 
consequences are mostly preventable with early detection and appropriate lifestyle changes(1, 32). A 
normal, healthy vascular system is fundamental to maintain the cardiovascular health and it is 
necessary to understand the pathophysiology of CVD including atherosclerosis and endothelial 
dysfunction to develop preventative strategies(33). 
1.2.1 Underlying Pathophysiology: Endothelial Dysfunction and Atherosclerosis 
 
Endothelium is a single layer of cells that lines the intima of artery walls and plays a vital role in the 
regulation of vascular homeostasis(34, 35). In a healthy endothelium, relaxed vascular tone and low 
levels of oxidative stress are mainly maintained by the release and balance of mediators including nitric 
oxide (NO), prostacyclin (PGI2) and endothelin (ET-1) and also with controlled local angiotensin-II 
activity (35). NO, which is synthesised by endothelial NO synthase (eNOS), is an important signalling 
molecule responsible for vasodilation and has important effects on the vessel wall such as promoting 
the relaxation of the arteries and preventing the proliferation of smooth muscle cells, inhibiting the 
activation and aggregation of platelets and the inflammatory leukocyte adhesion (36, 37). PGI2, 
another signalling molecule acts synergistically with NO to inhibit platelet activation (Figure 1.1 A) (36). 
On the other hand, vasoconstrictors ET-1 and angiotensin II are responsible for smooth muscle cell 
proliferation and increase oxidative stress(35, 36). When the endothelial cell layer is injured or there 
is an imbalance between the mediators of vasodilation and vasoconstriction such as reduced 
bioavailability of major vasodilator NO, endothelial dysfunction occurs and it is considered as an early 
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sign of atherosclerosis (36, 38). Endothelial dysfunction is associated with increased expression of 
vascular cell adhesion molecules (VCAM), increased oxidative stress, and increased synthesis of pro-
inflammatory and pro-thrombotic factors, platelet activation, smooth muscle cell activation and 
modulation of vascular tone(Figure 1.1 B)(36). 
 
 
Figure 1.1 Endothelial function and dysfunction 
A-endothelial function in healthy vessels. B-endothelial dysfunction in atherosclerosis. (Adapted from 
Douglas et al, 2010)(36) 
The development and progression of atherosclerosis can be considered as a form of chronic 
inflammation(39). The condition usually starts with an increase in endothelial permeability to 
lipoproteins and adhesiveness of leukocytes and platelets causing atherosclerotic lesions and as 
described above, endothelial dysfunction (Figure 1.1 B and Figure 1.2 A) (40). Foam cells are 
macrophages that form the fatty streaks together with lipid-laden monocytes and T-lymphocytes (41). 
These inflammatory cells are joined by the proliferation and migration of smooth muscle cells and 
forms the intermediate lesions (Figure 1.2 B) (40, 41). The formation of advanced lesions of 
atherosclerosis result in fatty streaks (39). Fibrous cap forms and causes the further enlargement and 
restructuring of the lesion (40). Accumulation of inflammation to the area increase the number of 





hydrolytic enzymes (40, 42, 43). These cells may then lead to the formation of a necrotic core 
underneath the fibrous cap, which results in necrosis, apoptosis, lipid accumulation and proteolytic 
activity (Figure 1.2 C) (39, 44). The rupture of fibrous cap, degradation of the whole matrix by 
proteolytic enzymes and haemorrhage from the lumen followed by thrombosis can result in the 




Figure 1.2 Progression of atherosclerosis (Adapted from Ross et al., 1999)(40). 
 
1.2.2 Cardiovascular Disease Risk Factors 
 
1.2.2.1 Plasma lipids and blood pressure 
 
A normal plasma lipid profile and lower blood pressure are important factors involved in cardiovascular 
health (45). Cholesterol is transported in plasma lipoprotein particles via circulation and it is required 
for various biological processes such as making bile acids, hormones and providing cell membrane 
support (46). An atherogenic lipid profile can be characterized by high levels of TC, LDL-C, TAG (47) and 
low levels of high density lipoprotein cholesterol (HDL-C) (45, 48, 49). Statin therapy has been shown 


































coenzyme A reductase , a regulatory enzyme in cholesterol biosynthesis(50). It has been estimated 
that a 10% reduction in plasma cholesterol leads to a decrease in coronary artery disease risk of 50% 
at age 40, 40% at age 50, 30% at age 60, and 20% at age 70 (45). National Health Service (NHS) in the 
UK recommends the following target levels of cholesterol to people at high CVD risk: TC< 4mmol/l, 
LDL-C< 2 mmol/l, TAG<1.7 mmol/l and HDL-C>1 mmol/l (51). Research suggests that a healthy diet has 
a significant role in the maintenance of normal lipid profile (52). A 1% reduction of energy from 
saturated fat or trans-fat and replacement with n-6 polyunsaturated fat can lead to a decrease in LDL-
C (- 0.05 mmol/L) (53, 54). Additionally, replacement of same amount of saturated fat with unrefined 
carbohydrates may also be beneficial but further research is necessary as the findings are conflicting 
(53, 54). Substitution of low glycaemic index carbohydrates  with high glycaemic index carbohydrates 
has been reported to decrease TAG levels by 12-25% (52, 55, 56).On the other hand , consumption of 
fish oil ( omega-3 poly-unsaturated fatty acids , 3.5 g/day) is effective in lowering TAG levels (-0.45 
mmol/ L)(57). Soluble fibre (3.5 g/day) such as oat B-glucan can also lower LDL-C concentration (- 0.19 
mmol /L) (58). Plant sterols and stanols (2 g/day) have shown to lower LDL-C by about 10% (59).  Finally, 
a recent meta-analysis of RCTs highlighted the association between flavanol-containing tea, cocoa, and 
apple products and lower levels of TC (-0.21 mmol/L), LDL-C(-0.23 mmol/L) and TAG(-0.11 mmol/L) 
and higher levels of HDL-C (0.15 mmol/L)(60). 
Blood pressure (BP) is another strong risk factor for CVD, with higher BP being linked to higher 
incidence of CVD (61). Based on recent revisions, BP can be categorized as follows: Normal BP (Systolic 
BP (SBP) <120 mm Hg and Diastolic BP(DBP) 80 mm Hg), elevated BP (SBP 120-129 mm Hg and DBP<80 
mm Hg), stage 1 hypertension (SBP 130-139 mm Hg or DBP 80-89 mmHg) and  stage 2 hypertension 
(SBP ≥140 mm Hg or DBP ≥90 mm Hg)(62). Evidence is suggesting a higher risk of CVD for SBP levels 
from <115 mm Hg to 180 mmHg and DBP levels from 75 mm Hg to 105 mm Hg(63). However, a 2 mm 
Hg reduction in SBP may result in a 10% decrease in stroke mortality and 7% decrease in heart disease 
and other vascular causes mortality (63). There are numerous classes of antihypertensive agents, 
which can be used in the treatment of hypertension. These agents include thiazide diuretics, 
angiotensin converting enzyme inhibitors, angiotensin II receptor blockers and calcium channel 
blockers(64). On the other hand, a solid body of evidence states that healthy lifestyle changes including 
diet can prevent hypertension in normotensive subjects and help to reduce BP in hypertensive 
subjects(64). There is a well-established relationship between salt reduction and BP, a 5g of reduction 
dietary sodium intake can lead to 1-2 mmHg lower SBP in normotensive subjects and 4-5 mmHg lower 
SBP in hypertensive subjects (65, 66).  Heavy alcohol consumption is another contributor of sustained 
elevated levels of BP and limitation of 20-30g of ethanol per day  in men and 10-20g of ethanol per day 
in women is suggested to be necessary (64, 67, 68). Moreover, a diet rich in fruits , vegetables, soluble 
fibre, wholegrains, low fat dairy products and plant proteins is important for the reduction of BP (69). 
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Total polyphenol intake assessed via the amounts excreted in urine was also negatively associated with 
hypertension (70). 
Although there are effective therapeutic treatments available to control CVD risk factors, it is not 
manageable in terms of costs and potential health complications to treat all subjects with drugs. 
Therefore, preventative impact of lifestyle interventions such as regular physical activity, non-smoking, 
maintaining a healthy BMI and healthy diet high in fruits and vegetables are key to manage these risk 
factors (33).  
1.2.2.2 Nitric Oxide bioavailability and Nicotinamide Adenine Dinucleotide Phosphate 
(NADPH) oxidase activity  
 
As briefly described above, NO is an important signalling molecule that has various roles in 
physiological and pathological processes including the endothelium (71). NO is synthesised from the 
amino acid L-arginine through the L-arginine nitric oxide synthase (NOS) pathway by eNOS (72-74). An 
alternative way of generating this molecule in vivo has more recently been suggested as the nitrate-
nitrite-nitric oxide pathway which consists of oxygen-independent and NO-synthase-independent 
single electron transfer reactions (75-77). The vascular effects of NO include the maintenance of 
vascular homeostasis. This can be described by a continuous and basal release of the molecule at low 
levels in the endothelium via cGMP-mediated relaxation of vascular smooth muscle cells, resulting in 
vasorelaxation (73, 78). Therefore, NO is an important regulator of blood pressure and blood flow (79).  
NADPH oxidase is a membrane bound enzyme complex consisting of a guanosine triophosphate 
(GTPase) subunit and different phox subunits. NADPH oxidase can be expressed in various ways in the 
cardiovascular system and subunits of the enzyme can be activated in the events of cardiovascular 
diseases (80). Although moderate activity of NADPH oxidase is important for angiogenesis and 
immunity, excessive reactive oxygen species (ROS) produced by an overactive NADPH oxidase may 
lead to endothelial dysfunction (81-83). The primary function of NADPH is to generate superoxide 
and/or hydrogen peroxide (H2O2). Reduction of O2 to generate a superoxide anion (O2•−), is considered 
to be the major source of ROS and this reaction is catalysed by NADPH oxidase. The secondary ROS is 
then produced with the direct or enzyme catalysed interaction of O2•− and other molecules. Reduction 
of O2•− leads to the formation of H2O2, which is further converted into hydroxyl HO•. O2•− can also react 
with NO to form peroxinitrite (ONOO−), ultimately leading to the uncoupling of eNOS and 
subsequently, a reduction in the production of NO, generation of superoxide and an increase in 
oxidative stress (84). Figure 1.3 illustrates the role played by NADPH oxidase activity and NO 






Figure 1.3 The role of NADPH oxidase activity and NO bioavailability in increasing oxidative stress 
NADPH oxidase, the main generator of superoxide (O2−•), and eNOS expression are major factors 
upregulated in the pathophysiology of vascular disease. Hydrogen peroxide (H2O2) is produced with 
the dismutation of O2−•, mediated by superoxide dismutase (SOD) and can lead to increased eNOS 
expression. O2−• generated through NADPH oxidase activity and NO produced through increased 
eNOS activity react to form peroxynitrite (ONOO−). ONOO− oxidises tetrahydrobiopterin (BH4), an 
essential cofactor of eNOS, causing uncoupling of eNOS. As a result, functional NO-producing eNOS is 
converted to a dysfunctional O2−•-generating enzyme which increases oxidative stress in the vascular 







1.2.2.3 Extracellular Vesicles (EVs) 
 
EVs are membrane-bound vesicles released from cells as result of cellular stress, cell activation and 
apoptosis and their roles include intercellular communication between cells with the of transport cargo 
that contains DNA, RNA and proteins(86, 87). EVs are mainly classified into different classes depending 
on their biological function, cellular origin or their biogenesis(88). The three main classes of EVs are 
exosomes, microvesicles and apoptotic bodies(88). Exosomes are considered to be the smallest 
vesicles (∼50-150nm) and are produced in structures called multivesicular bodies which facilitate their 
transfer into extracellular environment by exocytosis through the fusion with plasma membrane(89). 
Microvesicles (∼100nm-1 μm) that contain cytoplasmic cargo, bud from plasma membrane and cause 
cellular activation or stress (86, 89). While some of the microvesicles can be characterized with the 
expression of phosphatidylserine serine (PS) on their outer membrane, they can also be identified with 
the expression of a surface antigen arising from their parent cell (90). For instance, microvesicles 
derived from platelets express CD41 antigen whereas endothelial derived microvesicles can be 
characterized by the expression of CD105, CD31 or CD62e (91, 92). There are also apoptotic bodies 
(∼200 nm–5 μm) which are being generated from apoptosing cells and overlap in size with 
microvesicles (89).  
EVs are considered as potent mediators of both physiological and pathological processes (93). 
Depending on their numbers in the circulation, composition and content which represent particular 
signs of cell activation and injury, they can be used as potential biomarker of diseases including CVDs 
(87, 94). In the process of endothelial dysfunction, endothelial injury has shown to trigger the release 
of EVs (95, 96). Accordingly, subjects with CVDs show significantly high levels of circulating endothelial 
cell derived EVs (97). However, it is not only the release of EVs that reflects vascular dysfunction, when 
a vascular cell is targeted by EVs and incorporated via ligand or receptor signalling, through its plasma 
membrane or fusion of vesicle, EV cargo that contains cytokines, mRNA, noncoding RNAs and transfer 
proteins is released into target cell nucleus or cytoplasm (87, 95, 98). Thus, the phenotype and 
biological function of recipient vascular cell is influenced and this can contribute to CVD progression 
(95). For example, circulating endothelial microvesicles were reported to carry eNOS which originated 
from their parent cell and have crucial role in NO bioavailability (99). Elevated levels of circulating 
CD31+ /AnnexinV+(PS+) EVs were reported in CAD patients and circulating levels of CD62e+ 
endothelial EVs were shown in patients with pulmonary hypertension(100, 101). Increased numbers 
of EVs have been associated with CVDs such as coronary artery disease (CAD) peripheral artery disease 
and CVD risk factors such as hypertension (97, 102, 103). Platelet derived EVs (PDEVs) which form the 
majority of EV population in plasma with procoagulant activities, were associated with atherosclerosis 
and CAD and linked to CVD risk factors such as hypertension and abnormal lipid profile(103-107). On 
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the other hand, elevated levels of endothelial derived EVs (EDEVs) which mainly originates from 
activated and apoptotic endothelial cells were correlated with endothelial dysfunction in CAD 
patients(108). Increased numbers of EDEVs were also shown in patients with hypertension, heart 
failure, dyslipidaemia and atherosclerosis (109-111). These promising evidence support the notion that 
EVs have the potential to contribute to the progression of CVDs and they can be considered as 
emerging CVD risk factors.  
 
1.3 Dietary Polyphenols 
 
1.3.1 Classification, Chemical Structure and Dietary Sources of Polyphenols 
 
There is a growing interest in the role of polyphenols including flavonoids and phenolic acids as 
protective agents of the human diet. Polyphenols are present as  secondary metabolites in plants and 
have various roles including protection against herbivores, microbial infection, and UV light, attraction 
of pollinators, seed-dispersing animals and cell signalling to regulate nitrogen-fixation (112). 
Flavonoids contain 15 carbons with two aromatic rings connected by a three-carbon bridge  and consist 
of C6–C3–C6 structure with the main subclasses including flavones (parsley and celery) , flavonols (tea, 
apples and onions) , flavan-3-ols (tea, cocoa, red grapes and red wine), isoflavones (soybeans and 
legumes), flavanones (citrus fruits), and anthocyanidins (berries and red wine) (Figure 1.4). Phenolic 
acids are also present in some plants as non-flavanoid polyphenolic compounds. Main phenolic acids 
are hydroxybenzoic and hydroxycinnamic acid derivatives with  C1-C6  and C3-C6 structure, 
respectively(113). Coffee contain high levels of hydroxycinnamates, particularly chlorogenic acids such 
as 5-caffeoylquinic acid(114). After coffee, wholegrains such as oats are the second richest dietary 
source of phenolic acids , containing in particular the hydoxycinnamate ferulic acid (115). The mean 
dietary intakes of flavonoids is 352mg/d in the UK, flavanones being 9 mg/d, flavan-3-ols 110mg/d, 






                              
 Figure 1.4 Structure of the main flavonoid skeleton and subclasses (23). 
 
1.3.2 Phenolic Acids and Avenanthramides in Oats 
 
Phenolic acids and avenanthramides contain one aromatic ring bearing an acid group and one or more 
hydroxyl groups. Phenolic acids are found in three different forms within the oat food matrix: as 
soluble free acids, as soluble conjugates esterified to low molecular weight components such as sugars, 
and as insoluble bound acids esterified to high molecular weight components including lignin, cell wall 
polysaccharides and storage proteins (119, 120). Hydroxybenzoic acids and hydroxycinnamic acids are 
the two classes of phenolic acids found in oats (Figure 1.5). Hydroxybenzoic acid derivatives present in 
oats include, protocatechuic, syringic, vanillic , p-hydroxybenzoic and gallic acids, while 
hydroxycinnamic acid derivatives are ferulic, p-coumaric, o-coumaric, caffeic and sinapic acids. (121, 
122) Avenanthramides are a unique group of compounds in oats, consisting of an amide conjugate of 
anthranilic acid and hydroxycinnamic acids. The 3 major subgroups are avenanthramide-A, 
avenanthramide -B and avenanthramide -C, which occur in the bran or outer layers of kernel (123). 
Typical amounts of hydroxycinnamic acids, particularly, ferulic and p-coumaric acids are ranging from 
96.2-327 μg/g and 56.7-109 μg/g, respectively in oats. For hydroxybenzoic acids, namely vanillic and 
syringic acids, the amounts are ranging between 25.7-119.7 μg/g and 31-59.9 μg/g respectively. For 

















              
                     




Benzoic acid derivatives 
R3=R4=R5=OH; gallic acid 
R4=OH; p-hydroxybenzoic acid 
R3=R4=OH; protocatechuic acid  
R3=OCH3, R4=OH; vanillic acid 
R3=R5=OCH3, R4=OH; syringic acid 
Avenanthramides 
R1= R3=OH; Avenanthramide-A 
R1=R3=OH, R2=OCH3; Avenanthramide-B  
R1=R2=R3=OH; Avenanthramide-C 
Cinnamic acid derivatives 
R2=OH; o-coumaric acid 
R4=OH; p-coumaric acid 
R3=R4=OH; caffeic acid  
R3=OCH3, R4=OH; ferulic acid 
R3=R5=OCH3, R4=OH; sinapic acid 
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1.3.3 Absorption and Metabolism of Polyphenols: A Focus on Wholegrain Phenolic Acids 
and Oat Avenanthramides. 
 
Before evaluating the bioactivity of polyphenols in the body, one needs to consider the absorption and 
metabolism in order to understand the fate of these compounds before reaching to the blood stream 
to exert potential health benefits. After ingestion, the modification of the polyphenol glycosides starts 
in the oral cavity by the enzymes in saliva to a limited extend and then most of them reach to small 
intestine after passing through the stomach and thereafter the colon (22) (Figure 1.6). Many enzymes 
play role in the hydrolysis and absorption of these compounds within the gastrointestinal tract. Most 
importantly, lactase phloridzin hydrolase (LPH) in the brush border of epithelial cells of the small 
intestine cleaves the glycoside unit of the molecules. LPH has a broad specificity for flavonoid-O-B-D-
glucosides and the released aglycones are highly lipophilic which helps them to enter the epithelial 
cells via diffusion (124). Cytosolic B-glucosidase is another enzyme that mediates glycoside hydrolysis 
with the involvement of the active sodium-dependent glucose transporter (SGLT-1), which might be 
involved in the transportation of flavonoid glycosides into epithelial cells(125). 
After absorption, polyphenols are subjected to phase II enzymatic metabolism where they can be 
conjugated with sulphate, glucuronic acid and methyl groups with the catalysis of specific enzymes 
such as UDP-glucuronosyltransferases , sulphotransferases and catechol-O-methyltransferases(23, 
126). Following the phase II metabolism that initially takes place in the wall of the small intestine, 
metabolites are passing to the liver via portal vein where they might be subject to further phase II 
metabolism before undergoing renal excretion (127). It has been estimated that only 5-10% of total 
polyphenol intake is absorbed in the small intestine, whilst the remainder may persist to the colon, 
where it is metabolised by the gut microbial community (128, 129) Decarboxylation, reduction, 
demethylation and dihydroxylation reactions are common bacterial reactions which form low 
molecular weight metabolites from original structures that can be absorbed, undergo further phase II 
metabolism locally and/or in the liver before entering the systematic circulation where the tissue 
exposure and uptake can take place for the exertion of some of the health benefits (130, 131). 
Additionally, some of the carbon glycosides and flavonoid A ring might be converted to short chain 
fatty acids as a source for energy metabolism by the host and exhaled as CO2 (132). Factors such as 
age, sex, genetic polymorphisms, pathophysiological status, individual variability of composition of gut 
microbiota, food matrix and  food processing may affect the bioavailability of polyphenols and 





Figure 1.6 Schematic representation of the absorption and metabolism of polyphenols. Green dots 
are aglycones and white dots are metabolites. Figure adapted from Cipolletti et al, 2018(134). 
To focus on hydroxycinnamates that are present in wholegrains, both in situ and ex vivo experiments 
show that p-coumaric acid, ferulic acid and caffeic acid can be absorbed in the stomach, jejenum, ileum 
and colon of rats (135-139). Fast gastric absorption of p-coumaric acid and ferulic acid in rats and only 
free ferulic acid in humans have been reported in the gastrointestinal tract (136, 140). The type of 
hydroxycinnamate highly affects the absorption rate with ferulic and p-coumaric acids having higher 
absorption efficiency than caffeic acid in caco-2 cell lines (141-144). Although the exact mechanism of 
absorption is not well understood, facilitated diffusion suggested to play a role (141). To detail the 
metabolism of ferulic acid, it is mainly absorbed in the foregut and sulphated and or glucuronidated in 
the liver (135, 145). Some studies have shown that intestinal mucosa and kidneys might also play a 
role in the conjugation process (138). Intake of high doses of the compound might saturate this 
pathway and also increase its secretion via bile which can then reach the colon and be metabolized by 
gut microbiota(146). Ferulic acid can be converted into m-hydroxy-phenylpropionic acid with 
demethylation, reduction and dehydroxylation in the gut(147). Furthermore, it can be metabolized via 
B-oxidation in the liver and be accounted for urinary metabolites such as vanillic acid and 
dihydroferulic acid in rats (146-148).As stated previously, hydroxycinnamates also found in the bound 
form in oats as esterified with hydroxy acids, sugars and polymers. The metabolism of bound 
hydroxycinnamates are different than free forms, esterases located in the lumen of the intestine can 
hydrolyze the bound hydroxycinnamates or fibre-phenolic bond can be cleaved by intestinal 
microbiota to generate free forms which can then be absorbed and further metabolized (141, 149). 
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Human studies that examined the absorption, metabolism and bioavailability of phenolic acids in 
wholegrains reported the concentration in the blood and urine at the peak times (150, 151). Kern et 
al., investigated the absorption of hydroxycinnamic acids from high-bran wheat based breakfast cereal 
in 6 subjects (40 g portion containing 130 mg of phenolics). The results of this study showed an increase 
in plasma ferulic and sinapic acid concentrations (200 and 40 nM, respectively) with absorption peaks 
between 1 and 3 h suggesting that absorption might primarily take place in the small intestine from 
the soluble phenolics. These findings suggested that covalently bound diferulic acids are only absorbed 
in small amounts (<10nM in plasma), showing that the bulk of ester-linked compounds can be further 
metabolized by bacteria in the colon or excreted in the feces. Additionally, increases of 4 fold in ferulic 
acid and 5 fold in feruloylglycine in 24h has indicated the urinary excretion of hydroxycinnamates and 
the form of ferulic acid present both in plasma and urine was found as conjugates( feruloylglycine 
and/or glucuronides) (151). On the other hand, Bresciani et al., looked at the absorption, metabolism 
and bioavailability of phenolic acids in wholegrain bread (WGB) (94 g portion containing 87 mg of 
ferulic acid)  or bread enriched with an aleurone fraction, AB-94 and AB-190 ( 94 and 190g portions 
containing 43  and 87 mg of ferulic acids, respectively)  in 15 subjects. The metabolites found in plasma 
and urine were in the form of sulfate and glucuronide conjugates of phenolics. Plasma kinetics showed 
a peak at 1 h for ferulic acid-4’-O-sulphate,76.6 nmol/L ( AB-94) and  a peak at 7 h for dihydroferulic 
acid 4’-O-sulfate ,11.9 nmol/L (AB-190). Additionally, urinary excretion of ferulic acid 4-O-sulphate 
between 0-3h indicated an early absorption in the small intestine, excretion of sinapic acid sulfate and 
ferulic acid 4-O-sulphate between 3-6h showing the release of the most accessible fibre-linked 
phenolic acids by microbiota leading the increased absorption and finally vanillic acid excreted 
between 6-48h indicated a deeper microbiota catabolism (150). A 3-way crossover avenanthramide 
bioavailability study carried on 6 subjects with the consumption of 360mL skim milk (control) , 0.5 or 
1g avenanthramide enriched mixture showed that oat avenanthramides are also bioavailable. 
Maximum plasma concentrations of avenanthramides after consumption of 0.5 and 1 g AEM were 
112.9 and 374.6 nmol/L at around 2h after consumption. However it must be noted that the amounts 
provided in this study was really high and cannot be consumed in a portion of wholegrain oats (27). 
Finally, a pilot study that we previously performed in our group (see Appendix), reported  that intake 
of oat bran (60g, 2.5 mg of avenanthramides and 28.6 mg of phenolic acids) resulted in elevated levels 
of urinary excretion of 30 phenolic acid metabolites, mainly between 0-2 and 4-8h in 7 healthy men. 
The major excreted metabolites were vanillic acid, 4- and 3-hydroxyhippuric acids and sulphate 
conjugates of ferulic and benzoic acids. The findings showed that free and conjugated phenolics can 
be absorbed early (0-2h) from the small intestine and bound phenolics are subjected to the quick 




1.4 Dietary Polyphenols and Vascular Health 
 
1.4.1 In vitro bioactivity of polyphenols and their metabolites in relation to cardiovascular 
diseases. 
 
Representative studies investigated the mechanisms of action exerted by polyphenols or their 
metabolites in cell culture models in relation to cardiovascular diseases are summarized in Table 1.1. 
There are several proposed mechanisms in relation to interactions of flavonoids with NO, key regulator 
of vascular health.  The NO related non-specific mechanisms were described by high antioxidant nature 
of phenolic groups and the reaction of these groups with superoxide and other reactive oxygen species 
which can reduce NO breakdown (153-155). However, there is insufficient evidence to support this 
mechanism of action due to the lack of data emerging from studies that have utilised physiological 
metabolites of polyphenols at adequate concentrations in vivo (126). On the other hand, there is an 
accumulating evidence showing  the inhibitory or stimulatory actions of polyphenols or their 
metabolites in protein kinase and lipid kinase signalling pathways such as phosphoinositide 3-kinase , 
Akt/protein kinase B and mitogen activated protein kinase which might be resulting in increased eNOS 
activity and expression and hence increased NO production (81, 156). Finally,  polyphenols, or their 
circulating phenolic metabolites, might also have an inhibitory action on enzymes involved in the 
generation of reactive oxygen species (ROS), such as NADPH oxidase, xanthine oxidase and 
lipoxygenase, and this can prevent NO breakdown (153, 157). Specific mechanisms related to NO can 
be more dependent on particular flavonoid structure and some of the proposed mechanisms include 
increased eNOS activity and expression and hence increased NO production (81).  
Huang et al. showed that the 50 μM of dihydrocaffeic acid increased scavenging of ROS  ability and 
activity of NO synthase  in human-derived EA.hy926 endothelial cells but the concentration tested was 
higher than the values observed in plasma after ingestion (158). A recent study by Claude et al. 
addressed this issue and showed the inhibitory effects of 4'-O-methyl(-)-epicatechin ( at 0.2,0.5 and 2 
μM with a magnitude from -21 to-33%), 4'-O-methyl(-)-epicatechin-7-β-d-glucuronide (at 2 μM by 
about -14%), and (-)-epicatechin-4'-sulfate (at 0.2 and 0.5 μM from -18% to -27%) on human aortic 
endothelial cells (159). The findings from this study has shown that these flavanol metabolites can help 
to preserve vascular endothelium integrity with  decreasing the adhesion of monocytes to endothelial 
cells (159).On the other hand, 10-40 μM protocatechuic acid, a colonic catabolite of cyanidin-O-
glucoside, has been shown to inhibit  monocyte adhesion to  tumour necrosis factor-alpha activated 
mouse aortic endothelial cells (MAECs) and to reduce vascular and intracellular adhesion molecule  
(VCAM1 and ICAM1) levels both in MAECs and in Apo-E deficient mice, a well-established animal model 
of atherosclerosis (160). For example, one of the most potent flavanols, quercetin and its metabolites, 
methyl-quercetin and quercetin glucuronide have been tested in vitro (5 and 10 μM) on human 
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endothelial aortic cells and the results suggested an increase in the phosphorylation of eNOS via AMPK 
pathway and the production of NO (161).The inhibitory effects of (-) epicatechin and its metabolites 
were tested in vitro on NADPH oxidase activity with using human umbilical vein endothelial cells 
(HUVEC) and cell lysates. The findings suggested that (-) epicatechin is an O2•− scavenger but not an 
inhibitor of NADPH oxidase whereas the opposite results was obtained for the 3’- and 4’-O-methyl 
epicatechin. The dimer procyanidin B2 and (-) epicatechin were also shown to be O2•− scavengers but 
also  the inhbitors of the enzyme (28).  
The protective effects of polyphenolic compounds on CVDs is promising but there are important 
factors need to be considered when establishing these effects in in vitro models. Polyphenols are 
metabolized in the human body after ingestion and they mostly appear in the system as methyl, sulfate 
and glucuronide metabolites which can change their fate. Moreover, their concentration in the plasma 
rarely exceeds nM/L after normal dietary intake (162). Additionally, these compounds might not be 
absorbed in the small intestine but degraded to smaller phenolics with the action of bacteria in the 
colon and then absorbed into the blood before being excreted (22). Biologically relevant 
concentrations and the form of the compounds that are likely to occur in the vascular system should 
be taken into account when performing in vitro experiments on different cell lines. It is also important 
to use human metabolites with human cell lines and animal metabolites for animal cells to increase 















Table 1.1 Effects of polyphenols or their metabolites in cell culture models in relation to 
cardiovascular diseases. 
Signaling/effect activation;     , signaling/effect inhibition;       , - expression inhibition              ,  HUVECs, 
human umbilical vein endothelial cells; SMC, smooth muscle cells, ICAM-1,intercellular adhesion 
molecule 1; NO, nitric oxide; NOS, nitric oxide synthase; ROS, reactive oxygen species; VCAM-1, 
vascular cell adhesion molecule 1. 
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1.4.2 Epidemiological evidence of human studies 
 
The evidence from epidemiological studies suggest that daily consumption of polyphenols may protect 
from CVDs (22). A meta-analyses of 14 prospective cohort studies has shown that consumption of 
anthocyanins, flavonols, proanthocyanidins, flavones, flavan-3-ols and flavanones is inversely linked to 
a reduction in the CVD risk of 11, 11, 10, 12, 13 and 12% respectively, when comparing quintiles of 
highest versus lowest intake (170). Another study reported the association between decreased CVD 
incidence/mortality and consumption of flavonoids in six out of twelve cohorts, flavonol consumption 
being the strongest association with CHD mortality (171). Cassidy et al.,  reported that high intake of 
anthocyanin is associated with a 32% reduction in the risk of myocardial infraction(MI) in 100,000 
women, aged 25-45 years and  followed up over 18 years(172). Additionally, Zamora-Ros et al has also 
shown that the link between high flavonoid consumption and 29% reduction in CVD mortality and in 
particular flavanones and flavanols reduced CVD mortality by 40 and 41%, respectively, in 40,000 
subjects aged 29-69 years and followed up for 13 years (173). While promising evidence is 
accumulating on protective roles of polyphenols, it must be noted that some other epidemiological 
studies did not report a relationship between intake of polyphenols and CVD risk (174-176).  
Limitations of these type of studies should be taken into account when considering the findings. There 
is a need for greater uniformity on a number of factors such as study design variability, potential 
cofounding factors by other nutrients and bioactives, dietary assessment tools used, flavonoid classes 
assed, population characteristics (age/sex/health status), length of follow up and also CVD endpoints 












1.4.3 Clinical Human Intervention Studies 
 
The necessity of well powered and designed, double-blind randomized controlled trials (RCTs) is 
inevitable to confirm the observations made by epidemiological studies are causal. Blood pressure, 
endothelial function, vascular reactivity, arterial stiffness, and blood lipids are a range of prognostically 
validated surrogate markers of CVD risk commonly used in polyphenol intervention RCTs and will be 
discussed in this literature review.  
1.4.3.1 Endothelial Function: FMD, NO and NADPH 
 
The endothelium plays a key role in the regulation of vascular homeostasis and any functional and 
structural alterations correlate with CVD progression (177). Assessment of endothelial function can 
identify endothelial damage and provides prognostic data for risk degree in a later phase of the disease 
(34, 178). Endothelial function can be measured directly by assessing endothelial-dependent 
vasomotion, using flow-mediated dilation (FMD), or indirectly by circulating endothelial markers. FMD 
is widely considered as the ‘gold standard’ non-invasive technique to assess vascular function in 
cardiovascular research (179). It measures the ability of the arteries to dilate in response to endothelial 
NO release during reactive hyperemia induced by a 5-minute occlusion of the brachial artery (178). A 
meta-analysis of 23 RCTs reported that an improvement in FMD of 1% is associated with a decrease of 
8-10% CVD risk over 4 years (180). 
To date, a considerable amount of acute and chronic studies tested the protective effects of 
polyphenol-rich foods on endothelial function measured by FMD, with evidence being strongest for 
flavan-3-ols, cocoa and tea (23). A meta-analyses of 42 RCTs reported an improvement on FMD after 
both acute and chronic consumption of cocoa flavan-3-ols by 3.18% and 1.34% respectively (181). 
Another meta-analyses found that chronic  tea consumption improved  FMD by 2.6% when consuming 
a daily dose of 500 ml or 2-3 cups (182). The effects of berry polyphenols on endothelial function have 
been examined in a number of studies with reporting mixed results. A study conducted to test the 
vascular effects of cranberry juice consumption (835 mg total polyphenols and 94 mg anthocyanins 
per day) in patients with stable CAD, did not show an effect on FMD (183).  Another study which looked 
at the acute consumption of a blueberry drink (766 mg of total polyphenols, 310–727 mg anthocyanin) 
by healthy young men reported improvements on FMD at 1,2 and 6 h post –consumption (184). An 
acute study which used flavanone intervention as both juice and whole orange (128-452 mg TPs, 107-
352·80mg hesperidin), has shown the attenuation of vascular impairments measured as FMD in 
middle-aged healthy men(185). Daily consumption of hesperidin intervention (500 mg) for 3 weeks 
improved FMD by 2.5% in subjects with metabolic syndrome (186). 
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Emerging evidence from RCTs looking at the effects of polyphenols reported improvements on FMD, 
as discussed above. As FMD is a measure of in vivo endothelium derived NO bioavailability, it also 
shows the improvement in NO status (187). Indeed, a study of flavan-3-ol rich cocoa suggested to 
enhance vasodilation after consumption and this effect was shown to be reversed with a specific NOS 
inhibitor, administered intravenously (188). Elevated levels of NO have also been reported following 
both acute and chronic cocoa consumption (189, 190). Acute intake of pure (-) epicatechin and 
quercetin has also shown to improve the markers of NO and reduction in ET-1 in healthy men (191). In 
an RCT with healthy subjects, improvements in FMD were paralleled by the increase in NO levels 
following the intake of flavonoid-rich apples(192). Acute consumption of flavonoids and phenolic acids 
in champagne have also been shown to increase NO bioavailability and improve vascular function in 
15 healthy adults (31). Finally, an acute study has reported that consumption of blueberry flavonoids 
(766, 1278, and 1791 mg doses) and their circulating small phenolic acid metabolites such as vanillic 
and homovanillic acids which have structural homologies to the pharmacologic NADPH oxidase 
inhibitor, apocynin were linked with decreases in neutrophil NADPH oxidase activity in healthy men 
(184). 
There is a growing body of evidence suggesting the protective effects of polyphenols on endothelial 
function through increasing NO bioavailability. However, how exactly polyphenols exert these acute 
and chronic effects on NO status is still need to be elucidated. To understand the exact mechanisms of 
action, more cell and animal studies conducted with physiologically relevant doses and well-designed 
chronic human intervention studies are necessary. 
 
1.4.3.2 Blood Pressure 
 
Blood pressure is an important CVD risk factor, a lower blood pressure is linked to a healthier vascular 
system(193). It has been reported that a decrease in SBP of 2 mm Hg may lead to a 10% reduction in 
stroke mortality and 7% reduction in ischaemic heart disease and other vascular diseases(63). There 
are mixed findings on blood pressure and consumption of polyphenols. Similar to the evidence on 
endothelial function, the most promising results were reported for the consumption of cocoa and tea. 
A meta-analyses of 20 RCTs suggested that chronic intake of flavan-3-ol containing cocoa interventions 
lowered both SBP and DBP by 2 mmHg, mainly in healthy adults (194). Another meta-analyses 
comprising 11 chronic RCTs concluded that consumption of flavan-3-ol rich black tea can lower SBP 
and DBP by 1-2 mm Hg whereas green tea by 3 mm Hg (195). On the other hand, a meta-analyses of 
11 RCTs reported that consumption of soy isoflavones were also shown to be effective in lowering both 
SBP (-2.5mm Hg) and DBP (-1.5 mm Hg) in hypertensive patients, but not in normotensive subjects 
(196). The evidence of anthocyanin rich foods such as berries on BP are inconsistent. While a meta-
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analyses of 22 RCTs concludes a 2mm Hg reduction following the chronic intake of berries in SBP in 
subjects with CVD risk factors, a systematic review and few more RCTs reported no changes in 
overweight and hypertensive subjects, following the consumption of pure anthocyanin extracts or 
anthocyanin rich foods (197-200). Similarly, the evidence on grape polyphenols and red wine is 
inconsistent (22). For example, chronic intake of red wine by hypertensive subjects providing 280 and 
560 mg of polyphenols did not change  24 h ambulatory blood pressure, a more reliable measurement 
of BP (201). Finally, non-flavanoid polyphenols of coffee mainly chlorogenic acids (400 mg) was 
inconsistently shown to have an effect on BP (202) and chronic intake of olive oil polyphenols such as 
hydroxytyrosol (30 mg/day) lowered BP in young pre-hypertensive women(203).  
 
1.4.3.3 Microvascular Function, measured by Laser Doppler Iontophoresis 
 
Microvascular dysfunction may be the cause of microvascular complications and vascular dysfunction 
that can subsequently precede to the development of atherosclerosis (204). Laser Doppler 
Iontophoresis (LDI) is a technique that measures the microvascular reactivity with focusing on the 
vasodilation of the forearm’s peripheral microvasculature in response to a vasodilator called 
Acetylcholine (Ach) to measure endothelium dependent vasodilation and sodium nitroprusside (SNP) 
to measure endothelium independent vasodilation (205). A limited number of studies investigated the 
effects of polyphenols on microvascular function. Increased intake of flavonoid rich fruit and 
vegetables for 6 weeks were reported to improve endothelium dependent microvascular reactivity in 
men with CVD risk factors (206). Additionally, moderate consumption of champagne that contained 
flavonoids and phenolic acids (61.63 mg/l) suggested an acute improvement in endothelial 
independent microvascular function in healthy subjects (31). In contrast, acute consumption of 
blackcurrant juice ( providing 50 mg of anthocyanins and 200 mg of phenolic acids) did not affect the 
microvascular function in healthy subjects (207). Daily consumption of green tea extract containing 
flavanols (714 mg/day, total polyphenols), for 3 weeks also did not change the microvascular reactivity 
in healthy men(208). 
 
1.4.3.4 Arterial Stiffness 
 
Arterial stiffness has been associated with the risk of CVD and often evaluated together with BP and 
endothelial function as all these parameters can have an effect on each other or modulated by 
oxidative stress and inflammation (209, 210). Pulse wave velocity (PWV) is considered to be the ‘gold 
standard’ technique to assess aorta stiffness whereas augmentation index (AIx) defined as the 
percentage of central pulse pressure related to reflected wave overlap in systole. Alx is also associated 
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with CVD risk factors and determined by age, SBP and heart rate (209). There are few studies examining 
the effect of different classes of polyphenols on arterial stiffness. For example, acute consumption of 
flavonoid-rich dark chocolate (2.62g of procyanidins per 100g ) suggested to decrease Alx and improve 
FMD, without changing PWV in healthy subjects (211). Another study, examining the chronic effects 
of cocoa-flavanol containing drink (450 mg of flavanols) in both young and elderly healthy subjects, 
reported an improvement in FMD and PWV in both groups and a decrease in Alx only in elderly subjects 
(212). Conversely, chronic supplementation of pure (-)-epicatechin (100mg/d) and quercetin (160 
mg/d) has failed to show an effect on both FMD and arterial stiffness in healthy subjects (213). One 
year supplementation with isoflavones (90mg /day) and flavan-3-ols (850 mg/day) has shown to 
improve PWV in patients with type-2 diabetes and post-menopausal women (214). Acute consumption 
of red wine polyphenols and chronic supplementation of cranberry juice (835 mg of total polyphenols 
and 94 mg of anthocyanins  per day) have also been reported to decrease both PWV and Alx in CAD or 
CHD patients (183, 215). Finally, anthocyanin rich red orange juice (53.1 mg/L) was also reported to 
improve Alx acutely in healthy subject following the consumption of a fatty meal (216). However, there 
are numerous studies showing no effect on arterial stiffness after the consumption of cranberry juice, 
blueberry drink or pomegranate juice in healthy, obese or at CVD risk subjects(29, 217, 218).  
 
1.4.3.5 Extracellular Vesicles 
 
As previously described, EVs are released from cell types such as platelets and endothelial cells, as a 
result of cellular stress, activation and apoptosis and the elevated numbers are associated with 
pathologies related to CVDs including endothelial dysfunction(86, 87). There is a small body of 
evidence investigating the effect of polyphenols, majorly cocoa flavanols on the numbers of circulating 
EDEVs and PDEVs. A chronic study reported decreased levels of EDEVs following the consumption of 
high flavanol drink (375 mg) in CAD patients (99). Similarly, another chronic study testing natural cocoa 
bars (containing 701mg of flavanols) reported significant reduction of circulating EDEVs in women 
subjects (219). Consumption of cocoa flavanols (450 mg) for 2 weeks was also reported to decrease 
circulating EDEVs and correlated with decreases in SBP, Alx and inversely correlated with FMD 
improvements in both young and elderly subjects(220, 221). However, the same study failed to show 
any changes in the numbers of PDEVs following the consumption of cocoa flavanols (220). Another 
acute RCT providing relatively higher dose of flavanols (897 mg) has reported the decreased levels of 
PDEVs in healthy subjects(222). It is evident that flavanols may maintain endothelial integrity with 
improving FMD, other vascular measures and in parallel to these improvements, decreasing levels of 
circulating EDEVs and PDEVs. However, further in vitro studies examining the potential mechanism of 
action and more in vivo studies testing other polyphenol containing foods are necessary to understand 




1.5 Wholegrain Foods, Nutritional Composition, Types and Health Benefits 
 
Wholegrain foods are defined by the FDA as consisting of the  “ intact, ground, cracked or flaked fruit 
of the grain whose principal components, the starchy endosperm, germ and bran, are present in the 
same relative proportions as they exist in the intact grain “ (223).  Wholegrains are a major source of 
dietary fibre that can be defined as carbohydrates that are resistant to digestion and absorption in the 
small intestine and partially or completely fermentable in the large intestine(224).Dietary fibre can be 
classified into two groups: soluble and insoluble, the former slows down the digestion process by 
dissolving in water and forming a gel that delays the gastric emptying whereas the latter does not 
dissolve in water and speeds up the passage of food and waste through the stomach (225).  
Dietary phytochemicals defined as bioactives , non-nutrient plant compounds can also be found in 
wholegrains, including flavonoids, phenolics, carotenoids, lignans and vitamin E compounds (226, 227).  
Phenolics are the most complex and distinct type of phytochemicals in wholegrains including 
derivatives of cinnamic and benzoic acids and avenanthramides, present in oats (228). Ferulic acid and 
diferulates comprise by far the largest amount of phenolics in wholegrain foods and distinguishes them 
from other sources of phytochemicals (146, 229).  
Although whole grains are a rich source of many nutrients, most cereals are less nutritious as they are 
being consumed after milling which is the removal of bran and germ and preservation of starch rich 
endosperm that is processed into flour (226, 230). In some countries, mandatory fortification might 
replace some of the lost minerals and vitamins from the grains (231). On the other hand, whole grains 
might be subjected to various types of processing which does not change the nutritive value of the 
product in most cases and enhance the texture, flavour, colour, appearance and elongate the shelf life. 
Also, processing can help the grain digestion and absorption by the human body(232). 
Important whole grains consumed in the western diet include wheat, oats, rice, maize, corn, rye and 
barley (226, 233). Increased consumption of wholegrain is linked to reduced risk of chronic diseases 
including  CVD (234-236), type-II diabetes(237, 238) ,some cancers(239) body weight (240) and 
gastrointestinal disease (241). Although recommended daily intakes of whole grains are not clearly 
defined and vary between countries, the 2010 Dietary Guidelines for Americans (242) recommended  
6-11 servings per day of grains (243) depending on person’s energy needs (244).On the other hand, 
the NHS  (172) eat well plate gives more general advice with stating the consumption of rice, potatoes, 
pasta, bread and other foods rich in starch as a third of a plate and promoting the consumption of 




1.5.1 Wholegrain consumption and CVD risk 
 
Evidence from observational studies suggests that increased consumption of less-refined wholegrains 
is associated with a reduced risk of CVDs. A series of large observational studies such as Iowa Women’s 
Health Study (IWHS), the Nurses’ Health Study, Norwegian County Study (NCS) and the Physician’s 
Health Study, established the beneficial effects of wholegrains on CVDs (172, 188, 230, 235, 236, 245, 
246). For example, in the IWHS trial, an inverse association between wholegrain intake and risk of 
death from ischemic heart disease was observed after adjustment to potential confounding factors 
and total dietary fibre intake in 34,492 postmenopausal women aged 55-69 y (226, 235). Moreover, a 
strong inverse association between wholegrain intake and risk of coronary heart disease was observed 
in 75,521 women aged 38-63 y in the highest quintile of whole grain consumption compared with those 
in the lowest quintile (226, 236). In addition to these large prospective studies, recent systematic 
reviews and meta-analysis are also suggesting the same link between wholegrain consumption and 
CVDs. For example, Ye et al. performed a meta-analysis to assess findings from 10 prospective cohort 
studies in the area and suggested a 21% reduction in CVD risk with highest category of intake(3-5 
serving/d, 44.4 g/d) of wholegrains when compared to lowest category (rare/never consumers) after 
adjustment for known risk factors (247). The same study also assessed the dietary fibre intake in 
relation to CVDs in 15 prospective cohort studies and stated that greater consumption of fibre was 
significantly and inversely associated with CVDs, although there were substantial heterogeneity across 
studies (247). A dose-response meta analyses carried out by Aune et al, suggested reductions in the 
relative risk  per 90g/day for coronary heart disease and cardiovascular disease, 19% and 22% 
respectively and  for the highest versus lowest category of wholegrain intake, 21% and 16% 
respectively(15). Although the consistent findings from observational studies suggest a cardio 
protective effects of a diet rich in wholegrains, the limitations of these studies such as uncontrolled 
confounders, inaccurate and different methods of measurements (including food-frequency 
questionnaires) should be considered and the proposed evidence should be supported with well 
controlled and long-term RCTs (248). 
Intervention studies that have been carried out in relation to the cardiovascular health benefits of 
wholegrains are less consistent but still majorly report the positive impact of wholegrain consumption. 
A meta-analysis of 24 RCTs assessed the effect of daily whole-grain dose ranged from 28g to 213 g in 
comparison to a background diet low in wholegrains on blood lipid biomarkers. The duration of the 
studies ranged from 2wk to 16wk, mostly lasted 6-8wk and 16 out of 24 studies included 
hypercholesteraemic subjects with mean baseline concentrations >5.2mmol/L. This study found out 
that wholegrain consumption may reduce total and LDL cholesterol by 0.09 and 0.12 mmol/L, 
respectively (249). The study especially highlighted a causal link between grains high in viscous B-
glucans-found mainly in oat and barley and lower total and LDL cholesterol (249). Another meta-
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analyses of 21 RCTs investigated the effects of wholegrains on metabolic risk factors and reported 
significantly lower concentrations of fasting glucose, total and LDL cholesterol.(250) The inconsistency 
of the results obtained from other RCTs might be due to different study designs and incorporation of 
different types of wholegrain foods within the intervention diet.(231)  
1.5.2 Oat Structure and Nutritional Composition 
 
Oats (Avena sativa) are member of the wholegrain family with a nutritional profile that exert health 
benefits (251). The morphology of the oat grain is shown in Figure 1.7 (252). The outer hull is tightly 
attached to the oat groat which mainly consists of bran, germ and endosperm (253). The bran that 
underlies the hull is acting like an envelope to the rest of the groat and is composed of the outermost 
pericarp, seed coat, aleurone  and sub-aleurone layer (253). The aleurone layer of the bran is 
particularly rich in phenolics, minerals, vitamins and also contain cell wall polysaccharides including 
cellulose, arabinoxylan and β-glucan. Starchy endosperm mainly contains β-glucan that is metabolically 
inactive but supplies nutrients to the growing embryo during germination (252, 253). Thick cell walls 
that are resistant to digestion surround aleurone and subaleurone cells whereas thin cell walls cover 
endosperm(252). The germ is the metabolically active part in the germination process and transports 




Figure 1.7 Schematic representation of the oat grain. Different oat tissues (bran, germ and 
endosperm) are shown in higher magnifications together with nutrients they contain. Figure 




As with other cereals, oats are a good source of slowly-digestible starchy carbohydrates, protein, 
vitamins, minerals and soluble fibre. Table 1.2 gives an overview of macro and micronutrient content 
of oats with contribution of each nutrient to the total dry matter in % and where they are located 
within the plant structure. Wholegrain oats are typically very rich in dietary fibre, constituting 20-37% 
of hulled and 10-12% of de-hulled oats (254).  Fibre can be classified as into soluble and insoluble 
fractions, forming 40% and 60% of the total oat fibre, respectively (254). Insoluble oat fibre is mainly 
cellulose, hemicellulose and lignin whereas soluble fibre is predominantly coming from β-glucan (254). 
Oat β-glucan is linear, unbranched polysachharide composed of 1-4-O-linked (70%) and 1-3- O- linked 
(30%) B-D-glucopyranosyl units (255). In addition to dietary fibre, oats are also considered as a source 





















Table 1.2  Nutritional Composition of Oats. 








Starch  Amylose:60 % Endosperm (257-260) 
Protein Total:11-15 % 
Globulins: 80 % of total 
protein 
Prolamins: 15% of total 
protein  
Glutelin: 5-66 % of total 
protein 






Lipids  Total:5-7%  
mono and 
polyunsaturated fatty 
acids: mainly oleic (18:1) 
and linoleic (18:2) 
saturated fatty acids 
including myristic (14:0) 





Trace Minerals Calcium: 0.54% 
Iron: 0.047% 
Bran (264) 




Fibre Total: 10-12% 
β-glucan : 2.3–8.5 % 
Bran (254, 265) 
Phytochemicals   α-Tocotrienols and α-













Bran (266, 267) 
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1.5.3 Oat Consumption and CVD Risk 
 
Epidemiological studies provide strong protective evidence of wholegrain and dietary fibre intake on 
CVDs as discussed in the previous section (268-270). However, it is difficult to assess the association 
between oats and CVDs specifically from these studies and there are not any epidemiological studies 
focusing solely on oats. On the other hand, evidence accumulating from RCTs strongly suggest that 
regular consumption of oats, particularly β-glucan is lowering CVD risk markers (58, 271). To highlight 
the findings of some meta analyses in the area, Whitehead et al. showed that consumption of at least 
3g of oat β-glucan per day is associated with decreased levels of total cholesterol (0.25mmol/L) and 
LDL (0.30mmol/L) relative to control without changing HDL cholesterol and triglycerides in lean, 
overweight, or obese subjects with or without type 2 diabetes (271). Thies et al. also highlighted that 
the regular consumption of oats, even when containing less than 3 g β-glucan,  has a beneficial effect 
on total and LDL-cholesterol, particularly in hypercholesteraemic subjects(25, 272). Although the form 
of oat intervention differed between oat bran, wholegrain oats or oatmeal in the studies, Thies et al 
mentioned that this fact did not affect the outcomes(25).Most recently, Ho et al. further supported 
the dose dependent intake of β-glucan for decreasing LDL-cholesterol, non-HDL cholesterol and ApoB 
in middle aged subjects(58). The strong evidence about  β-glucan led to health claims on cholesterol 
lowering properties of oats and their contribution to heart health, approved by FDA and EFSA (120, 
273).  
Additionally, oat consumption is  reported to improve insulin sensitivity and post-prandial glycaemic 
control which may be explained by delayed glucose absorption due to high viscosity of β-glucan in the 
upper gastrointestinal tract (274, 275). Finally, there are limited number of RCTs examining the impact 
of oat consumption on BP and endothelial function. While the evidence regarding to BP is still 
inconsistent, studies measuring endothelial function by FMD did not report any changes following the 
chronic oat intake in healthy or hypercholesteraemic subjects(25, 276-279). However , a study testing 
the intake of wild green oat extract (1500mg/day) for 12 weeks found  significant improvements in 










In conclusion, there is substantial amount of data emerging from epidemiological, clinical and in vitro 
studies that suggest cardio protective effects of polyphenols in humans. While flavonoids are 
demonstrating the great body of evidence, their circulating metabolites as phenolic acids or phenolic 
acid containing foods have also shown to be exerting the health benefits on vascular measures through 
NO related mechanisms. Oats are a source of phenolic acids and avenanthramides, however, most of 
the studies to date have predominantly centred on β-glucan without being controlled for their 
phenolics content and suggested cardiovascular benefits. Considering the evidence from polyphenol  
studies, oat phenolics may also have similar vascular health benefits or they may act synergistically 
with fibre to exert their health benefits. Therefore, more human studies are necessary to address the 
gap and understand the role of oat phenolics in defining cardiovascular benefits of oats. 
  
1.7 Hypothesis and Study Objectives 
 
The hypothesis of this thesis is that consumption of oats containing phenolic acids and 
avenanthramides will be effective at inducing beneficial improvements in human circulatory function, 
through the influence of absorbed small phenolic acids on endothelial function, microvascular function 
and blood pressure and lead to a healthy cardiovascular system. 
Objectives of the thesis are as follows: 
- To determine phenolic acid and avenanthramide composition and content of different 
varieties of commercial oats to see the variation in the levels of phenolic content and to 
estimate the amounts delivered to the consumer in a portion of oats. This objective was set to 
inform the following clinical work to provide an achievable dietary intake level of these 
compounds in intervention products. 
 
- To examine effects of acute (i.e. 1-24h post-intake) consumption of oats containing phenolic 
acids and avenanthramides on markers of CVD risk relative to an energy matched control 
intervention in pre and stage one hypertensive men, with a randomized controlled trial. 
 
- To examine the dose-dependent effect of 4 weeks of daily consumption of soluble fibre 
matched meals providing either a high dose or a moderate dose of oat phenolic acids and 
avenanthramides on markers of CVD risk relative to an energy and soluble fibre matched 
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Oats contain a range of phenolic acids and avenanthramides which may have health benefits.  
Analysis of 22 commercial oat products (oat bran concentrate, oat bran, flaked oats, rolled oats and 
oatcakes) using HPLC-DAD detected eleven bound and thirteen free + conjugated phenolic acids and 
avenanthramides. The oat products (excluding concentrate) provided between 15.79 to 25.05 mg 
total phenolic acids (9.9 to 19.33 mg bound, 4.96 to 5.72 mg free +conjugated) and between 1.1 and 
2 mg of avenanthramides in a 40g portion while an 11g portion of oat concentrate provided 16.7 mg 
of total phenolic acids (15.17 mg bound, 1.53 mg free + conjugated) and  1.2 mg of avenanthramides. 
The compositions and concentrations of the components in the different products were broadly 
similar, with the major component being ferulic acid (58-78.1%). The results show that commercial 

















 Epidemiological evidence suggests that regular consumption of whole grains is associated 
with a lower risk of chronic diseases, such as cardiovascular disease (CVD), type 2 diabetes 
and certain cancers(281).Meta-analyses of multiple human intervention studies provide strong 
evidence that regular oat intake lowers blood cholesterol, improves insulin sensitivity and post-
prandial glycaemic control (58, 275). Oats (Avena sativa) are wholegrain cereals which provide 
proteins, unsaturated fatty acids, vitamins, minerals (282),  phenolics (including avenanthramides 
that are unique to oats), and significant quantities of dietary fibre, including cellulose, arabinoxylan 
and β-glucan (21). There is a solid body of evidence and a health claim approved by EFSA approving 
the cholesterol lowering properties of oat β-glucans. (20, 58, 271). 
A diet rich in oats can provide phenolic acids and avenanthramides that may contribute to the 
beneficial health effects. Although there are mixed findings from different studies testing different 
foods, well designed randomized controlled trials investigating a variety of foods such as coffee and 
blueberries showed protective effects of circulating phenolics against CVD (29, 30, 283-285). 
Avenanthramides have also been shown to be bioavailable in humans and may exert anti-
inflammatory, anti-proliferative and vasodilatory effects to protect against CVD and colon cancer (27, 
119, 165, 286, 287). 
Phenolic acids comprise one aromatic ring bearing an acid group and one or more hydroxyl groups 
(288) and are present in the oat grain in three forms:  as soluble free acids, as soluble conjugates 
esterified to low molecular weight components such as sugars, and as insoluble bound acids 
esterified to high molecular weight components, notably cell wall polysaccharides (dietary fibre and 
lignin) (289). Cereal phenolic acids consist of two major types: based on either hydroxycinnamic acid 
or hydroxybenzoic acid. Hydroxybenzoic acids in oats include protocatechuic, syringic, vanillic , p-
hydroxybenzoic and gallic acids, while hydroxycinnamic acids in oats are ferulic, p-coumaric, o-
coumaric, caffeic and sinapic acids (Figure 1.5) (26). Avenanthramides consist of an amide conjugate 
of anthralinic acid and hydroxycinnamic acids. The 3 major types are esters of 5-hydroxyanthranilic 
acid with p-coumaric (2p aka A), and ferulic (2f aka B), and caffeic (2c aka C) acids which occur 
predominantly in the bran layer of the oat grain (Figure 1.5) (290, 291). 
Several previous studies have reported the presence and amounts of phenolic acids and 
avenanthramides in oats (115, 267, 292, 293). However, some of these studies analysed 
experimental material (including hulled grains) which would not be available to consumers while 
others analysed either avenanthramides or phenolic acids but not the two groups together. 
Therefore, the aim of this study was to determine the composition and amounts of phenolic acids 
and avenanthramides in a number of commercial oat samples, determining differences between 
products (oat bran, oat bran concentrate, rolled, flaked oats  and oat cakes) and  estimating the 
amounts consumed in typical portions of oat-based products in order to understand their 
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contribution to dietary intakes of phenolics and to inform further clinical trials aiming to test the 
bioactivity of these compounds at normal intake levels.  
 
2.3 Materials & Methods 
 
2.3.1 Chemicals and reagents 
 
All individual phenolic acid and avenanthramide standards were obtained from Sigma-Aldrich (St. 
Louis, MO, USA). HPLC column and guard cartridges were obtained from Phenomenex (Torrance, CA, 
USA). Unless otherwise stated, all chemicals and reagents were obtained from Sigma-Aldrich or 
Fisher Scientific. 
2.3.2  Oat Samples 
 
22 commercial oat products were purchased in local shops or online and comprised 4 oat brans, 5 
oat flakes, 6 rolled oats, 5 oatcakes and one oat concentrate (Table 2.1). The samples were milled 











































Brand Type Number 
Oatwell Bran concentrate 1 
White’s (Fine cut) Bran 2 
Mornflake Bran 3 
Sante (Otreby Owsiane) Bran 4 
Greenlands (organic) Bran 5 
M&S (Traditional British porridge oats) Flaked 6 
Sainsbury’s (SO organic Scottish oats) Flaked 7 
Sainsbury’s ( Scottish porridge oats) Flaked 8 
Flahavan’s (Irish organic jumbo oats) Flaked 9 
Kupiec (plain) Flaked 10 
Quaker (Oats so simple original-sachets) Rolled 11 
Sainsbury’s (Taste the difference Scottish) Rolled 12 
Asda (Original porridge) Rolled 13 
Quaker (Jumbo oats) Rolled 14 
Quaker Rolled 15 
Scott’s (Porridge oats) Rolled 16 
Nairns (Fine milled, 85% oats) Oatcake 17 
Nairns (Organic, enriched with oatbran, 85% oats) Oatcake 18 
Savour Bakes (Scottish rough, 89% oats) Oatcake 19 
Clearspring (Organic, 83% oats) Oatcake 20 
Paterson’s (Rough, % *ng) Oatcake 21 
Stockan’s (Orkney, thin, 76% oats) Oatcake 22 
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2.3.3 Extraction of free, conjugated and bound phenolic acids  
 
Phenolic acids and avenanthramides were extracted in two separate fractions (i.e. free + conjugated 
and bound) (Figure 2.1), in three replicates, using the method of Schär et al (152). 2 ml of hexane 
were added to 20.0 ± 0.1 mg of milled oat samples for defatting. Solutions were vortexed for 30 
seconds, sonicated for 10 min, vortexed and kept on a shaker for 50 min. Following centrifugation for 
15 min at 5000 rcf, the supernatant was discarded and the wet samples were dried with a 
SavantTM SPD131DDA SpeedVacTM Concentrator (ThermoFisher Scientific, Waltham, MA, USA) for 10 
min. The first extraction step was carried out by adding 80:20 ethanol/water (1mL) and samples were 
vortexed until all of the flour was suspended. 0.375µg of internal standard (3-5,dichloro-4-
hydroxybenzoic acid) was added and the samples were extracted for 10 min by sonication in a sonic 
bath. Samples were then heated to 80°C for 15 min and centrifuged for 15 min at 5000g. The 
supernatant was removed into a test tube and evaporated with a SpeedVac. This extraction was 
repeated twice without the heating and the addition of internal standard. The combined 
supernatants were evaporated to dryness. For the extraction of free + conjugated fractions, the dried 
supernatant was hydrolysed with 2M NaOH (400μl) with 10μM EDTA and 1% (w/v) ascorbic acid for 4 
h and then acidified with 12 M HCl (125μl) to pH 2 and kept at -20 °C overnight. For the extraction of 
the bound fraction, the pellet was dried in a Speedvac for 5 min, 30 μg internal standard added and 
hydrolysis was carried out with 2 M NaOH solution (800μl) , 10μM EDTA and 1% (w/v) ascorbic acid 
for 16-18h with gentle agitation. Following hydrolysis, samples were centrifuged for 15min at 
16100g, supernatants were transferred to clean Eppendorf tubes and acidified with 12 M HCl (220 
μl). Bound and free + conjugated fractions were extracted with ethyl acetate (3 x 800 μL), evaporated 
to dryness and re-dissolved in 2% (v/v) aqueous acetic acid (100 μL) using vortexing for 30s, 
sonication for 1 min and shaking for an hour. Final solutions were centrifuged for 5min at 16100g and 





Figure 2.1 Flow chart illustrating the extraction of phenolic acids and avenanthramides from free, 











2.3.4 HPLC Analysis  
 
Phenolic acids were identified and quantified using an Agilent 1100 series HPLC (Agilent Technologies 
Ltd, Santa Clara, CA, USA) equipped with a quaternary pump, autosampler, column thermostat, 
sample thermostat and photodiode array detector. Phenolic acids were separated on a Kinetex 
biphenyl column (100A 250x4.6 mm length, 5μM particle size; Phenomenex) using a gradient elution 
programme developed in house for the separation of 18 different phenolic acids and 3 
avenanthramides. Mobile phase A consisted of 0.1% (v:v) formic acid in HPLC grade water (A), while 
mobile phase B was 0.1% (v:v) formic acid in methanol. The following optimised gradient protocol 
was run: 0 min, 95% A; 20 min,75% A; 25min,74% A; 30 min, 65% A; 40 min,64% A; 53 min, 30% A; 56 
min, 5% A; 61 min, 5% A; 62 min, 95% A; 65 min, 95% A. The flow rate of the mobile phase was 
1.0mL/min, the column temperature was 30°C and the sample injection volume was 20µl.  
Quantification of phenolic acids and avenanthramides were made at 280 nm. The retention time and 
absorbance of each compound was established by running standards (Table 2.2). All standards were 
prepared as stock solutions at 1mg/mL in methanol and stored at -80°C. Phenolic acids and 
avenanthramides were quantified by calculating the ratio of the area of the analyte to the area of the 
internal standard (i.e. 3-5,dichloro-4-hydroxybenzoic acid). Quantification was based on 10 point 
linear calibration curves of phenolic acid and avenanthramide standards which covered the range 
present in the oat samples and had R2 values above 0.9 (Table 2.2). The concentrations of individual 
components were stated as μg/g. Good reproducibility was observed between replicate analyses 
with an average of 9% for the coefficient of variation for all samples. All data were analysed using 











2.3.5 Statistical Analysis  
 
Means and standard errors of 3 replicates were calculated for each sample. Data were quantified and 
expressed as μg/g fresh weight. Calibration curves of phenolic acid and avenanthramide standards 






Compound RT (min) MW           PA (nm) R2 
 Gallic acid 5.4 170.1 218 - 
4-Hydroxybenzoic acid 15.1 138.1 255 0.997 
2,4-Dihydroxybenzoic acid 17.2 154.1 255 - 
4-Hydroxyphenyl acetic acid 18.4 152.2 235 - 
Caffeic acid 21.0 180.2 324 0.995 
Vanillic acid 23.0 168.2 218 0.986 
4-Hydroxybenzaldehyde 23.7 122.1 224 0.997 
Homovanillic acid 24.5 182.2 280 - 
Syringic acid 28.3 198.2 220 0.940 
p-Coumaric acid 30.5 164.2 310 0.995 
Vanillin 33.0 152.2 280 0.996 
Salicylic acid 33.7 138.1 238 - 
Ferulic acid 36.8 194.2 323 0.995 
Syringaldehyde 38.6 182.2 218 - 
Sinapic acid 39.8 224.2 320 0.998 
3-5,Dichloro-4-hydroxybenzoic acid 40.5 207.0 217 - 
o-Coumaric acid 41.2 164.2 278 - 
Avenanthramide C 47.1 315.3 340 0.980 
Avenanthramide A 50.5 299.3 320 0.943 
Avenanthramide B 52.0 329.3 338 0.965 
Identities (compound), retention times (RT), molecular weights (MW) and peak absorbances (PA) of phenolic 




Table 2.2  Identities (compound), retention times (RT), molecular weights (MW) and peak absorbances (PA) of 




2.4 Results and Discussion 
 
2.4.1 Identification of Phenolic Acids and Avenanthramides in Commercial Oat Products. 
 
Standards of twenty different phenolic compounds (including phenolic acids and avenanthramides) 
which could be present in oat products were analysed by HPLC-DAD (Figure 2.2 A), measuring their 
absorbance maxima and retention times (Table 2.2). Comparisons with these standards identified 
eleven components in the bound fractions and thirteen in the free + conjugated fractions extracted 
from the products. This is illustrated by the typical chromatograms for oat bran (product 3) in Figure 
2.2 B and C. While both the bound and free + conjugated fractions contained 4-hydroxybenzoic acid, 
vanillic acid, caffeic acid, 4-hydroxybenzaldehyde, syringic acid, p-coumaric acid vanillin, ferulic acid 
and sinapic acid, the three avenanthramides (avenanthramide A, avenanthramide B and 




















Figure 2.2 Chromatogram of analytical phenolic acid standards at 280nm. (A) Representative 
chromatograms of oat sample 3 for bound phenolic acids (B) and free &conjugated phenolic acids 
at 280nm (C).Compounds were identified based on retention time and absorbance spectrum(Table 
2.2): 1, gallic acid; 2 , 4-hydroxybenzoic acid; 3, 2,4-dihydroxybenzoic acid; 4, 4-hydroxyphenyl 
acetic acid; 5, caffeic acid; 6, vanillic acid; 7; 4-hydroxybenzaldehyde ; 8, homovanillic acid; 9, 
syringic acid; 10, p-coumaric acid ; 11,vanillin ; 12,salicyclic acid; 13, ferulic acid; 14, 
syringaldehyde; 15, sinapic acid; 16, 3-5,dichloro-4-hydroxybenzoic acid; 17, o-coumaric acid; 18, 







2.4.2 Total Contents of Phenolic Acids and Avenanthramides. 
 
The mean total contents of phenolic acids and avenanthramides in the groups of oat products was 
highest for the oat bran concentrate (1518.6 μg/g) followed by oat bran (626.3±60.1 μg/g), flaked 
oats (438.1±27.0 μg/g), rolled oats (415.8±14.9 μg/g) and oatcakes (394.8±24.2 μg/g) (Figure 2.3 A).  
All the results are reported on a fresh weight (FW) basis. The bound phenolic acid fraction made the 
greatest contribution to the total phenolic contents of all products (62.7-90.8%) while the amounts 
of the free + conjugated fractions were lower in all products (9.2-37.2%). This is in agreement with 
other studies (295, 296). When the contents and compositions of phenolic acids and 
avenanthramides were compared within each group of oat products, the bran products showed the 
greatest variation in both free + conjugated (ranging from 100.9 to 194.9 μg/g) and bound (ranging 
from 359.5 to 592.4 μg/g) fractions, the free + conjugated fraction also varied between the samples 
of oat flakes ( 115.7 -210 μg/g). Oat bran concentrate comprises mainly fibre and,  in agreement with 
the literature, our analysis showed that this fraction was rich in bound phenolic acids (266). The total 
contents of phenolic acids in the oat bran products were only slightly higher than those in the flaked 
oats, rolled oats and oatcake products. Similar results for different oat products were reported by 
Matilla et al (2005) who suggested that the similar phenolic content of oat bran might be due to the 
processing method which results in the bran containing some aleurone and starchy endosperm as 
well as outer  layers of the grain (pericarp and testa) (267, 297). 
Avenanthramides were only present as soluble forms with the mean total concentrations being 
highest in oat bran (49.6±8.3 μg/g) followed by flaked oats (48.8±10.3 μg/g), oatcakes (43.8±6.9 
μg/g), oat bran concentrate (30.6 μg/g) and rolled oats (28.3±2.9 μg/g) (Figure 2.3 C). 
Avenanthramides have been reported to be heat stable under conditions of commercial processing 
and the levels of these compounds in oatcakes, which are mostly processed products in our sample 
range, were higher than in the oat bran concentrate which contained highest total levels of phenolic 
acids (298). The concentrations determined in this study were broadly consistent with those 
reported previously (115, 267, 297, 299). However, whereas Chen et al. (2018) and Pridal et al. 
(2018) reported higher concentrations of avenanthramides in oat bran samples in comparison to 
whole oats, including rolled oats, Mattilla et al (2005) reported that commercial oat bran products 
produced by conventional milling techniques could not be discriminated from oat flakes based on 
their avenanthramide content, which is in agreement with our results. It should also be noted that 
the contents of phenolic acids and avenanthamides in oat grain will vary with the crop genotype and 





         
         
Figure 2.3 Comparison of total, conjugated+free and bound phenolic acid levels(A), ferulic acid (B) 
and total  avenanthramides(C) between oat products including oatbran , oatbran concentrate, 
flaked oats, rolled oats and oatcake.  Data are expressed as the mean ± SEM. n indicates the 






























































































2.4.3 Compositions and Individual Contents of Phenolic Acids and Avenanthramides. 
 
The most abundant bound phenolic acids in all oat products analysed were ferulic acid, caffeic acid 
and sinapic acid (Table 2.3).  The oat bran concentrate had the highest concentrations of these 
compounds in the bound fraction (1153.6 μg/g, 72.2 μg/g and 80.3 μg/g, respectively) whereas 
oatcakes had the lowest (191.1±14.2 μg/g, 11.9±0.9 μg/g and 21.7±1.1 μg/g, respectively).  Ferulic 
acid, sinapic acid and avenanthramide B were the major components in the free + conjugated 
fractions of all products, with rolled oats having the highest concentration of ferulic acid (40.8±2.2 
μg/g), oat bran concentrate the highest concentration of sinapic acid (36.2 μg/g) and oat bran the 
highest concentration of avenanthramide B (27.6 ±4.6μg/g).  
The compositions of oat phenolics reported in other studies are largely in line with our findings, but 
there are few inconsistencies. Ferulic acid was reported to be the major component in both fractions 
by other workers (26, 295, 301). However, p-coumaric acid has also been reported to be highly 
abundant in other studies whereas the concentrations in our study were low (26, 302, 303). In 
agreement with Chen et al (2018), avenanthramide-B was the predominant avenanthramide. 
However, the concentrations of avenanthramide-C reported here are lower than in other studies (26, 
295). These inconsistencies may be due to differences in samples used (e.g. the samples analysed by 
Shewry et al (2008) contained the hulls which are rich in p-coumaric acid), the methods used for 






























Flaked                    
(10) 
Rolled                             
(11) 
4-hydroxybenzoic acid              
Free &Conjugated 7.1± 0.1 4.1± 0.2 9± 0.1 3.67± 0.2 3.3± 0 4.6± 0.2 3.6± 0.1 5.1± 0.1 4.3± 0.1 4± 0 6.3± 0.3 
Bound 15.5± 0.1 4.5± 0.2 8.5± 0.4 12.3± 0.7 10.7± 0.8 3.9± 0.4 3.2± 0 1.9± 0.2 3.5± 0.3 5.6± 0.2 3.9± 0.1 
Vanillic acid             
Free& Conjugated 5.5± 0 6.8± 0.2 10.7± 0.2 4± 0.6 4.5± 0.2 7.1± 0.4 9.5± 0.4 8.1± 0.2 6.3± 0.4 3.5± 0.1 9.6± 0.6 
Bound 12.9± 0.3 6.9± 0.1 12.2± 0.3 16.9± 1.2 15.3± 1.1 5.6± 0.4 6.5± 1.4 9.2± 1 6.5± 0.5 3.4± 0.2 5.8± 4.2 
Caffeic acid            
Free& Conjugated 8.8± 0.1 1.1± 0.2 1.9± 0.1 19.3± 0.9 19.4± 0.4 1.4± 0 1.5± 0 1.9± 0 27.1± 0.3 11.8± 0.3 1.8± 0.1 
Bound 72.7± 0.7 21.1± 0.9 33.2± 0.3 39± 3.8 32.5± 2.6 15.4± 0.4 17.9± 0.6 13.1± 0.8 15± 0.7 17± 0.1 17.4± 1.2 
4-Hydorxybenzaldeyhde            
Free& Conjugated 2.6± 0 2.8± 0.1 3.8± 0 2.3± 0.1 2.5± 0 2.7± 0 3.5± 0.1 3.1± 0 3± 0.2 2.3± 0.1 3.6± 0.1 
Bound 4.1± 0.1 2.2± 0.1 3.6± 0.2 4.5± 0.2 4.1± 0.2 1.6± 0 1.6± 0.1 1.4± 0 2.3± 0.1 1.6± 0 2.9± 0.1 
Syringic acid            
Free& Conjugated 10.7± 0.1 6.8± 0.9 13.1± 0.2 6.8± 0.3 8.6± 0.1 7.5± 0.5 8.5± 0.4 11.9± 0.1 10.7± 0.1 8.2± 0.3 10.2± 0.7 
Bound 18.2± 0.4 5.1± 0.7 15.2± 0.7 20.8± 2 21.1± 1.8 5± 0.6 6.4± 0.1 5.2± 0.1 7.2± 0.4 6.8± 0.2 6.7± 1 
P-coumaric acid            
Free& Conjugated 2.3± 0 6.3± 0.5 6.8± 0.5 2.1± 0.1 2.1± 0.1 5.5± 1.4 3.1± 0.2 4.3± 0.1 3.3± 0.1 2.3± 0.1 4.1± 0.3 
Bound 17.5± 1.3 49.4± 3.9 36.6± 32.7 5.7± 0.7 5.8± 0.9 6.8± 1.5 13.7± 5.2 3.5± 0.5 5.3± 0.3 2.7± 0.2 5.4± 0 
Vanillin            
Free& Conjugated 2.8± 0 nq 2± 0 2.7± 0 2.7± 0 nq nq nq 3.5± 0.2 2.7± 0 nq 
Bound 4.5± 0.4 3.3± 0.1 3.9± 1 3± 0.2 2.4± 0.1 2.3± 0.1 2.2± 0 2.3± 0.4 2.5± 0.1 2± 0.2 2.1± 0.1 
Ferulic acid            
Free& Conjugated 32.8± 0.1 32.8± 2.8 58.6± 0.1 24± 1.9 23.1± 0.9 34.1± 0.8 40.8± 2.6 38.1± 0.7 44.2± 1.2 20.2±0.8 50.6± 3.5 
Bound 1153.6± 5.8 247.2± 8.2  348.7±3.3 416.9±29.7 317.1±10.2 230.1±10.3 255.7±3.6  222.7±7.9 251.8±3.1 187.2±6.2 262.7±4.7 
Sinapic acid            
Free& Conjugated 36.2± 0.1 14.2± 0.8 32 ± 0.2 15.4± 1.1 17.1 ± 0.5 19.9 ± 0.4 21.7 ± 1.4 26.3± 0.4 25.9 ± 0.5 15.4±0.1 8.7 ± 0.6 
Bound 80.3± 1.3 20.6± 0.6 50.2± 0.4 74.1± 4.9 60± 3.3 23.3± 1.9 23.1± 0.7 19.5± 3.5 32.8± 1.6 20.5±1.2 25.7± 2.1 
Avenanthramide-C            
Free& Conjugated 11.5± 0.2 2.2± 0.2 1.6± 0.2 11.6± 3.2 12.4± 1.8 1± 0.1 1± 0.1 1.4± 0.1 18.1± 0.4 18.5±8.5 8.3± 0.4 
Avenanthramide-A            
Free& Conjugated 6.8± 0.2 8.5± 0.9 23.8± 4.7 12.9± 3.4 15.4± 2.4 14.9± 0.8 9.2± 1.3 15± 0.7 25.4± 0.8 18.7±4.9 6.7± 0.3 
Avenanthramide-B            
Free& Conjugated 12.3± 0.3 15.3± 1.5 31.5± 1.5 26.6± 4.7 36.8± 6.9 25.7± 1.9 13.3± 2.5 18.7± 0.8 38.3± 1.5 24.5±3.7 7.3± 1.2 
Total Free&Conjugated 139.3± 0.5 100.9±8.2 194.9± 2.6 129.5±14.1 146.8± 9.4 124.4± 5.2 115.7±8.3 134± 2.8 210± 1.9 130.3±15.8 117.2± 7.1 
Total Bound 1379.3± 6.9 359.5± 14.8 512.2± 36.9 592.4± 43 469± 19.1 294± 13.7 330.2±2.8 278.8± 13.6 326.9± 3.7 246.7± 8.1 332.5± 13.1 
Total Phenolics 1518.6±277.3 460.5± 58.3 707± 80.3 721.9±105 615.7± 72.2 418.2± 38.5 445.9±48.1 412.8± 35.8 536.9± 26.2 377± 27.2 449.7± 48.6 





Concentration (μg/g of 
FW)a 
Rolled 
       (12) 
Rolled        
        (13) 
Rolled     
      (14) 
Rolled     
      (15) 
Rolled      
       (16) 
Oatcake  
     (17) 
Oatcake    
      (18) 
Oatcake   
      (19) 
Oatcake   
      (20) 
Oatcake   
      (21) 
Oatcake 
     (22) 
4-hydroxybenzoic acid              
Free &Conjugated 3.1± 0.2 5± 0.1 5.4± 0.3 6± 0.3 5.2± 0.7 4.7± 0.1 4.5± 0.2 4.1± 0.1 3.9± 0.2 4.9± 0.5 3.5± 0 
Bound 2± 0.2 2.7± 0.5 3.5± 0.5 3.7± 0.1 3.9± 0.2 3± 0.1 3.7± 0.3 2.5± 0.2 2.8± 0.2 3.6± 0.3 2.6± 0.3 
Vanillic acid             
Free& Conjugated 8.6± 0.6 7.3± 0.2 7.2± 0.3 8.6± 0.3 7.8± 0.5 6.9± 0.1 8.3± 0.3 7.4± 0.2 7.5± 0.3 8.5± 0.6 5.6± 0 
Bound 8.9± 1 5.8± 0.8 8.1± 1.2 6.4± 0.5 6.7± 0.4 6.3± 0.1 5.6± 0.1 5.8± 0.4 4.9± 0.4 7.6± 0.7 5.1± 0.4 
Caffeic acid            
Free& Conjugated 1.4± 0 19.4± 0.6 1.5± 0 1.7± 0 1.8± 0.1 8.5± 0.3 11.5± 0.5 10± 0.3 12.8± 0.5 16± 1.2 12.8± 0.2 
Bound 14.7± 1 12.1± 2.4 15.1± 0.6 18.4± 0.4 16.4± 0.3 11± 0.4 11± 0.7 10.4± 0.6 11.2± 1.2 16.4± 1.3 11.2± 1.2 
4-Hydroxybenzaldeyhde            
Free& Conjugated 3.3± 0.1 2.9± 0 3± 0.1 3.4± 0.1 3.2± 0.1 2.9± 0 3.5± 0.1 3.3± 0 3.3± 0.1 3.5± 0.1 2.6± 0 
Bound 1.5± 0.1 2.2± 0.2 2.3± 0.1 2.4± 0.1 2.4± 0.1 2.1± 0 2.1± 0.1 2.2± 0.1 1.9± 0.1 2.6± 0.1 1.8± 0.1 
Syringic acid            
Free& Conjugated 7.7± 0.5 10.1± 0.4 8± 0.5 11± 0.7 9± 0.8 8.8± 0.2 11.8± 0.6 9.8± 0.2 12.2± 0.5 10.5± 0.8 7.3± 0.1 
Bound 5.3± 0.7 4.7± 0.7 6.2± 0.7 7.8± 0.3 6.5± 0.5 4.5± 0.2 7.2± 0.7 4.9± 0.1 4.8± 0.4 5.9± 0.7 4.5± 0.5 
P-coumaric acid            
Free& Conjugated 3.1± 0.3 3.5± 0.1 3.8± 0.1 4.4± 0.1 4.6± 0.2 2.9± 0.1 4.2± 0.2 2.9± 0.1 8.2± 0.3 4± 0.2 3.2± 0 
Bound 3.5± 0.7 2.6± 1.7 3.9± 0.4 5.5± 0.6 5.7± 0.7 4.1± 0.2 8.5± 0.3 3.3± 0.8 5.6± 1.1 7.4± 1.6 1.9± 0.4 
Vanillin            
Free& Conjugated 3.1± 0 4.6± 0.1 3.2± 0.1 3.5± 0.3 2.8± 0.4 4.3± 0.1 3.5± 0 3.2± 0.1 5.4± 0.1 3.6± 0.1 3.6± 0.1 
Bound 2± 0.1 1.4± 0.7 3.5± 0.9 2.2± 0.1 2.1± 0.1 1.7± 0 1.8± 0.1 1.6± 0.1 1.4± 0.1 2± 0.1 1.4± 0.1 
Ferulic acid            
Free& Conjugated 38± 1.9 37.3± 0.7 35.5± 2.6 41.1± 1.5 42.1± 3.3 32.4± 0.5 42.5± 1.9 34.8± 0.6 48.3± 1.5 40.1± 2.8 27.2± 0.5 
Bound 238.5± 22.3 175.7± 33.3 177.3±21.1 243± 3.3 218.2± 8.3 181.7± 3.5 214.3± 10.4 198.9± 25.6 152.5± 17.9 242.7± 8.5 156.9± 16.1 
Sinapic acid            
Free& Conjugated 17.4± 0.8 22.7± 0.5 17.9± 1.1 25.9± 1 15.2± 6.7 17.3± 0.4 22.9± 1 25.4± 1.3 21.9± 0.6 26.1± 2 16.1± 0 
Bound 24.2± 2.4 23± 3.5 22.8± 2.7 28.6± 1.1 25.1± 1.4 19.9± 0.5 23.3± 1.7 22.8± 1 18.9±2.2 25.9± 2.6 19.6± 1.1 
Avenanthramide-C            
Free& Conjugated 0.9± 0.1 9.4± 1.1 1.2± 0.1 1.5± 0.2 1.3± 0.3 5.8± 0.3 6.1± 0.9 10.7± 4.5 6.6± 0.4 23.3± 2.6 16.3± 4.2 
Avenanthramide-A            
Free& Conjugated 7.8± 0.5 8± 0.2 11.4± 0.4 12.6± 0.6 16.8± 1.7 5.3± 0.1 6.5± 0.6 10.7± 2.5 13.8± 1.4 18.9± 1.2 14.6± 4.4 
Avenanthramide-B            
Free& Conjugated 10.9± 0.6 12.3± 0.6 14± 0.9 19.1± 0.8 20.5± 3.1 11.5± 0.3 17.6± 1.8 23.7± 8.5 19.7± 2.2 26.5± 1.8 25± 10.4 
TotalFree&Conjugated 103.3± 3.8 142.4± 0.8 112.2± 5.7 138.8± 4.1 130.2± 15.9 111.2± 1.9 142.9± 7.8 140.4± 7.7 163.5± 6.7 185.8± 13 137.7± 18.4 
Total Bound 300.8± 28 270± 43.6 242.6±24.2 318± 5.8 287± 7.4 234.2± 4.5 277.5± 14.1 252.3± 28.5 203.9± 23.5 314.1± 14 205.1± 20.2 
Total Phenolics 404.1± 45.9 412.4± 27.7 354.8±31.2 456.8±40.2 417.2±35.9 345.4± 27.6 420.4± 30.9 392.7± 28.3 367.4± 14.2 499.9± 29.9 342.8± 19.4 
    a Values are expressed as means± SEMs (n=3). nq=not quantified. 
Table 2.4(continued) Composition and contents of phenolic acids and avenanthramides in individual oat products. 
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2.4.4 Multivariate Analysis of Phenolic Acid and Avenanthramide Composition. 
 
Principal component analyses (PCA) of the phenolics present in the bound and free + conjugated 
fractions are shown in Figures 2.4 and 2.5, respectively. Panels A, C and E are PCA score plots which 
show the grouping of oat products based on their overall phenolic acid compositions while panels B, 
D and F are the corresponding loading plots which show the individual phenolic acids responsible for 
the separation. For the bound fraction, all three score plots showed clear clustering of the rolled 
oats, oatcake and flaked oats in the centre of the plot, and separation of the single oat concentrate. 
Comparison of the score and loadings plots indicates that the latter separation mainly results from 
the very high content of ferulic acid (see also Table 2.3). The four bran samples do not cluster in the 
score plots, but pairs of samples group together in all three plots and these pairs can be 
distinguished by their high and low contents of p-coumaric acid as seen in loading plots.  
By contrast, the free + conjugated fraction does not show any clear clustering (Figure 2.5). However, 
a grouping of a flaked and oatbran sample is observed in score plots, which could be explained, by 
the avenanthramide A and B content of these products seen in the loading plots. Because bound 
phenolic acids represent about 80% of the total, PCA analysis of the total fraction was essentially 
similar to that of the bound fraction (not shown).  
The greater variation in the contents of free + conjugated components compared to bound, both 
within and between the types of sample, may reflect wider variation in the composition of the raw 
material. For example, studies of wheat have shown that the growing conditions have a much 
greater impact on the content and composition of free and conjugated phenolic acids than on bound 
phenolic acids, with heritabilities calculated as 6.4%, 9.8% and 28.5%, respectively (304). The 







Figure 2.4 Principal component analysis of phenolic acid content of different oat products, bound 
fraction. A, C, E represents score plots which show the grouping of oat products based on their 
overall phenolic acid compositions and B, D, F represents corresponding loading plot of each score 
plot which show the individual phenolic acids responsible for the separation. Letter codes seen in 
loading plots respresent phenolic acids: A 4-Hydroxybenzoic acid, B Caffeic acid, C Vanillic acid, D 4-








Figure 2.5 Principal component analysis of different oat products, free+conjugated fraction. A, C, E 
represents score plots which show the grouping of oat products based on their overall phenolic 
acid compositions and B, D, F represents corresponding loading plot of each score plot which show 
the individual phenolic acids responsible for the separation.Letter codes seen in loading plots 
respresent phenolic acids: A 4-Hydroxybenzoic acid, B Caffeic acid, C Vanillic acid, D 4-
Hydroxybenzaldehyde, E Syringic acid, F p-Coumaric acid, G Vanillin, H Ferulic acid, I Sinapic acid, J 








2.4.5 Potential Health Benefits of Phenolic Acids and Ferulic Acid and Intake from 
Commercial Oat Products 
 
It has been  suggested that the consumption of dietary phenolics  may reduce the risk of  chronic 
diseases such as CVD, diabetes, cancer and neurodegenerative diseases (305). The average daily 
intake of phenolic acids in Europe is 605 mg/day, with wholegrains contributing about 5.5% of the 
total,  while the ferulic acid intake is 38 mg/day (306). Previous studies carried out in humans 
reported significant improvements in vascular function following a single dose of phenolics in 375 ml 
of champagne (61.63 mg/l) and chlorogenic acids (89 and 310 mg/g) in 3.6 g of coffee (30, 31). Our 
study showed that the consumption of a 40g portion of commercial oat products provides from 15.8 
to 25.1 mg total phenolics (from 9.9 to 19.3 mg bound and from 4.9 to 5.7 mg free+ conjugated 
phenolics) including 1.1 - 2 mg avenanthramides and 16.7 mg of total phenolics (15.2 mg of bound 
and 1.5 mg of free + conjugated phenolics) including 1.2 mg of avenanthramides in a 11g portion of 
oat bran concentrate. 
Ferulic acid is the major component present in all commercial oat products and our analyses show 
that between 9.1 and 14.7 mg of total ferulic acid (from 7.6 to 13.3 mg bound and from 1.4 and 1.6 
mg free + conjugated fraction) can be provided in a 40g portion of commercial oat products and 13.1 
mg of total ferulic acid ( 12.7 mg of  bound and 1.3 mg free + conjugated fraction) can be provided in 
a 11g portion of oat bran concentrate. A number of studies have reported therapeutic effects of 
ferulic acid against diseases related to oxidative stress, with an increasing body of evidence for a role 
in the prevention or management of chronic disease (307). For example, randomized controlled trials 
to determine the effect of coffee and cranberries on vascular health showed improvements on 
outcomes such as flow mediated dilatation (FMD) and these findings were correlated with the 
presence of ferulic acid metabolites (30, 283). We would therefore predict that the consumption of 
oat phenolics, and ferulic acid in particular, may have similar health benefits.   
In conclusion, this study showed that wholegrain oat products can provide a source of phenolic 
compounds. The total concentrations of phenolic acids and avenanthramides ranged from 
394.8±24.2 μg/g to 1518.6 μg/g, with oat bran concentrate having the highest content and the other 
wholegrain products and oat bran containing lower but similar amounts. However, the total contents 
of free + conjugated phenolic acids and avenanthramides were similar in all products. This is 
important as this fraction should be more bioaccessible and absorbed in the small intestine, whereas 
the bound fraction will only be released, at least partially, during fermentation in the colon.  
Consequently, similar potential health benefits could be delivered by all products analysed.  
These data could be useful to inform studies of human dietary intake and interventions with oat 
products to better understand the health benefits of oats. 
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 Acute consumption of phenolic acid and avenanthramide 
rich oats improves microvascular function in pre- and stage 1 
















Background : Wholegrain consumption is linked to lower risk of cardiovascular disease. Randomized 
controlled trials (RCTs) have established that the consumption of wholegrain oats lowers blood 
cholesterol and improves post-prandial glycaemic control. While some of these benefits are 
mediated by β-glucan fibre, the extent to which oat phenolic acids and avenanthramides are involved 
is unknown.  
Objective: We examined the potential acute effects of phenolic-rich oat intake on vascular function 
and assessed potential underlying mechanisms by the assessment of NADPH oxidase activity and 
circulating metabolites in men with prehypertension and stage 1 hypertension relative to a fibre and 
macronutrient-matched control.  
Design: A 2-arm, randomised, crossover, single-blind clinical trial was conducted with 16 male 
participants.  Volunteers received either 90.2g oats containing 5mg avenanthramides and 45mg 
phenolic acids or a macro- and micronutrient matched rice control containing 4.2mg phenolic acids 
and 0 mg avananthramides.  Vascular function was measured at baseline and post-treatment (i.e. 1, 
2, 4, 6 and 24 h). Serum and urine phenolic acids, avenanthramides and their metabolites were 
analysed by (UPLC)-MS/MS. 
Results: Flow mediated dilation was not significantly different between treatments, although there 
was a small improvement in FMD at 1h (0.21 ± 0.7%; p =0.5) and 24h (0.28 ± 0.4%, p=0.1), following 
oat intake relative to the control.  Significant increases in both endothelium dependent (iAUC, 
p=0.04, and AUC p=0.02) and independent ( iAUC, p=0.007) microvascular function were observed 
after consumption of the oat intervention relative to control at 2h. We observed large variations in 
phenolic acid absorption between participant’s, 2h after intake, and changes in microvascular 
function were positively correlated with the blood concentration of eight phenolic acid metabolites 
at 2h, notably ferulic acid 4-O-β-D-glucuronide, ferulic acid-4-O sulfate and p-coumaric acid.  No 
significant changes in blood pressure or NADPH oxidase activity were observed between treatments.  
Conclusion: This study indicates that consumption of oats delivering 50mg of phenolic acids and 
avenanthramides acutely improves microvascular function in pre- and stage 1 hypertensive men 
which appears to be partly mediated by the appearance and concentration of specific phenolic acid 










Epidemiological studies suggest that regular consumption of whole grains is associated with a lower 
risk of  cardiovascular disease (CVD), the meta-analyses of multiple human intervention studies are 
also providing strong evidence that regular oat (Avena sativa) intake lowers blood cholesterol, 
improves insulin sensitivity and post-prandial glycaemic control (58, 271, 275, 281). A health claim 
approved by European Food Safety and Authority (EFSA) states the daily consumption of 3 g of oat  
soluble fibre , β-glucans  can lower blood cholesterol and improves heart health (20, 58, 271). Studies 
have also suggest oats may reduce blood pressure, but the results are mixed and evidence is not 
conclusive (25, 308).  While oats contain a range of macro and micronutrients such as proteins, 
unsaturated fatty acids, dietary fibre in the form of arabinoxylan and β-glucan, vitamins and minerals 
(282), they are also a rich source of phenolic acids, particularly ferulic acid and structurally similar 
avenanthramides (21). These compounds present in oats in three forms: as soluble free acids, as 
soluble conjugates esterified to low molecular weight components such as sugars, and as insoluble 
bound acids esterified to high molecular weight  components, notably cell wall polysaccharides and 
lignin(289).  
Existing scientific data from epidemiological and human intervention studies suggest that polyphenol-
rich foods have a range of beneficial effects on cardiovascular health (23, 309-311). The ability of such 
foods to attenuate the incidence of CVD risk factors such as endothelial dysfunction, hypertension, 
abnormal lipid profile and platelet activation in at-risk individuals has been the main focus(23, 311). 
Their potential to influence endothelial nitric oxide synthase (eNOS) and increase nitric oxide (NO) 
bioavailability is likely to underpin the actions at the physiological level(187).  NO is the most potent 
vasodilator in the body and any defect in its synthesis or activity may lead to endothelial dysfunction, 
signalled by impaired endothelium-dependent vasodilation.  Impaired endothelium-dependent 
vasodilation is the common cause of vascular dysfunction, one of the most important, early markers 
of atherosclerosis (38).  Studies suggest that phenolic acids and avenanthramides may contribute to 
the beneficial effects of a diet rich in oats and clinical trials have shown protective effects of circulating 
phenolic acids against CVD (29, 30, 283, 312). For example, an acute intervention with cranberry juice, 
increased flow mediated dilation (FMD) in healthy men and this finding was correlated in time with 
changes in plasma cranberry phenolic acids such as ferulic and caffeic acid sulfates (283). Similarly, an 
acute investigation of blueberry flavonoids in healthy men has shown to increase the FMD response 
and correlated well with plasma metabolites such as vanillic acid, benzoic acid, hippuric acid, 
hydroxyhippuric acid and homovanillic acid(29). Additionally, those small phenolic compounds 
including hippuric, vanillic, and homovanillic acids predicted declines in NAPDH oxidase activity in 
neutrophils which might also increase NO bioavailability and improve endothelial function(28, 29). 
Coffee chlorogenic acids have also improved FMD acutely and appeared in the circulation as phenolic 
acids such as ferulic acid sulfate and isoferulic acid glucuronide which were linked with the vascular 
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improvement(30).  Avenanthramides in oats have also been shown to be bioavailable in humans and 
may exert anti-inflammatory and vasodilatory effects to protect against CVD (27, 165, 313-315). In 
order to exert health benefits, free and conjugated phenolic acids and avenanthramides and/or their 
methylated, sulfated or glucuronidated metabolites are likely to be absorbed early in the small 
intestine whereas bound phenolic acids might reach to colon where they may be subject to extensive 
catabolism by colonic microbiota and converted into bioactive phenolic acids and/or metabolites (149, 
152, 316).  
There is limited evidence with respect to the potential of oat intake on the vascular system and a 
reduction in CVD risk (277, 278, 280). However, these studies do not differentiating the impact of 
phenolic acids and avenanthramides from fibre and the contribution of these compounds to health 
benefits of oats is still not known. Considering the evidence from RCTs examining other phenolic 
containing foods and stating that small phenolic acids are bioavailable and have the potential to 
mediate vasodilatory effects, we tested the acute intake of phenolic rich oat based breakfast or a 
soluble fibre matched cream of rice to investigate potential vascular benefits of oat phenolic acids and 
avenanthramides in pre-and stage 1 hypertensive men. Vascular function was mainly assessed by FMD 
and LDI and correlated with serum phenolic acid and avenanthramides and/or their metabolites to 


















All phenolic acid aglycones were obtained from Sigma-Aldrich (Gillingham, UK) except 4‐
hydroxyhippuric acid and 3‐hydroxyhippuric acid which were purchased from Enamine (Kiev, Ukraine). 
All the phenolic acid metabolites (glucuronides and sulfates) were obtained from Toronto Research 
Chemicals Inc (Toronto, Canada). All solvents were LC MS grade and were obtained from either Sigma-
Aldrich or Fisher Scientific (Loughborough, UK). 
3.3.2 Study Intervention  
 
The study intervention materials comprised of 90.2 g oats (67.7 g CDC dancer: oat flakes and 22.5 g 
oat bran concentrate) (Pepsico, Barrington, USA) and 420 ml water to make oat based breakfast.  This 
provided 45.0 mg of phenolic acids and 5.0 mg avenanthramides (total 50.0 mg).  The control 
intervention consisted of cream of rice (B&G Foods, Inc.), dry skimmed milk, sunflower oil, cellulose 
powder and pectin powder containing 3.97 mg phenolic acids and was closely matched to oat porridge 
for macro- , micronutrient content and soluble fibre content (Table 3.1).  β- glucan, betaine, choline 
and trigonelline were present at levels too low to induce any observable vascular effects (317-319).Oat 
interventions were measured by using HPLC as previously described in Chapter 2  (320) for phenolic 
acid and avenanthramide content and analysed for macro and micronutrients by Campden BRI 
(Gloucestershire, UK ).  All dry materials were frozen until needed to prevent degradation. Both 












Table 3.1  Nutritional analysis of the study intervention materials 
 
 
  Oat intervention 
1
 Control intervention 
2
 
Energy (kcal) 322.0 322.0 
Fat (g) 6.3 6.3 
Saturated fatty acids 1.2 0.9 
Monounsaturated fatty acids 2.2 1.3 
Polyunsaturated fatty acids 2.6 3.9 
Carbohydrate (g) 47.1 47.1 
Fibre (g) 12.1 12.1 
Protein (g) 13.3 13.3 
Total Phenolics (mg) 50.0 3.97 
Conjugated and Free Fraction (mg) 11.96 0.89 
4-Hydroxybenzoic acid 0.85 0.14 
Vanillic acid 0.63 0 
4-Hydroxybenzaldehyde 0.25 0 
Syringic acid 1.38 0 
p-Coumaric acid 0.33 0.11 
Vanillin 0.27 0 
Ferulic acid 3.40 0.37 
Sinapic acid 3.30 0.27 
Caffeic acid 1.55 0 
Bound Fraction  (mg) 33.04 3.08 
4-Hydroxybenzoic acid 0.79 0 
Vanillic acid 0.53 0.05 
4-Hydroxybenzaldehyde 0.21 0 
Syringic acid 0.85 0 
p-Coumaric acid 0.09 0.19 
Vanillin 0.23 0 
Ferulic acid 24.93 2.74 
Sinapic acid 3.16 0.11 
Caffeic acid 2.24 0 
Total Phenolic acids  (mg) 45.02 3.97 
Aveanthramide A 1.31 0 
Avenanthramide B 2.93 0 
Avenanthramide C 0.77 0 
Total Avenanthramides (mg) 5.01 0 
 
1
 67.7g CDC dancer oat flakes, 22.5g oat bran concentrate and 420ml water containing 5.6g 
of β -glucan as soluble fibre. 
2
39.4g cream of rice, 6.1g sunflower oil, 29.5g skimmed milk, 5.6g pectin powder as soluble 




Pre- and stage 1 hypertensive (SBP 120-159 mmHg and DBP 75-99 mm Hg) male subjects (n 16) aged 
between 25 and 75 years, were recruited by study researchers from the University of Reading and 
surrounding area( Figure 3.1). Individuals with hypertension (SBP/DBP ≥ 160/100 mm Hg), body mass 
index (BMI) > 35, abnormal biochemical and haematological results as assessed at health screening, 
past or existing medical history of vascular disease, diabetes, hepatic, renal, gastrointestinal, 
haematological, neurological, thyroidal disease or cancer, current smoker or ex-smoker, allergic to 
whole grains and taking any dietary supplements, lipid lowering, antihypertensive, vasoactive, anti-
inflammatory, antibiotic or antidepressant medication, having flu vaccination or antibiotics within 3 
months of trial start, having vigorous exercise (more than five times x 30 min per week), or consuming 
alcohol ≥21 units /week were excluded from the study. Health was ascertained by medical 
questionnaire and normal concentrations of plasma glucose, total cholesterol, triglyceride, creatinine, 
bilirubin, uric acid and liver enzymes (aspartate aminotransferase, alanine aminotransferase and g-
glutamyl transferase) levels and normal haemoglobin concentration, packed cell volume and leukocyte 
counts at the screening visit. 
 
 





3.3.4 Study Design 
 
A two-arm, single-blinded (researcher blinded; participant not), placebo-controlled randomised 
crossover intervention trial was conducted where volunteers were asked to consume an 
avenanthramide and phenolic acids-rich porridge or an energy and fibre matched control intervention. 
FMD, blood pressure and blood samples were taken before (baseline) and at 1, 2, 4, 6 and 24h post-
acute consumption of each treatment on two different study visit days by 2 weeks washout. LDI and 
NADPH oxidase activity were measured at 0, 2, 4, 6 and 24h and urine samples were collected at 0, 3, 
7 and 24h post consumption (Figure 3.2).  
FMD of the brachial artery to assess vascular endothelial function was the primary endpoint of the 
study (detailed below). Secondary endpoints included LDI, blood pressure and measuring NADPH 
oxidase activity (all detailed below). Tertiary endpoint was quantification of serum and urine oat 
avenanthramides and phenolic acids to investigate the link between primary and secondary endpoints. 
Before vascular assessments, body composition and weight were measured, using a Body Composition 
Analyser (Tanita BC-418MA, TANITA, UK). Standing height was measured with a stadiometer (Medical 
scales and measuring system, Seca Lt., UK).  Body Mass Index was calculated as weight/height2 (kg/m2). 
Office blood pressure was also measured three times after 15 mins of rest in a temperature-controlled 
(22 ± 1 °C), dimmed room using an automated clinical digital sphygmomanometer (Omron M6 
Intelli-Sense Comfort; model HEM-72211-E8, Omron Healthcare Co.) with appropriately sized cuff in 
the subject’s non-dominant arm. 
Volunteers were asked, in preparation for the visit, to fast overnight (i.e. no intake of food or drink for 
10 h before the visit, except water) and to restrict their diet, which included refraining from consuming 
polyphenol-rich foods such as oats , oat products, wholegrains, fruits, vegetables, spices, chocolate, 
nuts, seeds, coffee, tea, plant-based milk, caffeinated drinks, wine, beer and spirits, moderate the 
consumption of alcohol to ≤ 21 units /week and to refrain in exercise 48 h prior to the study visits. 
Compliance to the diet and lifestyle restrictions was verified with 24h-dietary recall sheet. 
After completion of baseline measurements, an independent researcher who previously generated 
computer based paper list of random number sequences and volunteer allocation also provided the 
intervention products, which the volunteers were asked to consume completely over a 15min period. 
To minimise bias study researchers were ‘blinded’ to the food (intervention) products.  Between the 6 
h and 24 h assessments, volunteers were allowed to leave the facility.  To ensure the volunteers’ well-
being, they were encouraged to keep well-hydrated during the study by drinking water ad libitum, 
while otherwise consuming just the meals as provided. Meals comprised a cheese sandwich consumed 
5 h after the study intervention, and a main meal of pasta bake and crème brûlée which volunteers 
took home and consumed 8 h after the study intervention.  Water intake throughout the day was 
recorded.   
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The study was conducted according to the guidelines laid down in the Declaration of Helsinki and all 
procedures involving human subjects were approved by the University of Reading Research Ethics 
Committee (ref. 15/60). The study was registered with the National Institutes of Health (NIH) 
randomised trial records held on the NIH ClinicalTrials.gov website (ref.NCT02731755) Written 









































Clinical measures: flow mediated dilation (FMD), laser Doppler iontophoresis 


































3.3.5 Plasma- urine collection and biochemical analysis 
 
Blood samples were collected in lithium-heparin and serum separating tubes (Greiner Bio-one, USA). 
A qualified research nurse was involved in the study to cannulate the volunteers for the blood 
collection. Thereafter, the lithium-heparin tubes were used immediately for NADPH oxidase activity 
analysis whereas serum separating tubes were allowed to coagulate for 30-60 minutes before 
centrifugation for 15 min at 1700 X g at 4 ˚C, in order to separate the serum. Collected urine was kept 
on ice packs, the excretion volume measured and was spun for 15 min at 1700 X g at 4 ˚C. All samples 
were frozen at-80˚C until analysis. 
All biochemical parameters to determine baseline characteristics of volunteers were assayed by ILAB 
600 chemistry analyser (Instrumentation Laboratory, Warrington, Cheshire, UK) using enzyme based 
colorimetric tests supplied by Instrumentation Laboratory. The following parameters were determined 
in all samples: total cholesterol, triglycerides and glucose. 
 
3.3.6 Flow-Mediated Dilatation (FMD) 
 
Endothelial-dependent vasodilation was measured according to standard guidelines by using an ATL 
Ultrasound HDI5000 system (ATL Ultrasound) together with a semiautomated computerized analysis 
system (Brachial Analyzer; Medical Imaging Applications-llc)(321). The procedure used an ECG-gated 
trigger and the image-grabbing software (MIA-llc) to collect images at 0.25 frames/s.  After a supine 
rest lasting 15 minutes in a quiet, temperature-controlled room, the brachial artery 2-5 cm above the 
antecubital fossa was imaged.  Doppler-derived velocity of arterial blood flow was measured for 1 min 
prior to commencing each FMD measurement.  Baseline images were taken for 1 min, after which the 
BP cuff inflates to 220 mm Hg to occlude blood flow. After 5 min of occlusion, the pressure was rapidly 
released, allowing reactive hyperaemia to occur; measurement collection continued for 5 min post 
release. Image files were analysed by a single researcher who was blinded to the measurement details, 
and peak diameter was defined as the largest diameter obtained after the occlusion is released.  FMD 
response calculated using change from baseline to peak diameter divided by baseline and reported as 
a percentage value (% FMD).  Velocity analysis performed over a minimum of 5 cardiac cycles and 





3.3.7 Laser Doppler Iontophoresis (LDI) 
 
LDI is a validated  technique used as a surrogate marker of microvascular function (322, 323). It is non-
invasive and quantifies vasodilator responses in the forearm after stimulation with 1 % acetylcholine 
(Ach) (endothelium dependent vasodilatation) and 1 % sodium nitroprusside (SNP) (endothelial-
independent vasodilatation), delivered transdermally using iontophoresis. In all subjects, 
measurements were carried out in a temperature-controlled room (22 ± 1 °C) in a supine position, 
after calibration of the machine.  Two chambers were set 1 cm apart on the alcohol cleansed volar face 
of the subject's forearm, using double-sided adhesive rings.  Chambers were filled with acetylcholine 
chloride (2·5 ml; 1 % (w/v) in 0·5 % (w/v) NaCl solution; Sigma Aldrich, Poole, Dorset, UK) and sodium 
nitroprusside (2·5 ml; 1 % (w/v) in 0·5 % (w/v) NaCl solution; Sigma Aldrich).The Ach and SNP were 
transferred trans-dermally via the anodal and cathodal chambers, iontophoresis was achieved using 
an electrical current which incremental increase from 0 to 20 µA.  Microvascular function was 
measured by LDI2-IR Laser Doppler imager (Moor Instruments Ltd, Axminster, Devon, UK). Scans with 
5 μA incremental increases in current from 0 to 20 μA and skin perfusion, or erythrocyte flux were 
measured to determine the elasticity of the small peripheral blood vessels at the lower arm.  A median 
flux against time graph was plotted and the area under the curve calculated to analyse the recorded 
scans by moorLDI V5.3 Software (324).  
 
3.3.8 NADPH Oxidase Activity 
 
Inhibitory action of oat phenolic acids on neutrophil NADPH oxidase activity in whole blood samples 
was measured with a flow cytometry assay modified from previous studies (29, 325). Whole blood 
aliquots (50μL) were incubated in the presence of phorbol myristate aceate (PMA) (50 ng/mL) 
(Sigma) for 45 min at 37°C to stimulate superoxide production by neutrophils. The un-stimulated and 
blank tubes were also incubated likewise, but in the presence of phosphate buffered saline (Sigma) 
instead of PMA. Dihydrorhodamine 123 (30μg/mL) (Sigma) was added together with antibody CD16 
(20μl) (Becton Dickson) and incubated for 5 min at 37°C. Red blood cells were lysed with 1 mL of 
fluorescent activated cell sorting lysing solution (Becton Dickson) and incubated for 20 min in the 
dark at room temperature. The cells were then centrifuged at 400 x g for 5 min at 4 °C. 900μL of 
supernatants were discarded from the centrifuged tubes and cells resuspended with 1 mL of 2% fetal 
calf serum (Sigma) and 0.2% ethylenediaminetetraacetic acid (EDTA) in PBS. The tubes were then 
centrifuged again at 400 x g for 5 min at 4°C. A final 950μL of supernatants were discarded from the 
tubes, and 400μL of paraformaldehyde (1%) (Sigma) added to fix the cells. Data were analysed by the 
Accuri C6 flow cytometer (Becton Dickson), and median intensity of fluorescence was used to 
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evaluate the fluorescence of each sample tube. The NADPH oxidase activity was calculated as a 
percentage difference between values obtained in PMA activated and resting cells.  
 
 
3.3.9 Solid Phase Extraction 
 
Phenolic acids were extracted from serum and urine using a validated method as previously 
described (See Appendix) (152, 326). Briefly, 1 mL of urine or serum was spiked with an internal 
standard (i.e. 3,5‐dichloro‐4‐hydroxybenzoic acid) and subsequently extracted using SPE cartridges 
(Strata‐X columns 500 mg 6mL−1; Phenomenex). Cartridges were washed with 12 mL of 0.1/99.9 v/v 
hydrochloric acid/water, dried for 30 min under vacuum, soaked in 0.1/99.9 v/v hydrochloric 
acid/methanol for 10 min, and eluted into glass vials with 7 mL 0.1/99.9 v/v hydrochloric 
acid/methanol. Samples were evaporated to complete dryness under speedvac centrifugal 
evaporator (SavantTM SPD131DDA SpeedVacTM Concentrator, ThermoFisher Scientific) at room 
temperature. The dried samples were resuspended in 250μL of mobile phase (0.1/5/94.9, v/v/v, 
formic acid/methanol/water) by 30 s vortexing, 15min ultrasound sonicating, and 1 h shaking.  Serum 
samples were filtered with using Acrodisc syringe filter with 13 mm, 0.45μm pore size (Sigma-
Aldrich). Samples were stored at −80 °C until analysis.  
 
3.3.10 UPLC-MS/MS Analysis 
 
Serum and urinary analysis of phenolic acid metabolites were performed with UPLC–ESI–MS/MS 
system consisted of an Aquity UPLC Hclass (Waters) coupled to a Xevo TQ‐S micro ESI mass 
spectrometer (Waters) operated using MassLynx software (V4.1, Waters Inc, USA) as previously 
described, using a validated method (152). Briefly, compound separation was achieved using an 
Aquity UPLC HSS T3 1.8μm column (2.1 × 100 mm) attached to a Van guard precolumn of the same 
material and pore size, maintained at 45 °C with a flow of 0.65 mL min−1 and a sample injection 
volume of 2 μL. The mobile phase consisted of 0.1/99.9 v/v formic acid/water (A) and 0.1/99.9 v/v 
formic acid/acetonitrile (B); and a mobile phase gradient consisting of: 1% B at 0 min, 1% B at 1 min, 
30 % B at 10 min, 95 % B at 12 min, 95% B at 13 min, 1% B at 13.10 min, 1% B at 16 min. The 
scheduled multiple reaction monitoring (sMRM) method which  was  previously developed by syringe 
infusion of 34 analytical standards was further optimized with the addition of commercially available  
phase II metabolites  and phenolic acids to determine sMRM transitions, optimal sMRM modes (i.e. 
negative or positive) and collision energies(Table 3.2). 
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Regarding to compounds without analytical standards (i.e benzoic acid-O-sulfate, vanillin/4-
hydroxyphenyl acetic acid-O-sulfate, hippuric acid-O-sulfate, caffeic acid-O-sulfate, syringaldehyde-O-
sulfate, syringic acid-O-sulfate, sinapic acid-O-sulfate, dihydro avenanthramide C and dihydro 
avenanthramide B), retention times and sMRM transitions were tentatively identified by injecting a 
pooled extract of urine and serum (i.e. using samples collected after oat intervention intake from all 
participants and during all post‐intake time intervals, n = 14 and n=13, respectively). sMRM 
transitions were taken from the literature(152, 313). Collision energies were optimized to a limited 
extent by injecting the pooled extract three times and the best one was selected for each sMRM 
transition. In the final sMRM, a total of 50 potential compounds were targeted. Identification of the 
phenolic acids  for which standards were available was based on their retention times and the major 
sMRM ion transitions of the standards, while the tentative identification of phenolic metabolites for 
which analytical standards were not available was based on more than one sMRM ion transitions and 
the strongest one was selected for quantification (Table 3.2). 
Quantification was established using the most intense sMRM transition and calibration curves of 
analytical standards. Where pure standards were not available, quantification was conducted relative 
to standard curves of compounds with similar structures (e.g. the calibration curve of isoferulic acid‐
3‐O‐sulfate was used to quantify all tentatively identified sulfate metabolites). The LOD and LOQ 
were established for each compound as the concentrations of peaks with S/N of 3 and 10, 

















Table 3.2 LC-MS/MS identification of phenolics and metabolites in serum and urine  after the 
consumption of oat intervention1 
All compounds were analysed at negative ion mode except vanillic acid, isovanillic acid and 4-methoxy benzoic 
acid. 













3,4-dihydroxybenzoic acid-3-O-sulfate 3.33 232.2 233.2/153 13 0.91 3.03 0.999968 
3,5-dihydroxybenzoic acid 3-O-sulfate 2.75 232.2 233.2/153 15 0.93 3.10 0.999925 
4-methoxybenzoic acid 8.52 152.15 153.3/109 13 1021.90 3406.33 0.999829 
Caffeic acid 3-B-D-glucuronide 4.93 356.28 355.2/179 20 2.17 7.23 0.999991 
Caffeic acid 4-B-D-glucuronide 4.93 356.28 355.2/179 17 0.41 1.38 0.998562 
Dihydro caffeic acid 3-O-sulfate 4.95 260.25 261.24/181 15 30.16 100.52 0.999664 
Ferulic acid-4-0-sulfate 6.06 274,243 273.25/193 13 600.58 2001.92 0.999731 
Ferulic acid-4-B-D-G-glucuronide 5.5 370.31 369.27/193 14 2.26 7.54 0.999731 
Isoferulic acid-3-O-sulfate 6.57 272.25 273.25/193 15 397.46 1324.87 0.999702 
Dihydro isoferulic acid 3-O-B-D-glucuronide 6.52 372.32 371.3/113 16 61.33 204.44 0.999789 
Dihydroferulic acid 4-O-sulfate 5.81 276,263 275.27/195 15 0.27 0.90 0.999558 
Homovanillic acid sulfate 4.95 262,232 261.24/181 13 3.41 11.36 0.999930 
p-coumaric acid 4-O-B-D-glucuronide 4.95 338.27 339.28/113 13 0.27 0.91 0.998376 
p-coumaric acid 4-O-sulfate 5.68 244.22 243.24/163 11 0.20 0.65 0.999806 
p-salicyclic acid-4-sulfate 3.72 216.2 217.2/137 16 1.18 3.95 0.999946 
Salicylic acid-B-D-O-glucuronide 5.28 314.24 313.1/175 8 25.88 86.26 0.999991 
Dihydro avenanthramide-B 10.31 331 330/386.1 15 0.11 0.38 NA 
Dihydro avenanthramide-C 14.14 317 316/272.02 10 0.12 0.40 NA 
4-hydroxybenzoic acid 4.85 138,122 137.2/93 13 119.52 398.40 0.999969 
Vanillin 6.19 152.15 151.15/136 12 130.34 434.45 0.999324 
4-hydroxyphenylacetic acid 4.77 152.15 151.15/107 10 104.86 349.55 0.999910 
2,4-dihydroxy benzoic acid 4.75 154.12 153/109 11 191.93 639.77 0.999946 
3,5-dihydroxy benzoic acid 3.72 154.12 153/109 13 291.62 972.06 0.999786 
2,5-dihydroxy benzoic acid 4.76 154.12 153/109 11 282.60 942.00 0.999946 
p-Coumaric acid 6.95 164.05 163/119 13 231.72 772.40 0.999993 
Isovanillic acid 6.11 168 169/93 12 962.11 3207.04 0.999704 
Vanillic acid 5.8 168.14 169/93 12 1962.22 6540.73 0.999865 
Hippuric acid 5.53 179.17 178.17/134 11 52.09 173.62 0.998406 
Caffeic acid 5.87 180.16 179.2/135 15 314.54 1048.48 0.999746 
Homovanillic acid 5.86 182.17 181.17/137 10 153.65 512.17 0.993707 
Syringaldehyde 7.35 182.17 181.2/151 18 0.06 0.19 0.999816 
Isoferulic acid 7.95 194.18 193.2/178 10 0.16 0.55 0.999150 
Ferulic acid 7.64 194.18 193/178 10 0.15 0.50 0.999491 
4-hydroxyhippuric acid 4.34 195.17 194/100 11 2.22 7.38 0.999698 
3-hydroxyhippuric acid 4.6 195.17 194/100 11 50.45 168.18 0.999979 
2-hydroxyhippuric acid 6.8 195.17 194/100 11 61.36 204.54 0.999997 
Hydroferulic acid 7.26 196.21 195/136 15 0.29 0.95 0.999703 
Syringic acid 6.36 198.17 197/182 13 0.20 0.68 0.998364 
Sinapic acid 7.86 224.21 223.2/208 12 0.14 0.48 0.999562 
Avenanthramide A 9.86 299.28 298/254 17 0.48 1.60 0.999833 
Avenanthramide C 8.99 315.28 314.3/178 16 18.73 62.45 0.999871 
Avenanthramide B 10.32 329.31 328.3/268 10 0.05 0.16 0.998983 
Dihydroferulic acid-glucuronide 5.88 372.33 371/113 17 179.71 599.03 0.999464 
Benzoic acid-O-sulfate 3.65 216 217/137**/173* 11 226.19 753.98 NA 
4-hydroxyphenylacetic acid-O-sulfate 6.86 231 231/151**/136* 17 237.44 791.47 NA 
Hippuric acid-O-sulfate 4.24 259 258/178**/134* 17 45.11 150.37 NA 
Caffeic acid-O-sulfate 5.68 258.2 259/179**/135* 17 71.26 237.54 NA 
Syringaldehyde-O-sulfate 4.6 262 261/166**/181* 23 0.29 0.98 NA 
Syringic acid-O-sulfate 4.6 278 277/197**/182* 11 0.09 0.30 NA 
Sinapic acid-O-sulfate 5.96 304 303/233**/208* 11 63.01 210.05 NA 
 
 
1Abbreviations: RT, retention time; MW, molecular weight; sMRM, scheduled multiple reaction monitoring; m/z, signal to noise 
ratio, CE, collision energy; LOD, limit of detection (signal/noise=3); LOQ, limit of quantification (signal/noise=10), R2, linear 
regression coefficient of standard curve; NA, no analytical standard was available to make a standard curve.** ion transitions 





3.3.11 Sample Size and Statistical Analysis 
 
The power calculation was performed for the primary endpoint (FMD of the brachial artery) to 
determine the minimum number of participants required for the study.  The sample size was calculated 
using the variance of repeated measurements in the control group and on the control data; standard 
deviation within the participants was 0.35 % (based on previous studies performed in our group).  A 
sample size of 13 subjects yielded 80 % power at P ≤ 0.05 significance level to determine a significant 
within-subject difference between treatments of at least 0.3 % of FMD.  However, in order to provide 
power to use the secondary measures and achieve significant within-subject differences, we aimed for 
15 participants. 
To identify differences in study endpoints (i.e. markers of CVD risk and phenolic acid and 
avenanthramide levels in biological samples) between assessment time points and interventions, a 
linear mixed model was used to analyse with baseline values as a covariate and time, intervention and 
interaction between time and intervention as fixed effects. When model showed a significant 
difference, pairwise comparisons between interventions and time points was performed using post 
hoc analysis with Bonferroni adjustment. Significance was defined as p < 0.05, with p-values 
represented in the figures as *p < 0.05, **p < 0.01, ***p < 0.001. Correlation analysis between 
increased levels of phenolic metabolites in biological samples and beneficially affected markers of CVD 
risk was performed using Spearman’s correlation coefficient. All statistical analyses were carried out 
by using SAS version 9.4 software package (SAS institute) and GraphPad Prism version 7 software 





3.4.1 Baseline characteristics  
 
The baseline characteristics of pre and stage 1 hypertensive male subjects were largely within normal 
limits, with only BMI being slightly higher than the normal range (n =16) (Table 3.3). All interventions 














 Table 3.3 Baseline characteristics of the study participants at screening. 
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3.4.2 Vascular and microvascular function 
 
There was no significant changes in endothelium-dependent brachial artery vasodilation, measured by 
FMD following consumption of the oat or control interventions, although a small increase towards an 
improvement in the FMD response at 1h (0.21 %; p =0.5) and 24h (0.28 %; p = 0.1) following oat 
consumption relative to the control (Table 3.4 and Figure 3.3).  In contrast, endothelium-dependent 
microvascular function, assessed by LDI, significantly increased at 2h following oat intake (AUC: 1678.3 
PU/h-1; iAUC: 681.8 PU/h-1) relative to control (1358.3 PU/h-1; iAUC: 463.7 PU/h-1) (Figure 3.4 A; AUC: 
p = 0.02; iAUC: p= 0.04). Similarly, endothelium-independent microvascular reactivity significantly 
increased at 2h following oat intake (709.43 PU/h-1) relative to control ( iAUC: 502.88 PU/h-1) (Figure 
3.4 B; p=0.007).  No other vascular variables (peripheral SBP, DBP, pulse pressure (PP) or heart rate 
(HR)) were significantly altered following oat intervention relative to control  (Table 3.4), despite  the 
presence of significant effects of time (P = 0.006, P=0.02 and P < .0001 respectively). The reduction in 
NADPH oxidase activity, measured at 2h post intervention showed greater reduction following oat 






          Figure 3.3 Changes in % FMD after consumption of oats and control. 
Oats (45.0 mg of phenolic acids and 5.0 mg avenanthramides) (dotted lines) and control (black lines). Values 
are expressed as means ± SEMs, n=14 from Table 3.4 at baseline (BL) and 1, 2, 4, 6 and 24 h post intake. 
Data were analysed using linear mixed model of time, treatment as two factors and followed by Bonferroni 










 Figure 3.4 Changes in microvascular function measured with LDI after consumption of oats and 
control 
 
Oats (45.0 mg of phenolic acids and 5.0 mg avenanthramides) (dotted line) and control (black line) : (A) endothelium-
dependent vasodilation (Ach) represented by incremental area under the curve (Ach iAUC) (perfusion units per hour, 
PU/h-1) and (B) endothelium-independent vasodilation (SNP), represented by incremental area under the curve (SNP 
iAUC) (perfusion units per hour, PU/h-1).Values are expressed as means ± SEMs from Table 3.4 at baseline (BL) and 2, 
4, 6 and 24 h post intake. A linear mixed model analysis with time and treatment as two factors was performed, n = 13, 
followed by Bonferroni post hoc test where there was a significance of interaction of both factors. Significant 





A - oats 
B – control 
  
Baseline 
Time after intervention (Hours) p-values 
1 2 4 6 24 Treat-
ment Time 
Treat-
ment × Time 
FMD (%) 3.3 A 4.2 ± 0.6  4.4 ± 0.7  4.0 ± 0.7  5.0 ± 0.8  3.4 ± 0.6  4.4 ± 0.4  0.7 0.2 0.5 
B 4.7 ± 0.5  3.9 ± 0.9  3.4 ± 0.5  5.5 ± 0.8  4.4 ± 0.8  3.6 ± 0.7  
Ach-iAUC 3.4 
(A) 




0.04 B 465.0 ± 70.6  - 463.7 ± 55.4  702.6 ± 30.4  649.7 ± 51.5 315.0 ± 45.5  
SNP-iAUC 3.4  
(B) 
A 661.1 ± 52.4  - 709.4 ± 68.4  555.2 ± 85.8  552.1 ± 60.2  622.4 ± 50.6 
0.1 0.7 **   
0.0074 B 757.1 ± 43.2  - 502.9 ± 25.6  623.3 ± 57.0 681.1 ± 63.7  513.7 ± 35.8  
Ach-AUC NS A 1593.9 ± 198.9  - 1678.3 ± 140.6  1676.4 ± 234.0  1627.1 ± 182.3  1560.9 ± 161.3  0.9 0.3 * 
 0.0277 B 1534.1 ± 144.2  - 1358.3 ± 116.9  1621.8 ± 167.5  1757.7 ± 140.8  1701.6 ± 190.9  
SNP-AUC NS A 1897.9 ± 159.4  - 1693.6 ± 131.1  1406.2 ± 146.7  1796.0 ± 184.8  1889.9 ± 221.8  0.9 0.1 0.2 
B 2163.4 ± 209.1  - 1694.8 ± 144.7  1723.9 ± 140.1  1760.1 ± 220.5  1903.8 ± 158.3  
SBP NS A 125.4 ± 2.3  125.8 ± 2.2  125.7 ± 2.1  124.4 ± 2.3  126.4 ± 1.6  122.4 ± 1.5  0.9 *** 
0.0064 0.6 B 124.4 ± 2.3  124.9 ± 1.8  123.9 ± 1.8  122.3 ± 1.3  127.1 ± 1.9  123.8 ± 1.8  
DBP NS A 73.9 ± 1.5  72.8 ± 1.5  73.3 ± 1.5  74 ± 1.7  71.4 ± 1.5  72.5 ± 1.7  0.7 * 
0.0213 0.9 B 74.2 ± 1. 3  72.6 ± 1.3  73.5 ± 1.4  74.6 ± 1.6  72.8 ± 1.4  73.6 ± 1.9  
HR NS A 64.7 ± 2.8  63.9 ± 2.5  62.1 ± 2.4  61.3 ± 2.1  62.7 ± 1.7  64.2 ± 2.6  0.9 *** 




NS A 55.7±7.0 - 43.6±5.0 59.8±7.0 56.6±7.0 63.6±6.0 
0.5 ** 
0.0118 0.7 




Flow-mediated dilatation (FMD) (n=14);endothelial-dependent vasodilation(Ach) (n=13) and endothelial-independent vasodilation (SNP) (n=13), expressed as both 
area under curve (AUC) and incremental area under curve (iAUC); systolic blood pressure (n=14) (SBP); diastolic blood pressure (n=14)  (DBP); heart rate (HR);NADPH 
oxidase activity (n=13). 2 volunteers were excluded from all analyses as the values for vascular measurements were not physiologically relevant for some outcomes 
or volunteers were found to be not fasted.  
a
 Values are presented as mean measurement ± SEM, for units see the text. Data were analysed with linear mixed model 
of treatment, time, and time × treatment interaction, - *p<0.05 , **p<0.01 and *** p<0.001. Post hoc analyses were conducted as Bonferroni’s comparison test). 
NS;not shown, -; measurement is not taken at the timepoint. 
Table 3.4 Measurements of Cardiovascular Risk Biomarkers. 




3.4.3 Serum and urinary phenolic metabolites  
 
A total of 45 phenolic acids, avenanthramides and their metabolites were identified and quantified in 
serum (Table 3.5). Examples of main phenolic acids and avenanthramides  found in oats or their 
metabolites mainly increasing at 2h following to consumption of oats relative to control are shown in 
Figure 3.5 B, 3.5 C and 3.5 D. Major metabolites were hippuric acid, 4-hydroxyphenylacetic acid, 
syringaldehyde, isoferulic acid , benzoic acid-O-sulfate, 4-hydroxy benzoic acid and p-coumaric acid 
glucuronide contributing 10%, 6.9%, 6.3%, 5.7%, 5.6%, 4.5% and 3.2% respectively to the total serum 
concentration (Figure 3.5 A and Table 3.5). An increase in total phenolic acid and avenanthramide 
metabolites 2h following intake of oat, and to a lesser extent the control was observed (Figure 3.5 A). 
However, although the levels of phenolic metabolites peaked at 2h post consumption of oats, the 
majority of these increases failed to achieve significance due to a large variation in blood levels 
between study participants.  3,5-dihydroxybenzoic acid-O-sulfate and p-coumaric acid were the only 
metabolites to exhibit significant increases following oat intake relative to control (time and 
intervention interaction: p=0.0008 and p=0.02, respectively) (Table 3.5). Urinary analysis showed the 
presence of total 47 phenolic acids and avenanthramides (Table 3.6). Examples of main phenolic acids 
and avenanthramides  present in oats or their metabolites increased following to the consumption of 
oats relative to control are shown in Figure 3.6 B, 3.6 C and 3.6 D. Among 47 compounds quantified in 
the urine, ferulic acid-4-O-sulfate( p=0.03), 2,4 dihydroxy benzoic acid (p=0.02), 2,5 dihydroxy benzoic 
acid (p=0.01), isovanillic acid (p= 0.02), hippuric acid (p=0.01) , 2 hydroxy hippuric acid (p=0.01), 3 
hydroxy hippuric acid (p=0.05), avenanthramide A (p=0.01) and sinapic acid-O- sulfate (p=0.02) 
increased significantly relative to the control (Table 3.6). Predominant metabolites in urine were 
hippuric acid, benzoic acid-O-sulfate, syringaldehyde-O-sulfate, ferulic acid-4-O-sulfate, 4-
hydroxyhippuric acid and p-salicyclic acid-4-sulfate contributing 28.2%, 10.9%, 9.2%, 8.93%, 6.27% and 
5.6% at 3h and 27.3%, 11.7%, 8.6%, 7.7%, 6% and 6.2%, at 24 h respectively, to the total phenolic 
concentration (Table 3.6). Total concentration of phenolic compounds quantified in urine after the 
consumption oats elevated at 3h (9.72 ±1.3 mg oats vs 7.72 ±1.1 mg control) and also slightly increased 
at 24h (5.13± 0.71 mg  oats vs 4.12± 0.57 mg control) (Figure 3.6 A and Table 3.6), although these 
increases did not achieve significance relative to control intake. Excretion of some of the individual 
phenolics such as ferulic acid, ferulic-4-O-sulfate acid , ferulic acid glucuronide and avenanthramide- A 
also peaked at 7h as well as 3h after the consumption of oats (Figure 3.6 B and 3.6 C, Table 3.6). 
Phenolics had a urinary recovery of 5.7% after intake of 50 mg of phenolic acids and avenanthramides. 
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Figure 3.5 Serum concentrations of phenolic acids, aveanthramides and their metabolites following 
























































































Serum concentration(μM) measured with UPLC-MS/MS, total (A) and main phenolics (B; ferulic acid, C; ferulic 
acid glucuronide and D avenanthramide B) quantified after the consumption oats (filled bars) and control 
(dotted bars).Values are expressed as means ± SEMs (n=13). 3 volunteers were excluded from analyses as the 
values for vascular measurements were not physiologically relevant for some outcomes or volunteers were 
found to be not fasted. Significance was tested with using a linear mixed model with time and treatment as 




Figure 3.6  Urine concentrations of phenolic acids, aveanthramides and their metabolites following 






Hourly urinary excretion of urinary metabolites (mg) measured with UPLC-MS/MS, total (A) and main 
phenolics (B; ferulic acid glucuronide, C; ferulic acid sulfate and D isoferulic acid) quantified after the 
consumption oats (filled bars) and control (dotted bars).Values are expressed as means ± SEMs (n=13). 3 
volunteers were excluded from analyses as the values for vascular measurements were not physiologically 
relevant for some outcomes or volunteers were found to be not fasted.  C.24= cumulative excretion in 24 
hours. Significance was tested with using a linear mixed model with time and treatment as two factors and 
when the interaction was significant , post hoc analyses with Bonferroni corrections were performed.  
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Table 3.5  Concentrations of individual compounds in serum following the intake of oats and control. Phenolic acids, avenanthramides and their metabolites detected in serum(nM) 
at specified timepoints. Values are expressed as means ± SEMs. Significance was tested with using a linear mixed model with Bonferroni corrections (n=13). 
    Phenolic acid concentration (nM) Total amount (nM) p-value 
  






Benzoic acid aglycones     





± 11.7 19.1 ± 10.3 156.4 ± 150.9 24.1 ± 10.8 4.6 ± 4.6 16.3 ± 11.0 
238 ± 
24 
. . . 
  Control 21.9 
± 11.6 20.5 
± 11.1 7.2 
± 7.2 45.8 
± 18.9 8.1 
± 8.1 9.4 
± 6.4 113 ± 


















. . . 
  Control 17.4 
± 11.8 43.7 
± 31.3 7.7 





± 18.8 174 ± 


















. . . 
  Control 0.0 ± 0.0 14.9 ± 14.9 0.0 ± 0.0 23.3 ± 15.8 15.9 ± 15.9 0.0 ± 0.0 54 ± 
4    
4-hydroxy benzoic acid Oats 641.9 ± 104.7 626.6 ± 130.8 742.5 ± 236.5 526.4 ± 103.4 551.7 ± 131.5 592.2 ± 190.7 3681 ± 
31 0.2187 0.5601 0.4005 
  Control 507.6 ± 63.8 575.5 ± 88.1 526.5 ± 78.7 564.8 ± 83.6 555.9 ± 80.3 493.7 ± 64.2 3224 ± 
13    
syringic acid Oats 28.4 ± 19.5 25.4 ± 23.5 440.9 ± 436.4 11.8 ± 6.7 1.9 ± 0.9 29.7 ± 20.3 538 ± 
70 0.8127 0.5049 0.6595 
  Control 8.0 ± 4.0 26.3 ± 18.8 6.3 ± 5.3 29.0 ± 15.7 17.1 ± 16.4 27.8 ± 22.5 114 ± 
4       
syringaldehyde Oats 90.5 ± 58.5 65.6 ± 65.6 1032.9 ± 997.4 27.7 ± 15.9 1.6 ± 1.6 78.6 ± 46.9 1297 ± 
164 0.9015 0.3328 0.445 
  Control 42.6 ± 20.3 93.1 ± 59.5 14.0 ± 13.1 144.8 ± 76.3 100.5 ± 69.5 63.5 ± 38.5 458 ± 
19    
vanillic acid Oats 22.8 ± 16.0 16.8 ± 16.8 204.9 ± 194.7 0.0 ± 0.0 1342.7 ± 302.4 19.8 ± 13.4 1607 ± 
217 . 0.57 0.9382 
  Control 34.8 ± 18.7 36.7 ± 19.9 11.9 ± 11.9 35.9 ± 19.9 1047.1 ± 232.8 18.4 ± 12.4 1185 ± 
170    
isovanillic acid Oats 16.3 ± 11.5 11.1 ± 11.1 181.8 ± 178.5 5.7 ± 3.9 0.0 ± 0.0 12.7 ± 8.6 228 ± 
29 . . . 
  Control 6.8 ± 4.6 14.9 ± 11.0 0.0 ± 0.0 21.7 ± 11.6 12.0 ± 9.5 11.2 ± 6.1 66 ± 
3    
Benzoic acid sulfates                                           
        
benzoic acid-O-sulfate Oats 165.6 ± 80.6 75.6 ± 52.2 925.8 ± 869.0 67.6 ± 26.9 23.9 ± 17.7 82.8 ± 46.6 1341 ± 
142 0.3255 0.4708 0.6391 
  Control 84.5 ± 33.1 107.1 ± 58.6 29.4 ± 17.3 145.5 ± 66.5 80.9 ± 45.7 88.9 ± 39.2 536 ± 


















0.2098 <.0001 0.7519 
  Control 67.3 ± 27.4 36.6 ± 14.2 43.2 ± 15.4 34.2 ± 15.0 1563.0 ± 267.8 31.6 ± 10.5 1776 ± 


















0.1858 0.0002 0.0008 
  Control 5.9 ± 4.0 6.1 ± 5.3 0.5 ± 0.4 4.8 ± 2.5 2.5 ± 1.5 7.4 ± 5.4 27 ± 
1    
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p-salicyclic acid-4-sulfate Oats 76.6 
± 34.7 39.4 
± 22.8 448.1 
± 420.7 30.5 
± 9.7 12.3 
± 6.8 38.1 
± 20.0 645 ± 
69 0.2515 0.4868 0.2746 
  Control 39.0 
± 13.7 56.2 
± 25.6 17.4 
± 7.2 58.0 
± 25.4 47.4 
± 23.9 44.9 
± 18.4 263 ± 
6    
syringaldehyde-O-sulfate Oats 127.3 
± 56.1 163.1 ± 76.5 270.1 ± 142.3 98.7 ± 49.3 112.4 ± 54.0 79.7 ± 22.2 851 ± 
28 0.7496 0.5057 0.3257 
  Control 210.9 
± 94.3 262.8 
± 112.2 91.7 
± 27.4 105.3 
± 56.9 173.7 
± 62.1 147.5 
± 43.9 992 ± 





    
  
    
  
    
  
    
  
    
  
    
    
  
      
salicylic acid-B-D-O-
glucuronide 
Oats 36.7 ± 18.4 10.9 ± 10.9 294.7 ± 276.8 17.2 ± 9.9 4.6 ± 4.6 15.0 ± 10.4 
379 ± 
47 
0.9256 0.9821 0.977 
  Control 18.5 
± 9.8 33.0 
± 18.2 0.0 
± 0.0 20.3 
± 10.8 25.8 
± 17.8 22.4 
± 10.4 120 ± 





    
  
          
  
    
  
    
  
    
    
  
      
4-hydroxyphenylacetic 
acid 




1137.4 ± 591.1 345.9 ± 174.7 353.6 ± 242.3 321.9 ± 161.2 
3390 ± 
136 
0.0201 0.0821 0.0966 
  Control 280.3 ± 191.7 872.3 ± 316.1 729.2 ± 259.0 1066.3 ± 300.1 745.7 ± 394.2 314.5 ± 220.8 4008 ± 





    
  
    
  
    
  
    
  
    
  
    
    
  
      
4-hydroxyphenylacetic 
acid-O-sulfate 
Oats 58.4 ± 58.4 0.0 ± 0.0 59.3 ± 41.1 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
118 ± 
12 
. . . 
  Control 25.0 ± 25.0 42.8 ± 42.8 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 68 ± 
8    
homovanillic acid sulfate Oats 45.6 ± 24.2 27.6 ± 19.6 371.5 ± 360.4 15.7 ± 5.8 5.3 ± 2.3 32.7 ± 17.1 498 ± 
58 0.3621 0.7655 0.48 
  Control 25.5 ± 8.6 37.8 ± 21.9 13.3 ± 5.4 47.3 ± 21.4 26.0 ± 11.7 33.6 ± 15.4 184 ± 
5    
Hippuric acid aglycones                                           
        
hippuric acid Oats 1914.8 ± 732.0 1284.9 ± 631.2 1643.5 ± 687.7 1025.4 ± 333.2 1290.8 ± 441.7 1029.9 ± 209.8 8189 ± 
144 0.8684 0.6569 0.4595 
  Control 1177.6 ± 253.0 1392.3 ± 305.8 870.2 ± 105.5 985.7 ± 207.5 1129.6 ± 191.0 1085.6 ± 248.6 6641 ± 
73    
2-hydroxyhippuric acid Oats 64.7 ± 27.4 37.2 ± 19.0 283.5 ± 260.9 20.5 ± 8.1 27.4 ± 6.0 65.8 ± 28.7 499 ± 
41 0.1847 0.3636 0.3303 
  Control 45.0 ± 13.9 52.8 ± 21.9 20.8 ± 6.2 52.2 ± 21.6 37.7 ± 17.2 30.3 ± 13.2 239 ± 
5    
3-hydroxyhippuric acid Oats 76.1 ± 36.0 51.1 ± 28.4 200.6 ± 162.6 41.2 ± 19.3 13.7 ± 6.6 37.6 ± 20.6 420 ± 
27 0.2604 0.2229 0.4806 
  Control 45.7 ± 18.7 57.3 ± 24.5 27.8 ± 17.4 48.0 ± 23.0 43.3 ± 18.6 40.3 ± 21.4 262 ± 
4    
4-hydroxyhippuric acid Oats 149.1 ± 44.9 118.1 ± 34.7 364.9 ± 266.6 83.6 ± 22.5 90.3 ± 18.1 105.6 ± 27.3 912 ± 
44 0.2752 0.6256 0.413 
  Control 119.1 ± 28.7 127.3 ± 28.7 62.8 ± 20.8 111.4 ± 35.7 79.8 ± 20.6 138.7 ± 29.2 639 ± 
12    
Hippuric acid sulfates                                           
        
hippuric acid-O-sulfate Oats 25.6 ± 11.6 18.7 ± 9.8 18.8 ± 10.8 16.7 ± 8.3 18.4 ± 9.3 18.4 ± 8.6 117 ± 
1 0.279 0.3542 0.576 
  Control 14.3 
± 5.3 15.8 
± 6.1 11.6 
± 5.3 10.8 
± 4.7 13.3 
± 5.3 9.7 
± 4.5 76 ± 
1    
Cinnamic acid aglycones     
      
      
      
      
      
        
        
caffeic acid Oats 76.8 
± 18.7 51.7 ± 23.6 85.2 ± 30.6 37.2 ± 17.0 64.2 ± 24.2 39.5 ± 11.2 355 ± 
8 0.4437 0.4099 0.2222 
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  Control 64.7 
± 14.5 67.5 
± 18.4 46.1 
± 17.5 55.2 
± 18.8 65.4 
± 
18.8 74.4 
± 15.6 373 ± 
4    
ferulic acid Oats 10.6 
± 7.8 33.9 
± 17.5 153.5 
± 145.2 8.5 
± 2.7 3.5 
± 1.7 11.8 
± 5.6 222 ± 
24 0.7408 0.8658 0.9615 
  Control 6.4 
± 2.4 9.0 
± 6.4 10.3 
± 9.3 11.6 
± 6.0 13.9 
± 7.9 6.9 
± 3.3 58 ± 
1 . . . 
isoferulic acid Oats 89.1 
± 56.5 135.3 
± 71.3 942.3 
± 892.3 36.4 
± 19.8 5.6 
± 3.4 57.5 
± 29.8 1266 ± 
147 0.4831 0.4781 0.6443 
  Control 37.2 
± 16.7 52.4 
± 32.9 50.2 
± 38.2 104.5 
± 57.8 74.7 
± 38.3 51.0 
± 24.7 370 ± 
10    
hydroferulic acid Oats 16.2 
± 7.7 8.2 
± 4.7 118.1 
± 112.1 6.0 
± 2.6 23.5 
± 6.4 22.5 
± 7.7 195 ± 
17 0.2045 0.6931 0.4281 
  Control 16.7 
± 4.2 18.3 
± 6.5 7.1 





± 5.2 86 ± 
2    
p-coumaric acid Oats 12.5 
± 7.6 8.2 
± 8.2 152.3 
± 150.1 5.5 
± 3.0 0.0 
± 0.0 9.1 
± 6.2 188 ± 
24 . 0.0364 0.0225 
  Control 6.9 
± 3.0 10.5 
± 7.7 0.0 
± 0.0 20.6 
± 8.7 9.8 ± 7.8 10.9 
± 5.3 59 ± 
3    
sinapic acid Oats 0.0 
± 0.0 0.0 
± 0.0 2.1 ± 2.1 0.0 
± 0.0 0.0 
± 0.0 0.0 
± 0.0 2 ± 
0 . . . 
  Control 0.0 ± 0.0 0.1 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 0.2 ± 0.2 0.1 ± 0.1 1 ± 
0    
Cinnamic acid sulfates                                           
        
caffeic acid-O-sulfate Oats 0.9 ± 0.9 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 1.5 ± 1.5 0.0 ± 0.0 2 ± 
0 . . . 
  Control 1.0 ± 1.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 1 ± 
0    




± 20.9 22.9 ± 19.4 345.2 ± 337.4 12.1 ± 5.9 2.2 ± 1.7 25.6 ± 14.9 
440 ± 
55 
0.6429 0.2535 0.6156 
  Control 17.9 ± 8.2 30.8 ± 20.0 8.0 ± 4.3 41.3 ± 21.1 26.4 ± 16.3 19.2 ± 9.6 143 ± 
5    
ferulic acid-4-0-sulfate Oats 30.6 ± 22.1 18.9 ± 18.9 302.8 ± 294.6 0.0 ± 0.0 0.0 ± 0.0 19.0 ± 12.9 371 ± 
48 . . . 
  Control 8.1 ± 8.1 26.4 ± 18.2 0.0 ± 0.0 35.4 ± 19.3 14.7 ± 14.7 11.6 ± 11.6 96 ± 
















0.3658 0.5162 0.4652 
  Control 21.2 ± 8.2 34.0 ± 18.9 12.5 ± 4.1 37.3 ± 18.9 25.6 ± 16.0 29.4 ± 13.5 160 ± 


















. . . 
  Control 7.6 ± 7.6 27.8 ± 21.8 0.0 ± 0.0 40.0 ± 22.9 22.2 ± 22.2 14.5 ± 14.5 112 ± 
6    
p-coumaric acid 4-O-
sulfate 
Oats 21.8 ± 14.3 
14.2 









0.8279 0.1715 0.4567 
  Control 10.5 ± 5.0 22.3 ± 15.4 4.7 ± 3.3 26.9 ± 14.1 19.2 ± 13.7 16.1 ± 10.6 100 ± 
3    
sinapic acid-O-sulfate Oats 2.3 ± 2.3 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 2 ± 
0 . . . 
  Control 2.0 ± 2.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 2 ± 





                                  
    
  
      
caffeic acid 3-B-D-
glucuronide 
Oats 15.5 ± 10.0 10.7 ± 10.6 219.0 ± 212.0 8.0 ± 4.3 1.9 ± 1.8 12.7 ± 7.3 
268 ± 
35 
0.6472 0.4077 0.445 
  Control 5.2 
± 2.5 13.6 
± 9.1 2.0 
± 1.4 16.9 
± 9.6 14.2 
± 9.7 12.5 
± 7.2 64 ± 



















0.2518 0.2663 0.7215 
  Control 20.1 ± 9.2 34.7 ± 21.4 9.4 ± 4.5 47.4 ± 24.7 30.1 ± 18.0 30.8 ± 17.7 172 ± 


















0.8554 0.2649 0.5289 
  Control 35.9 
± 19.9 59.8 
± 34.9 16.8 
± 11.5 52.8 
± 28.6 33.9 
± 27.3 57.9 
± 26.9 257 ± 


















0.7414 0.7044 0.8318 
  Control 12.7 ± 5.4 18.1 ± 10.9 6.0 ± 1.8 33.9 ± 18.1 23.4 ± 13.8 16.2 ± 8.9 110 ± 
4    

















0.6649 0.2796 0.6295 
-glucuronide Control 23.8 ± 10.7 41.0 ± 29.6 4.4 ± 4.4 52.3 ± 28.4 28.5 ± 22.4 36.5 ± 19.5 187 ± 


















0.0798 0.5243 0.7962 
  Control 523.4 
± 70.8 604.5 
± 72.1 599.4 
± 76.2 581.5 
± 73.1 640.7 
± 94.5 578.1 
± 71.5 3528 ± 
16    
Benzaldehydes                                           
        
vanillin Oats 25.3 ± 17.2 12.2 ± 12.2 262.7 ± 262.7 0.0 ± 0.0 14.7 ± 14.7 11.5 ± 11.5 326 ± 
42 . . . 
  Control 0.0 ± 0.0 27.8 ± 19.2 0.0 ± 0.0 12.3 ± 12.3 17.6 ± 17.6 0.0 ± 0.0 58 ± 
5    
Avenanthramides     
      
            
      
              
        
Avenanthramide A Oats 27.5 ± 16.8 22.0 ± 19.1 400.1 ± 391.4 14.3 ± 6.1 2.2 ± 1.3 27.7 ± 16.1 494 ± 
64 0.8099 0.4344 0.4499 
  Control 15.1 ± 6.8 27.7 ± 19.7 5.6 ± 4.4 38.1 ± 20.6 23.2 ± 15.6 22.9 ± 13.7 133 ± 
5    
Avenanthramide B Oats 18.1 ± 11.5 10.7 ± 10.7 247.8 ± 244.3 7.0 ± 3.9 0.2 ± 0.2 16.3 ± 9.8 300 ± 
40 0.5522 0.35 0.7614 
  Control 6.1 ± 2.8 20.7 ± 14.0 3.4 ± 2.7 26.5 ± 14.3 15.4 ± 11.6 14.4 ± 8.9 87 ± 
4    
Avenanthramide C Oats 2.1 ± 2.1 1.7 ± 1.7 47.2 ± 47.2 1.2 ± 0.9 0.0 ± 0.0 3.6 ± 2.5 56 ± 
8 . . . 
  Control 0.5 ± 0.5 4.2 ± 3.5 0.7 ± 0.7 5.4 ± 2.9 3.0 ± 2.5 1.4 ± 1.0 15 ± 
1    
Total concentration                                            
        
  Oats 5685.0 ± 47.6 4300.0 ± 34.1 16416.6 ± 48.7 3217.6 ± 28.0 6518.2 ± 58.6 3737.5 ± 28.6 39875.0 ± 
211.7 0.5228 0.4112 0.8523 
  Control 3640.7 
± 30.1 5077.0 ± 38.7 3278.1 ± 29.4 4866.4 ± 34.5 6859.2 ± 50.9 3670.6 ± 28.7 27392.0 
± 
192.9       
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Table 3.6  Concentrations of individual compounds in urine following the intake of oats and control.Urinary excretion rate per hour of phenolic acids and avenanthramides (µg). 
Values are expressed as means ± SEMs.Significance was tested with using a linear mixed model with Bonferroni corrections (n=14). 
    Phenolic acid concentration (µg) Total amount (µg)  p-value 






Benzoic acid aglycones                                       
2,4-dihydroxy benzoic acid Oats 7.1 ± 1.8 45.8 ± 13.3 19.0 ± 5.9 17.7 ± 3.3 89.6 ± 8.2 0.60 0.01 0.02 
  Control 7.5 ± 1.9 34.4 ± 8.8 24.4 ± 5.4 11.4 ± 2.7 77.7 ± 6.2       
2,5-dihydroxy benzoic acid Oats 10.6 ± 2.0 95.8 ± 14.1 79.5 ± 12.8 125.4 ± 19.7 311.2 ± 24.3 0.01 0.07 0.01 
  Control 10.6 ± 1.3 67.0 ± 12.6 46.7 ± 7.8 33.2 ± 5.1 157.5 ± 11.9       
3,5-dihydroxy benzoic acid Oats 7.6 ± 1.6 41.8 ± 7.4 19.7 ± 3.9 21.3 ± 4.4 90.3 ± 7.1 0.39 0.01 0.06 
  Control 6.9 ± 1.0 37.0 ± 4.7 27.6 ± 5.0 18.9 ± 3.6 90.4 ± 6.4       
4-hydroxy benzoic acid Oats 18.3 ± 3.7 103.2 ± 15.0 53.8 ± 8.4 47.0 ± 9.6 222.3 ± 17.6 0.38 0.0002 0.23 
  Control 13.1 ± 1.7 105.7 ± 18.3 76.5 ± 10.7 39.3 ± 7.2 234.6 ± 20.4       
syringic acid Oats 1.4 ± 1.0 26.7 ± 6.6 12.2 ± 3.1 12.0 ± 2.3 52.5 ± 5.2 0.0009 0.1111 0.1035 
  Control 1.0 ± 0.3 3.1 ± 1.8 2.2 ± 1.1 5.2 ± 1.2 11.5 ± 0.9       
syringaldehyde Oats 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0.1 ± 0.0 . . . 
  Control 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0.1 ± 0.0       
vanillic acid Oats 5.6 ± 2.5 83.0 ± 28.0 111.3 ± 33.6 50.9 ± 12.8 250.8 ± 22.7 0.05 0.01 0.23 
  Control 4.6 ± 1.2 66.3 ± 31.9 213.5 ± 57.4 52.2 ± 14.7 336.7 ± 45.1       
isovanillic acid Oats 0.1 ± 0.1 1.4 ± 0.8 2.6 ± 1.2 1.8 ± 0.4 6.0 ± 0.5 0.1563 0.0096 0.029 
  Control 0.1 ± 0 1.4 ± 1.1 3.2 ± 1.3 1.6 ± 0.4 6.2 ± 0.6       
Benzoic acid sulfates                                       
benzoic acid-O-sulfate Oats 181.3 ± 35.9 1063.0 ± 194.8 659.2 ± 134.4 681.7 ± 145.7 2585.2 ± 180.6 0.51 0.0015 0.28 
  Control 190.2 ± 32.6 917.6 ± 181.8 736.3 ± 155.3 570.4 ± 114.1 2414.5 ± 155.0       
3,4-dihydroxybenzoic acid-3-O-
sulfate 






± 91.2 509.2 ± 41.4 0.36 0.96 0.81 
  Control 19.4 ± 7.8 185.6 ± 106.1 146.8 ± 111.3 204.5 ± 120.6 556.2 ± 41.7       
3,5-dihydroxybenzoic acid-3-O-
sulfate 






± 7.2 153.3 ± 11.3 0.79 0.0003 
0.1216 
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  Control 14.9 ± 2.5 64.3 ± 10.3 45.2 ± 7.3 36.2 ± 7.0 160.6 ± 10.2       
p-salicyclic acid-4-sulfate Oats 95.6 ± 19.2 546.5 ± 101.2 340.8 ± 69.2 379.0 ± 79.2 1361.9 ± 93.0 0.29 0.0011 0.34 
  Control 94.7 ± 15.0 470.8 ± 95.2 375.3 ± 77.3 295.7 ± 60.9 1236.5 ± 79.9       
syringic acid-O-sulfate Oats 0 ± 0 0.1 ± 0.1 0.1 ± 0.1 0.3 ± 0.1 0.5 ± 0.1 . . . 
  Control 0 ± 0 0.1 ± 0.1 0 ± 0 0.7 ± 0.2 0.8 ± 0.2       
syringaldehyde-O-sulfate Oats 119.6 ± 21.2 902.2 ± 113.0 459.0 ± 85.3 414.8 ± 55.5 1895.5 ± 161.4 0.6547 0.0001 0.34 
  Control 164.8 ± 35.7 836.4 ± 114.0 593.6 ± 90.9 362.2 ± 54.0 1957.0 ± 145.1       
Benzoic acid glucuronides                                       
salicylic acid-B-D-O-glucuronide Oats 10.4 ± 5.7 18.4 ± 8.2 7.6 ± 2.6 10.2 ± 2.9 46.5 ± 2.3 0.39 0.16 0.23 
  Control 1.7 ± 0.5 12.4 ± 2.8 6.7 ± 1.4 3.7 ± 1.3 24.6 ± 2.3       
Phenylacetic acid aglycones                                       
4-hydroxyphenylacetic acid Oats 48.2 ± 8.4 394.7 ± 140.2 334.8 ± 170.8 133.5 ± 32.9 911.2 ± 81.9 0.65 0.02 0.88 
  Control 132.0 ± 60.9 419.2 ± 208.3 317.5 ± 108.3 183.7 ± 53.8 1052.4 ± 65.1       
homovanillic acid Oats 7.4 ± 3.6 55.1 ± 37.8 8.0 ± 8.0 135.7 ± 61.0 206.1 ± 30.2 . . . 
  Control 18.7 ± 8.1 72.4 ± 39.4 47.8 ± 26.2 118.1 ± 36.2 257.0 ± 21.0       
Phenylacetic acid sulfates                                       
4-hydroxyphenylacetic acid-O-
sulfate 
Oats 14.3 ± 5.6 85.6 ± 19.4 39.0 ± 11.3 33.7 ± 8.8 172.6 ± 15.1 0.47 0.0002 0.46 
  Control 15.1 ± 4.6 49.8 ± 17.2 38.0 ± 11.2 29.5 ± 11.5 132.4 ± 7.3       
homovanillic acid sulfate Oats 33.1 ± 5.6 155.8 ± 19.8 78.2 ± 13.9 126.9 ± 22.5 394.0 ± 27.1 0.4132 0.0008 0.3509 
  Control 34.3 ± 4.2 159.8 ± 27.7 111.2 ± 14.9 124.9 ± 24.4 430.3 ± 26.5       
Hippuric acid aglycones                                       
hippuric acid Oats 458.8 ± 89.5 2764.6 ± 588.8 1442.3 ± 248.5 1348.1 ± 213.8 6013.8 ± 475.2 0.71 0.0005 0.01 
  Control 393.7 ± 51.7 2474.4 ± 305.3 1796.4 ± 242.5 993.4 ± 152.6 5657.9 ± 455.4       
2-hydroxyhippuric acid Oats 64.3 ± 26.0 199.1 ± 60.0 91.9 ± 19.3 151.1 ± 27.5 506.4 ± 30.2 0.236 0.0113 0.0195 
  Control 24.5 ± 3.8 143.1 ± 28.0 87.1 ± 12.6 62.1 ± 10.0 316.9 ± 24.9       
3-hydroxyhippuric acid Oats 28.5 ± 6.9 170.6 ± 45.0 83.3 ± 16.5 101.9 ± 15.3 384.3 ± 29.3 0.7313 0.0069 0.0558 
  Control 27.1 ± 98.9 199.5 ± 45.1 121.5 ± 26.3 57.7 ± 11.1 405.8 ± 38.1       
4-hydroxyhippuric acid Oats 98.4 ± 16.0 614.1 ± 69.5 334.4 ± 51.8 281.1 ± 39.0 1328.1 ± 106.8 0.90 0.0001 0.4782 
  Control 4.5 ± 12.8 555.0 ± 74.6 386.0 ± 46.3 309.9 ± 54.8 1255.5 ± 115.1       
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Hippuric acid sulfates                                       
hippuric acid-O-sulfate Oats 10.2 ± 4.5 73.9 ± 35.9 36.6 ± 17.0 19.7 ± 5.7 140.4 ± 14.0 0.89 0.12 0.39 
  Control 8.8 ± 3.0 46.0 ± 11.4 48.8 ± 15.8 22.4 ± 7.0 126.0 ± 9.6       
Cinnamic acid aglycones                                       
caffeic acid Oats 17.7 ± 3.5 106.6 ± 22.6 55.8 ± 9.7 50.9 ± 7.9 231.0 ± 18.3 0.51 0.0008 0.11 
  Control 15.4 ± 2.2 95.6 ± 11.4 68.5 ± 9.0 37.5 ± 5.6 217.0 ± 17.6       
ferulic acid Oats 1.9 ± 0.7 24.2 ± 5.5 11.9 ± 2.6 16.0 ± 4.8 54.0 ± 4.6 0.01 0.0233 0.64 
  Control 1.4 ± 0.3 9.9 ± 3.4 5.7 ± 2.0 9.0 ± 3.7 26.0 ± 1.9       
isoferulic acid Oats 4.1 ± 1.0 57.8 ± 14.6 22.3 ± 5.2 26.7 ± 8.9 110.9 ± 11.2 0.10 0.04 0.28 
  Control 4.4 ± 1.3 33.1 ± 9.6 19.1 ± 5.5 11.1 ± 2.6 67.7 ± 6.2       
hydroferulic acid Oats 2.5 ± 0.8 16.0 ± 3.9 7.4 ± 2.1 7.0 ± 2.3 32.9 ± 2.8 0.65 0.01 0.29 
  Control 3.1 ± 0.8 21.9 ± 5.5 10.8 ± 2.5 3.2 ± 1.3 39.0 ± 4.4       
p-coumaric acid Oats 0.3 ± 0.1 2.2 ± 0.6 0.9 ± 0.2 0.8 ± 0.2 4.1 ± 0.4 0.83 0.08 0.30 
  Control 0.2 ± 0 1.2 ± 0.2 1.0 ± 0.2 0.8 ± 0.4 3.3 ± 0.2       
sinapic acid Oats 0.7 ± 0.2 13.6 ± 2.4 5.3 ± 1.2 8.0 ± 2.2 27.5 ± 2.7 . . . 
  Control 0.8 ± 0.2 3.7 ± 1.4 2.2 ± 0.7 5.8 ± 3.0 12.5 ± 1.1       
Cinnamic acid sulfates                                       
caffeic acid-O-sulfate Oats 5.1 ± 1.3 97.5 ± 24.0 112.0 ± 42.9 40.5 ± 7.7 255.0 ± 24.9 0.02 0.04 0.17 
  Control 7.9 ± 3.2 35.5 ± 14.2 19.5 ± 4.9 20.9 ± 5.1 83.8 ± 5.7       
dihydro caffeic acid 3-O-sulfate Oats 17.9 ± 7.0 100.1 ± 28.9 43.1 ± 15.3 85.2 ± 27.2 246.3 ± 18.9 0.54 0.12 0.24 
  Control 16.0 ± 4.9 104.7 ± 39.8 70.7 ± 21.3 64.3 ± 30.4 255.7 ± 18.3       
ferulic acid-4-0-sulfate Oats 24.8 ± 6.1 873.5 ± 156.5 539.7 ± 128.3 251.9 ± 47.4 1689.8 ± 183.6 0.236 0.01 0.03 
  Control 36.3 ± 8.0 188.7 ± 40.1 119.1 ± 18.8 210.3 ± 51.0 554.4 ± 39.3       
dihydroferulic acid 4-O-sulfate Oats 11.0 ± 3.5 64.0 ± 15.4 29.1 ± 7.9 61.8 ± 14.2 166.0 ± 12.9 0.7824 0.0006 0.17 
  Control 15.4 ± 3.2 83.4 ± 23.4 40.1 ± 10.0 35.0 ± 7.6 173.9 ± 14.3       
isoferulic acid-3-O-sulfate Oats 1.1 ± 0.6 41.9 ± 10.7 26.6 ± 6.9 6.8 ± 1.7 76.3 ± 9.4 0.0121 0.03 0.18 
  Control 3.0 ± 1.1 10.7 ± 4.7 4.7 ± 2.3 5.5 ± 1.7 23.9 ± 1.6       
p-coumaric acid 4-O-sulfate Oats 1.5 ± 0.5 5.7 ± 1.1 3.0 ± 0.6 2.9 ± 1.0 13.0 ± 0.9 0.63 0.0039 0.35 
  Control 0.9 ± 0.3 3.7 ± 1.0 3.5 ± 1.0 5.7 ± 2.5 13.7 ± 1.0       
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sinapic acid-O-sulfate Oats 21.5 ± 6.2 450.6 ± 59.8 241.5 ± 48.6 234.3 ± 69.6 948.0 ± 87.6 0.01 0..22 0.02 
  Control 32.0 ± 9.5 105.6 ± 24.5 64.5 ± 11.6 151.3 ± 33.9 353.4 ± 25.8       
Cinnamic acid glucuronides                                       
caffeic acid 3-B-D-glucuronide Oats 0.9 ± 0.3 7.2 ± 1.3 5.7 ± 1.2 4.6 ± 2.0 18.4 ± 1.4 0.02 0.07 0.85 
  Control 1.0 ± 0.3 3.3 ± 1.3 2.2 ± 0.9 3.1 ± 1.3 9.6 ± 0.5       
caffeic acid 4-B-D-glucuronide Oats 0.6 ± 0.3 8.2 ± 1.2 5.6 ± 1.0 2.0 ± 0.5 16.4 ± 1.7 0.00 0.0001 0.36 
  Control 0.5 ± 0.2 5.1 ± 1.5 3.1 ± 1.0 1.2 ± 0.4 9.9 ± 1.0       
dihydroferulic acid glucuronide Oats 9.8 ± 2.4 54.8 ± 10.6 30.0 ± 8.9 47.8 ± 10.6 142.5 ± 10.1 0.739 0.01 0.10 
  Control 13.4 ± 2.6 80.8 ± 16.6 41.4 ± 8.6 30.3 ± 7.5 165.9 ± 14.3       
ferulic acid-4-B-D-G-glucuronide Oats 8.4 ± 2.3 161.6 ± 24.8 124.3 ± 28.6 61.0 ± 9.2 355.4 ± 33.9 0.06 0.01 0.12 
  Control 12.4 ± 3.0 69.8 ± 14.8 44.2 ± 6.2 46.7 ± 9.7 173.1 ± 11.8       
dihydro isoferulic acid 3-O-B-D Oats 10.5 ± 1.9 56.7 ± 11.6 23.5 ± 5.1 48.8 ± 11.5 139.6 ± 10.8 0.85 0.0006 0.08 
-glucuronide Control 11.4 ± 1.8 60.4 ± 14.8 29.1 ± 5.3 27.0 ± 4.8 127.9 ± 10.3       
p-coumaric acid glucuronide Oats 4.3 ± 1.1 40.0 ± 6.6 20.4 ± 3.6 4.9 ± 1.1 69.6 ± 8.4 0.27 0.0001 0.29 
  Control 3.8 ± 0.9 33.8 ± 6.9 24.2 ± 3.8 3.7 ± 0.7 65.5 ± 7.6       
Benzaldehydes                                       
vanillin Oats 1.0 ± 0.2 9.6 ± 1.1 5.8 ± 1.6 5.4 ± 0.8 21.8 ± 1.7 0.54 0.0001 0.52 
  Control 1.4 ± 0.2 10.5 ± 1.9 8.3 ± 1.4 4.5 ± 0.7 24.7 ± 2.0       
Avenanthramides                                       
Avenanthramide A Oats 0.2 ± 0 3.7 ± 0.8 2.8 ± 0.6 1.1 ± 0.2 7.9 ± 0.8 0.0016 0.0005 0.01 
  Control 0.3 ± 0 1.5 ± 0.3 0.9 ± 0.2 0.8 ± 0.2 3.5 ± 0.2       
Avenanthramide B Oats 0 ± 0 0.2 ± 0.1 0.2 ± 0 0 ± 0 0.4 ± 0.1 . . . 
  Control 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0.0 ± 0.0       
Avenanthramide C Oats 0 ± 0 0.1 ± 0.1 0.1 ± 0 0.1 ± 0 0.3 ± 0.0 . . . 
  Control 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0.0 ± 0.0       
Total concentration (µg)                                       
  Oats 1380.3 ± 10.9 9786.9 ± 67.9 5629.5 ± 37.0 5207.6 ± 33.8 22004 ± 148.5 0.22 0.08 0.71 
  Control 1361.4 ± 10.1 7848.6 ± 59.3 5815.6 ± 43.6 4194.1 ± 26.4 19220 ± 138.3       
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3.4.4 Serum metabolite levels predict improvements in endothelium independent 
microvascular function 
 
Analysis of phenolic metabolites indicated a large variability in terms of absorption between study 
volunteers (Figure 3.7 A and B) with some volunteers classified as absorbers and others low/non-
absorbers, 2h post consumption of oats. Endothelium independent microvascular function was found  
close to be significantly higher in those individuals who were classified as absorbers compared to those 
classified as non-absorbers (Figure 3.7 C; p value<0.06).  Correlation analysis indicated that the blood 
levels of salicyclic acid sulphate (ρ=0.38, p=0.04), syringic acid (ρ=0.38, p=0.04), ferulic acid sulfate 
(ρ=0.41, p=0.02), 2,5-dihydroxybenzoic acid (ρ=0.41, p=0.02), p-coumaric acid ( ρ=0.41, p=0.02), 
isovanillic acid ( ρ=0.41, p=0.02) , salicyclic acid glucuronide (ρ=0.45, p=0.01) and ferulic acid 
glucuronide ( ρ=0.50, p=0.01) in volunteers at 2h significantly correlated with endothelium 
independent microvascular function (Table 3.7). 


















Figure 3.7 Inter-individual variability of absorption between individuals and change in 
microvascular function. 
Examples of main phenolic acids showing inter-individual variability in absorption (A and B) and change in 
microvascular function in relation to high ( squared bar ,n=3) , all (filled bar, n=11) and low/non absorbers 
(lined bar, n=3) (C). One volunteer was very high absorber for all phenolics and excluded when plotting the 
data to see the distribution of others volunteers in A and B. Data expressed as area under the curve (AUC) of 
serum concentration (nM) for panel A and B and as means ± SEMs for SNP.iAUC (PU/h) for panel C.  For panel 























































































Metabolites correlating with 
SNP.iAUC at 2h 
Spearman’s  ρ p-value 
Salicyclic acid sulfate 0.38 0.04 
Syringic acid 0.38 0.04 
Ferulic acid sulfate 0.41 0.02 
2,5 dihydroxybenzoic acid 0.41 0.02 
P-coumaric acid 0.41 0.02 
Isovanillic acid 0.41 0.02 
Salicyclic acid glucuronide 0.45 0.01 
Ferulic acid glucuronide 0.5 0.01 
Table 3.7 Correlation analysis between metabolites and endothelium independent 
microvascular function. Significant correlations (p< 0.05) between serum derived phenolic 
metabolites and changes in endothelium independent microvascular function (SNP.iAUC) at 2 




This study aimed to examine whether the consumption of a single intake of oats containing phenolic 
acids and avenanthramides would acutely effect the cardiovascular risk biomarkers including 
endothelial function, microvascular blood flow , BP and NADPH oxidase activity in men with pre- and 
stage 1 hypertension. Additionally, pharmacokinetics of serum and urine phenolic metabolites and 
their associations with cardiovascular risk biomarkers were tested. Our data indicated an intake of 
phenolic acids and avenanthramides (50mg) led to an increase in both endothelium-dependent and 
endothelium-independent microvascular dilation at 2h, although not on FMD or BP, relative to control.  
Although similar clinical datasets that attempt to isolate the biological impact of phenolic acids and 
avenanthramides in oats are rare, data exist for the impact of other phenolic-containing foods and 
beverages on similar outcomes (29, 30, 202, 283, 312, 327).  Our study is broadly in agreement with 
other clinical trials which investigate the effects of consumption of wholegrain oats on vasodilation 
(278, 280, 328, 329), although our data show weaker associations in relation to FMD. For example, oat 
bread intake providing 30 g β-glucan per day has been shown to not affect FMD over a 4 week period, 
although it did induce a significant increase in baseline brachial artery diameters and post-ischemia 
diameters and also increased the NO levels(278) and whole grain oat or wheat cereals have been 
observed to have no effect on brachial artery vasodilatation chronically when consumed with a high 
fat diet(328).  Conversely, chronic consumption of wild green oat extract(1500mg), is reported to 
significantly improve vasodilator function in healthy older adults(>60yrs)(278). It must be noted that 
these studies did not isolate the effect of the phenolic acids and avenanthramides from fibre and it is 
difficult to evaluate whether there is a synergistic effect coming together from fibre and phenolics or 
an improvement caused by phenolics or fibre only.  
The impact of oat polyphenol intake on FMD and BP, appear to be more subtle than that observed in 
other studies, particularly those which administered higher doses of phenolic acids compared to our 
oat intervention (310 mg for coffee compared to 50 mg for oat)(30). Therefore, the relatively low oat 
phenolic acid intake in our study may not be sufficient to induce statistical reliable changes in FMD 
increase and BP as those observed for other phenolic acid- and flavonoid-containing interventions (29, 
192, 283, 330-332).  For example, small phenolic acids in blueberries and coffee have been shown to 
improve FMD that also correlated with the appearance of phenolic acid metabolites in blood (29, 
30).Our microvascular vasodilation results, while showing significant responses to the intervention, 
also agree broadly with a randomised, placebo-controlled trial indicating that the moderate intake of 
champagne(375ml) providing 23.7mg of phenolic acids acutely improves endothelium-independent 
vasodilation at 4 and 8 h post consumption (312), particularly with respect to endothelium-
independent blood flow 2 h following intake of oats. Interestingly, the doses administered in both 
studies (23.7 mg for champagne and 50mg for oats) were similar and sufficient to induce an increase 
in microvascular response.   
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We demonstrated the presence of 45 phenolic acids and avenanthramides in the blood. In line with 
the LDI results, there was a non-significant increase in serum phenolic acids, avenanthramides and 
their metabolites at 2h after oat consumption.  This is in agreement with other studies reporting the 
appearance of phenolic acid metabolites and avenanthramides at 1-2h post consumption of 
polyphenols or wholegrain cereals, which could be explained by the rapid absorption of free and 
conjugated oat phenolics from the small intestine to the circulation in our study (27, 29, 30, 150, 283, 
333-335). Similar to our results, structurally bigger oat avenanthramides have been repeatedly shown 
to be  bioavailable in humans when ingested at low (21.6mg, comparatively higher than our dose (5 
mg)) and high doses (75-150 mg) and exert certain cardioprotective effects in cell models and in 
humans (27, 119, 165, 336, 337).Oats contain a high proportion of bound phenolic acids and the bio-
accessibility of these compounds are limited until the action of gut microbiota cleave the linkages 
between phenolic acids and fibre to yield colonic metabolites. Comparable findings of plasma 
pharmacokinetics of phenolic acids were also reported after the consumption of high bran wheat 
cereals and aleurone rich wheat bread (150, 333). The similar profile of phenolics were also detected 
in urine mainly peaking at 3h and slightly increasing at 24h after the consumption of oats with a total 
recovery % of 5.7 which is in line with other studies(150, 333) . A previous work in our group suggested 
an increase in mean excretion between 0-2 and 4-8h, while the results of this current study also 
supports the early absorption of total phenolics from the small intestine at 3h, there was no significant 
increase at the later timepoint (152)(See Appendix). The increase of several individual phenolic acids 
such as ferulic acid and its glucoronidated and sulphated metabolites at 7h in our study could be 
explained by role of gut microbiota on specific phenolics.  
A large inter-individual variability in the absorption of oat phenolics could also explain the non-
significant results at 2h in our study. Based on this variability, it was observed that volunteers defined 
as ‘absorbers’ showed improvements in endothelium-independent microvascular response in 
comparison with those defined as ‘low or non-absorbers’ . There are number of factors such as genetic 
polymorphisms of metabolizing enzymes and transporters and the composition of the gut microbiota 
which can affect the metabolism and absorption and these factors may explain the broad variability 
between our study volunteers (338, 339).  In support of this, our data also indicated positive 
correlations between circulating levels of salicyclic acid sulfate, salicyclic acid glucuronide, ferulic acid 
sulfate, ferulic acid glucuronide, 2,5-dihydroxybenzoic acid , p-coumaric acid, isovanillic acid and 
syringic acid and endothelium-independent microvascular function 2h following oat consumption. 
Therefore, these phenolic acids may be important mediators of improvements observed in 
microvascular function.  
A potential mechanism behind the blood vessel vasodilation mediated by circulating polyphenol 
metabolites is suggested to be the reduced superoxide production and increased NO bioavailability, 
via inhibition of NADPH oxidase (28, 29, 340, 341). The same acute intervention study discussed above 
87 
that reported improvements in FMD also reported the significant reduction in NADPH oxidase activity 
at 1, 2 and 6h after blueberry polyphenol intake (766-1791 mg) in healthy men, correlated with plasma 
concentrations of vanillic acid, homovanillic acid and hippuric acid (29). Ferulic acid has also been 
shown to restore endothelial function through increasing the bioavailability of NO via a reduction in 
NADPH-dependent superoxide production in aortas of hypertensive rats (342). Furthermore, 
chlorogenic acid supplementation to spontaneously hypertensive rats improved endothelium 
dependent vasodilation with increasing NO bioavailability via NADPH oxidase and decreased blood 
pressure(343). Certain phenolic acids such as ferulic acid have structural similarities to the 
pharmacologic NADPH oxidase inhibitor, apocynin and this could explain the mechanistic insights of 
biological activity of phenolic acid metabolites on NADPH oxidase (344).  Inhibitory action of oat 
phenolic acids on NADPH oxidase activity have been tested in the present study and a reduction at 2h 
was observed. These results were also paralleled with the appearance of increased concentration of 
phenolic acids in the blood at 2h, however, there was a reduction with the control intervention as well 
and the results were non-significant  therefore,  they were only indicative. Our observations regarding 
a lack of influence of oat phenolic intake on this enzyme could be related to the dose provided or the 
variability seen between the study volunteers in terms of absorption of phenolics to the circulation. 
The use of an all-male sample reduces the likelihood of confounding factors between volunteers in this 
acute trial and also makes the results more comparable to other studies.  However, the short-term 
intervention and the lack of investigation of general population, e.g, women, CVD patients and elderly 
contributed to the limitations of the trial outcomes. Therefore, the trial was uninformative with 
respect to the long-term effects that oats consumption might have on CVD biomarkers in general 
population, and our knowledge, considering also the limited availability of published studies, remains, 
therefore, incomplete.  Further studies are required with a chronic design and a larger sample size, to 
analyse the long-term effect of oats consumption in a similar at-risk group for cardiovascular disease.  
In conclusion, our study revealed that a single moderate intake of avenanthramide and phenolic acid 
enriched oats may improve endothelium dependent and independent microvascular function and this 
finding is linked with presence of phenolics and their metabolites in the circulation. Oat phenolics may 
also influence mean % FMD beneficially, because there was a small improvement relative to the 
control, although this change failed to achieve statistical significance. To our knowledge, this is the first 
study isolating the phenolic acids together with avenanthramides from soluble fibre and investigating 
their sole effect on cardiovascular health and when consumed together with other food sources such 
as coffee and other wholegrains rich in phenolic acids, oat phenolics may have a stronger effect in 
maintaining the healthy circulatory function and may be contribute to the prevention of cardiovascular 
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4.1 Abstract  
 
Background: Wholegrain consumption is linked to a lower risk of cardiovascular disease. Evidence 
from randomized controlled trials have established that the consumption of wholegrain oats lowers 
blood cholesterol, via a mechanism partly mediated by β-glucan soluble fiber. However, oats contain 
an array of phenolic acids, including ferulic acid and avenanthramides, which may also contribute to 
the cardiovascular health benefits of oat intake. We investigated whether 4 weeks, daily 
consumption of oat phenolic acids leads to improvement in markers of CVD risk men and women. 
  
Methods: In a 3 arm crossover double-blind, placebo-controlled trial, 28 volunteers consumed 
either: 1) oatmeal/oatcake intervention (-containing 48.9mg of phenolic acids and 19.2 mg of 
avenanthramides); 2) oatbran concentrate+rice porridge/wheat cracker intervention (containing 
38.4mg of phenolic acids and 0.5mg of avenanthramides) or 3) rice porridge/wheat cracker 
intervention (containing 13.8 mg of phenolic acids). All treatments were matched in macro- and 
micronutrients, energy (500kcal) and total soluble fiber (4.8g). The primary endpoint was flow 
mediated dilatation (FMD) and other cardiovascular endpoints were laser Doppler imaging (LDI), 24h 
ambulatory blood pressure (AMBP), pulse wave analysis (PWA), LDL/HDL cholesterol, platelets and 
endothelial cell-derived extracellular vesicles (EVs).  All measures were taken at baseline and after 
three, 4 week long intervention periods and two washout periods. 
  
Results: Consumption of high phenolic oats for 4 weeks led to a significant improvement in 24-hour 
SBP (-1.16 mm Hg), night time SBP (-5.1 mm Hg) and night time DBP (-2.3 mm Hg) (P<0.05, P<0.01 
and P<0.05, respectively). Our data indicates an increase by 1.09 % ± 0.41 % in FMD response 
following high phenolic oat intake between baseline and post-intervention. However this difference 
did not reach to significance. Small increases in endothelial-dependent and –independent 
microvascular function and small decreases in total and LDL cholesterol after the consumption of 
moderate and high phenolic oat intervention did not achieve significance. The number of endothelial 
and platelet derived EVs remained unchanged after the consumption of any of the interventions. 
  
Conclusion: The findings of this study provide additional evidence regarding the role wholegrain oat 
intake may play in a healthy diet.  We provide evidence that the phenolic components within oats 








High intake of wholegrains has been associated with reduced incidence and mortality from coronary 
heart disease, stroke , type-2 diabetes and certain cancer types, as reported by a recent systematic 
review and meta-analyses of prospective studies and randomized controlled trials(281). Meta-analyses 
of human intervention studies focusing on health benefits of wholegrain oats reported that regular 
consumption of these cereals can lower blood cholesterol(271, 345), and improve postprandial 
glycaemic control and insulin sensitivity(275). Oats are a source of proteins, unsaturated fatty acids, 
vitamins, minerals (282), dietary fibre including soluble β-glucan and phenolic compounds (phenolic 
acids and avenanthramides) (21). Of the numerous published epidemiological and human intervention 
studies concerning the health effects of oats, the overwhelming focus to date has been on the benefits 
of increased wholegrain oat consumption and on diets or interventions incorporating β-glucan. 
However, the roles and contributions of bioactive phenolic acids and avenanthramides to health 
benefits of oats are still not known. 
 
Findings from previous studies suggest that polyphenols present in fruits, vegetables and whole grains 
may beneficially impact cardiovascular health (162, 346). The ability of these compounds or their 
circulating metabolites to attenuate well characterized, medically significant CVD risk factors such as 
hypertension (194, 195, 347), abnormal lipid metabolism (195, 348)  and endothelial dysfunction(203, 
349-351) have been reported by well-designed chronic randomized controlled trials, and mixed 
findings are also observed on measures of arterial stiffness improving with high flavonoid 
food/beverages such as cocoa flavanols (210).  In contrast, oats contain predominantly phenolic acids, 
most notably hydroxybenzoic acids and hydroxycinnamic acids(21, 115) . Hydroxybenzoic acids include 
protocatechuic, syringic, vanillic , p-hydroxybenzoic and gallic acids, while hydroxycinnamic acids are 
ferulic, p-coumaric, o-coumaric, caffeic and sinapic acids(115). These compounds are concentrated in 
the outer layers of the oat grain in three forms : as soluble, free acids, as soluble conjugates, esterified 
to low-molecular weight components such as sugars, and as insoluble, bound acids esterified to high 
molecular weight components, including cell wall polysaccharides (dietary fibre and lignin)(289). In 
addition, oats are unique, with respect to diet, in containing a structurally similar group of phenolic 
acids known as avenanthramides. These soluble acids are esters of 5-hydroxyanthranilic acid with p-
coumaric (2p aka A), and ferulic (2f aka B), and caffeic (2c aka C) acids (290, 291).  
 
There are a number of human intervention trials showing that circulating phenolic acids are positively 
correlated with improvements in measures of vascular function including flow mediated dilation (FMD) 
and laser doppler imaging (LDI) after the consumption of cranberries(283), blueberries(352), 
champagne(31) and coffee(30). Additionally, oat avenanthramides were also shown to be bioavailable 
in humans and promote cardiovascular physiology in in vitro studies (119, 152, 165, 337). Therefore, 
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oat phenolics may also mediate similar cardiovascular health benefits in humans. A limited number of 
randomized controlled trials have investigated the effects of oat consumption on vascular function and 
blood pressure with reporting mixed findings. Increases in % FMD by 1.80± 0.50% have been reported 
in elderly subjects (>60yrs) after consumption of wild green oat extract ( 1500mg/day) for  12 
weeks(280). In contrast, in a study of oat and wheat based bread interventions, showed no changes in 
FMD were found in hypercholesteraemic patients after a 6 weeks of consumption (279). Studies of 
mildly hypertensive subjects  showed significant 6mm Hg reduction in SBP (353)and of 7.5 mm Hg SBP 
and 5.5 mm Hg DBP (354) over a 6-week oat interventions. It has also been reported that ambulatory 
24h BP was not significantly altered in hypertensive men following oat intake for 12 weeks (355). 
Although some of these studies report the amount of fibre given to the subjects, the nutritional 
content of oats in particularly the amounts of phenolics (phenolic acids and avenanthramides) 
provided were not reported. Therefore, it is difficult to evaluate the potential impact of oat phenolic 
intake or synergistic effect of phenolics and fibre on vascular function.  
 
There have been many mechanisms proposed for this potential to improve human vascular function. 
Most importantly, the ability of polyphenol rich foods to attenuate endothelial dysfunction with 
increasing NO bioavailability has been reported by numerous human intervention studies (22, 31, 188, 
189, 192). NO is a vasodilator playing crucial role in the vascular homeostasis, any defect in its 
production or activity may lead to endothelial dysfunction, an early stage of atherosclerosis(187, 356). 
On the other hand extracellular vesicles (EVs) are small membrane derived vesicles originate from 
different cell types such as platelets and endothelial cells as a result of cell activation or apoptosis (90). 
Research suggest that circulating EVs increase in relation to CVD risk factors such as hypertension(103), 
endothelial dysfunction (100, 357) abnormal lipid profile(358), smoking(359) and type -2 diabetes(97) 
and they may be involved in disease pathogenesis. While the evidence is very limited, there are few 
studies examining the effects of polyphenols in particularly cocoa flavanols on the number of 
circulating endothelial and platelet derived EVs and endothelial functional integrity (99, 220-222).  
 
This randomized controlled trial aimed to address the chronic effects (i.e. after 4 weeks) of daily 
consumption of whole grain oats, with particular consideration given for the levels of phenolics 
(avenanthramide and phenolic acids) they contain, on vascular function and circulating EVs in pre- or 









Volunteers were recruited from the University of Reading and surrounding area using the Hugh Sinclair 
Unit of Human Nutrition database, local media and local GP practices. Eligible volunteers were required 
to be in general good health, but with moderately high blood pressure (i.e. systolic 120 - 159 mmHg 
and diastolic 75 - 99 mmHg). The inclusion criteria were non-smoking men and women, women taking 
the contraceptive pill or on hormone replacement therapy and aged 27 - 75 y. The exclusion criteria 
were: abnormal biochemical/haematological results assessed at the health screening, hypertension 
(i.e. SBP/DBP ≥ 160/100 mm Hg), BMI >35 kg/m2, current smoker or ex-smoker ceased <3 months ago, 
past or existing medical history of vascular disease, diabetes, hepatic, renal, haematological, 
neurological, thyroidal disease or cancer, prescribed or taking lipid lowering, anti-hypertensive, 
vasoactive, anti-inflammatory, antibiotic or antidepressant medication, allergies to whole grains, dairy 
and/or lactose intolerance, parallel participation in another research project, had the flu vaccination 
or antibiotics treatment within 3 months of the trial start, chronic constipation, diarrhoea or other 
chronic gastrointestinal complaint (e.g. irritable bowel syndrome), on a weight reduction regime or 
taking food, probiotic or prebiotic supplements or laxatives within 3 months of the trial start, 
performing high levels of physical activity (i.e. ≥ 150min aerobic exercise/week), consumption of 
alcohol ≥ 21 units/week for men and ≥ 15 units/week for women, females who were breast-feeding, 
or who may be pregnant or, if of reproductive age, were not using a reliable form of contraception. Of 
the 87 volunteers screened, 36 were recruited and randomized into the study, with 28 participants 
completed the study, 13 women and 15 men. The reasons given by the 8 participants who dropped 
out were: medical issues (n = 2) or could not commit the time for the visits (n = 6). Consort study flow 













                
   Figure 4.1 CONSORT study flow diagram 
 
4.3.2 Study Design  
 
A three-arm, double-blinded, placebo-controlled randomised crossover intervention study was 
conducted where volunteers were required to attend the Hugh Sinclair Unit of Human Nutrition. The 
primary outcome of the study was flow-mediated dilatation of the brachial artery (FMD). Secondary 
outcome measures were microvascular endothelial function (measured by Laser Doppler 
Iontophoresis),  24 h ambulatory blood pressure (AMBP) ,arterial stiffness (Pulse Wave Analysis, PWA) 
, enumeration of circulating extracellular vesicles and blood lipid levels which are all markers 
associated with CVD risk. 
During a 2 week run-in period and the total study duration, volunteers were asked to completely 
refrain from eating oats (apart from the study interventions), taking dietary, probiotic or prebiotic 
supplements, drink no more than 400ml/d of tea and only polyphenol-low coffee (i.e. a highly roasted 
commercial instant coffee provided by the researchers at the Hugh Sinclair Unit, University of Reading), 
maintain their habitual dietary and activity patterns and keep their body weight within 1kg of their 
starting weight. The study lasted 20 weeks and consisted of 3 periods: subjects consumed either 
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(n = 87) 
Started the study 
(n = 36) 
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(n = 28) 
Exclusion - not meeting 
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(n = 43) 
Withdrew before start of 
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(n = 8) 
Withdrew after the first 
intervention 
(n = 6) 
Dropped out because of 
illness 
(n = 2) 
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random order for 4 weeks, followed by 4-week washout period (without consuming any treatment 
products) and then switched to the next randomised assigned treatment. The study included six visits: 
baseline for each treatment (visit 1, 3 and 5) and at the end of the 4-week treatment (visits 2, 4 and 
6). All visits were standardised: participants attended the Hugh Sinclair Unit of Human Nutrition at the 
University of Reading after fasting overnight for 12 h (not eating or drinking anything but water). They 
were instructed to avoid polyphenol containing foods for 24 hours , moderate the consumption of 
alcohol (≤ 21 units )/week, refrain from exercise 48h prior to the study visits and asked to consume 
provided standard low fat polyphenol-free meal (<15 g fat) the evening before the visit. Compliance to 
a 24-hour polyphenol free diet and 12-hour fasting was monitored by a 24-hour dietary recall taken in 
the morning of each study visit. Adherence to the intake of the intervention materials was monitored 
using volunteer-maintained intake logs and returned, empty material sachets. 
Anthropometrical measures were performed (height, weight and % body fat composition (Tanita BC-
418 digital scale; Tanita Europe), following which the volunteers rested for 20 minutes in a supine 
position in a temperature-controlled (22 ± 1 C), light-dimmed room and blood pressure measurement 
was taken. FMD, LDI and PWA measurements were performed, following standard procedures.  Blood 
was collected and immediately processed, also following standardised procedures.  At the end of the 
visit, volunteers were asked to wear an ambulatory blood pressure monitor for 24h and to avoid intake 
of (poly)phenols, caffeine, alcohol and nitrite/nitrate. A polyphenol-low breakfast (white bread toast, 
butter, cheese, and water) was provided while the volunteers were in the Hugh Sinclair Unit.  
The study was conducted according to the guidelines laid down in the Declaration of Helsinki following 
a Good Clinical Practice and all procedures involving human subjects were approved by the University 
of Reading Research Ethics Committee as NCT02847312 and registered at www.clinicaltrials.gov (ID 
211656 and REC reference 16/LO/1542). Written informed consent was obtained from all subjects 






Figure 4.2 Study design. 
Timeline of the randomised crossover trial; three 4-week dietary treatments were assessed. The 
treatments were interspaced by 4-week washout period. Vascular measurements and blood samples 







Table 4.1 Nutritional content and quantities of study products. 













Study Products (g)          
Oatmeal - - - - - - 66.8 - 66.8 
Oatwell - - - 17.0 - 17.0 - - - 
Oat Cake - - - - - - - 60.0 60.0 
Cream of Rice 68.8 - 68.8 63.3 - 63.3 - - - 
Cream Cracker - 60.0 60.0 - 60.0 60.0 - - - 
  - - - - - - - - - 
Nutritional Content(g)          
Energy (kcal) 274.0 226.2 500.2 274.0 226.2 500.2 239.1 261.0 500.1 
Carbohydrate 55.04 45.2 101 52.7 45.2 97.9 37.8 30.8 68.7 
Protein 4.7 6.5 11.2 8.2 6.5 14.7 9.5 7.3 16.9 
Total Fat - 1.6 1.6 0.7 1.6 2.3 4.0 10.1 14.1 
 Saturated Fat 0 1 1.0 0.1 1 1.1 0.6 1.14 1.8 
 MUFA 0 0.2 0.2 0.4 0.2 0.6 1.4 6.6 8.0 
 PUFA 0 0.3 0.3 0.3 0.3 0.6 1.8 1.8 3.6 
Total Fibre 12.9 2.6 15.5 8.8 2.6 11.4 6.8 8.7 15.5 
 Soluble fibre 4.8 0 4.8 4.8 0 4.8 4.8 0 4.8 
 Insoluble fibre 8.1 2.6 10.7 4.0 2.6 6.6 10.7 0 10.7 
β-glucan 0 0 0 4.8 0 4.8 2.7 2.2 4.9 
Cellulose 8.1 0 8.1 0 0 0 0 0 0 
Pectin 4.8 0 4.8 0 0 0 0 0 0 
Total polyphenols(mg) 7.4 6.4 13.8 32.0 6.4 38.9 - - 68.1 
 Phenolic acid (mg) 7.4 6.4 13.8 32.0 6.4 38.4 25.5 23.3 48.8 
 Avenanthramide (mg) 0 0 0 0.5 0 0.5 13.6 5.7 19.3 
          
          
 
Quantities of intervention products phenolic acids, avenanthramides and β-glucan, and their nutritional content are shown in grams (g) unless specified as mg or kcal; for the control, moderate 
and high phenolic oats interventions. 
MUFA - monounsaturated fatty acids; PUFA - polyunsaturated fatty acids. 
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4.3.3 Study intervention Materials 
 
The study volunteers consumed either 1) high dose of avenanthramides and phenolic acids-containing 
(66.8 g of oatmeal (CDC Dancer oats,  provided by PepsiCo, Barrington, USA)  and 60 g of oatcake / 
day) ; 2) moderate dose of avenanthramides and phenolic acids-containing (17 g of oatwell blend with 
63.3 g cream of rice (B&G Foods, Inc) and 60g cream crackers) or 3) control diet (68.8 g cream of rice 
mixed with 8.1 g of cellulose and 4.8 g of pectin and 60 g cream crackers). To achieve the β-glucan 
matched moderate dose of avenanthramides and phenolic acids oat treatment we used Oatwell, an 
oat bran concentrate product, containing 28% β-glucan (Table 4.1).  
All interventions were measured by using HPLC as previously described in Chapter 2 (320) for phenolic 
acid and avenanthramide content and analysed for macro and micronutrients by Campden BRI 
(Gloucestershire, UK). All dry materials were frozen until needed to prevent degradation. Both 
interventions were well tolerated by all subjects, and no adverse events were reported. The breakfast 
products were packaged and labelled by PepsiCo and Covance Ltd (Ithaca, USA) in individually weighed 
sachets that displayed the product ID, ingredient statement, PEP protocol number, repacked date, 
expiration date, researcher name, telephone number and investigational use statement. 
 
4.3.4 Randomisation and Masking  
 
To minimise bias both researchers and subjects were ‘blinded’ to the food (intervention) product.  
Scientists not involved in the study generated random number sequences, and managed volunteer 
allocation and intervention meal administration.  Volunteers were randomly allocated to the 
intervention sequence (i.e. experimental interventions followed by control intervention or vice versa). 
Study Product Intake Logs were completed upon the dispensation of the study product to each subject. 
 
4.3.5 Assessment of vascular function and Twenty-four-hour AMBP  
 
Assessment of vascular function was carried out with FMD and LDI as previously described Chapter 3. 
Arterial stiffness of peripheral vessels was measured in triplicate with the use of a radial pulse wave 
analysis (SphygmoCor; AtCor Medical) by a single researcher. BP was measured with an automatic 
oscillometric digital BP monitor (OMRON) before the measurement and a sensitive transducer was 
used to record the applanation tonometry of the radial artery to detect waveform traces of the 
peripheral waveform. The corresponding aortic waveform was obtained using a validated transfer 
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function (209, 360) and mean arterial pressure, pulse pressure (PP), heart rate (HR), and augmentation 
index (AIx) were calculated.  Alx was corrected for an HR of 75 beats/min (%). 
Twenty four hour AMBP was measured with the use of A/A-grade automated oscillometric AMBP 
monitors (TM-2430, Scan Med, A&D Medical, UK) linked to a computer, and configured using Doctor 
Pro TM-2430-13 (version 2.40, A&D Company limited, Japan) software. Blood pressure examinations 
were taken following vascular measurements and breakfast over a 24 h period. Twenty four-hour 
AMBP and heart rate were recorded every 30 min from 07:00 h to 21:59 h and every 60 min from 22:00 
h to 6:59 h, the two initial measurements were discarded. Average 24-h day and night time 
measurements were analysed with the use of sleep times. PP was expressed as the difference between 
SBP and DBP. Participants recorded activities and sleep hours throughout the measurement period in 
a diary. 
4.3.6 Diet diary analysis 
 
For diet diary analysis, all the food and drinks consumed by volunteers, for four consecutive days, one 
during the weekend and the other three during the week was recorded  before each pre-intervention 
visit (1, 3 and 5).  Data for each diary was analysed using the Dietplan (Version 7) software package, 
using the McCance, Widdowson and ID2 databases, which contain an extensive list of nutritional 
information for a variety of foods available in the UK.  The nutrients compared were: saturated; 
polyunsaturated and monounsaturated fat; carbohydrate include fibre; protein and sodium intake.  
 
4.3.7 Biochemical analysis 
 
Fasted venous blood samples were collected in serum separation tubes (VACUETTE, Greiner Bio-One) 
and allowed to stand for 30 min before centrifugation (1700 x g for 15 min at 20°C). Lipids (total 
cholesterol (TC), LDL cholesterol, HDL cholesterol and triacylglycerol (TAG) and glucose were quantified 
from serum and analysed with ILAB 600 chemistry analyser by using enzyme-based colorimetric tests 
(ILAB600; Werfen (UK) Ltd.; reagents and analyser: Instrumentation Laboratory Ltd) to determine the 
baseline characteristics of the study population. Lipids (total cholesterol, LDL cholesterol, HDL 
cholesterol and triacylglycerol) were also assessed at every visit. LDL cholesterol was estimated by 
means of the Friedewald formula, i.e. ((LDL= (TC –HDL) – (TAG)/2.2)) (361). Screening samples were 




4.3.8 Enumeration of extracellullar vesicles 
 
Fasted venous blood was collected into sodium citrate tubes (BD vacutainer), the first tube was 
discarded, and the remainder was processed <30mins of collection. Samples were centrifuged at 1500 
X g for 15 min at 20°C and then at 13000 X g for 2 min at 20°C to obtain platelet poor plasma (PFP). 
PFP samples were kept at −80 °C until analysis. PFP (5 μl) was incubated with FcR (5 μl) (Miltenyi Biotec, 
Bergisch Gladbach, Germany) + argatroban (1 μl) (Sigma-Aldrich, St. Louis, Missouri, US) for 15mins at 
room temperature, in the dark to provide calcium and facilitate the binding of Annexin V (AV) to PS on 
EVs. PFP was then stained with 3 different antibodies; 2 μl AV (Fisher Scientific, Massachusetts, US) to 
identify PS positive EVs, 2 μl CD41-PE (Diagnostica Stago, New Jersey, US) to identify platelet derived 
PS positive EVs (PDEVs) and 4 μl CD105-eF450(Life Technologies , Invitrogen, California, US) to identify 
vascular endothelial EVs(EDEVs). Fluorescence-minus-one (FMO) for each antibody including isotype 
matched controls (1 μl of Immunoglobulin eF450 (IgGeF450) (Life Technologies, Invitrogen, California, 
US) and 2 μl IgG-PE (Diagnostica Stago, New Jersey, US) were also performed with same amount of PFP 
and FcR+argatroban. AV buffer alone (Cambridge Bioscience, Cambridge, UK) and PFP alone with the 
addition of FcR+argatroban were also included in the protocol to check for any background 
contamination. AV buffer or phosphate-buffered saline  (for AV FMO) (Sigma-Aldrich, St. Louis, 
Missouri, US) were then added to all test tubes to make up a final volume of 50 μl and samples were 
incubated for 15 mins at room temperature, in the dark. Prior to flow cytometry analysis, samples 
were further diluted with 200 μl of AV buffer or phosphate-buffered saline (for Annexin V FMO) and 
analysed on a BD FACSCanto II flow cytometer (BD Biosciences, New Jersey, US) with a medium flow 
rate. Flow cytometer was set with using a Cytometer Setup and Tracking (CS&T) beads (BD Biosciences, 
New Jersey, US) to perform quality control of the instrument’s optics, electronics and fluidics, and for 
adjusting fluorescence compensation. Rainbow calibration particles (8 peak beads) (BD Biosciences, 
New Jersey, US) with eight different fluorescent intensities were also used to calibrate and track the 
performance of flow cytometer. EV gate was set with using ApogeeMix beads (Apogee flow systems, 
Nortwood, UK) containing aqueous mixture of silica beads with different diameters 180nm, 240nm, 
300nm,590nm,880nm and 1300nm and a refractive index of 1.43 which is similar to the refractive 
index of biological vesicles. The EVs gate was set with using light scattering between 0.3μm and 1μm 
to include the events above the electronic noise of the cytometer and to cover upper size threshold 
for EVs (Figure 4.3). 10,000 events were recorded from EVs gate with using fluorescence channel 
signals, samples were triggered with Allophycocyanin (APC) channel to detect EVs labelled with AV and 
CD41 and triggered with Pacific Blue channel to detect EVs labelled with CD105eF450. From these 
events, staining for AV showed the PS-exposing, PS+ EVs (Figure 4.4- A and B)  and staining for CD41 
showed platelet derived PS+CD41+ double positive EVs (Figure 4.4- C and D). Additionally, endothelial 
derived EVs were demonstrated as PS +CD105+ (Figure 4.4- E and F). BD Trucount tubes (BD Biosciences, 
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New Jersey, US) were used to determine the absolute counts of EVs/ml. Values were reported as 




                                      





A total of 10,000 events were acquired in gate P17 to allow the 
analysis of EVs. Light scatter threshold based on EV granularity 
and size was used to set the gate. The gate was set to include 
events between 0.3 μm (lower detection limit defined as a 
threshold above the electronic noise of the flow cytometer)  and 1 
μm (which is the upper size threshold for EVs). SSC, side scatter 
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CD41 FMO        AV+ CD41+ EVs 
CD105 FMO CD105+ EVs 
 FMO controls for each antibody is shown to demonstrate any other events in the absence of the antibody. A: 
shows the FMO for AV triggered in APC and B: shows the AV+EVs. C: shows FMO for CD41 and D: shows AV+ CD41+ 
double positive platelet derived EVs (PDEVs). E: shows FMO for CD105 triggered in Pacific Blue and F: shows 
PS+CD1O5+ endothelium derived EVs (EDEVs). 
Figure 4.4 Analysis of EVs in PFP with flow cytometry after staining with AV, CD41 and CD105. 
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4.3.9 Sample Size and Statistical Analysis  
 
The power calculation was made for the primary clinical outcome measure (FMD) to determine the 
minimum number of participants required for the study.  The minimal measurable, statistically 
significant improvement on FMD is an absolute change of between 1.5 to 2 %, considering a baseline 
vasodilatation of 6-7 % in healthy subjects.  This has taken into account the statistical limitations 
related to our primary measure of vascular function. The sample size was calculated based on the 
variance of repeated measurement in the control group and on control data.  Consequently, with a 
standard deviation within participants of 2.4 % (based on previous studies performed in our group), a 
significance level of p ≤ 0.05 and a power of 80 %, 27 subjects were needed to determine a significant 
within-subject difference between interventions of at least 1.3 % of FMD.  However, to provide power 
to use the secondary measures and achieve significant within-subject differences, we aimed for 30 
participants to complete the trial.  A total of 33 volunteers were, therefore, recruited to allow for a 
drop-out rate up to 10 %.   
To identify differences in the study endpoints (i.e. markers of CVD risk and circulating levels of EVs), 
PROC MIXED in SAS 9.4 was used to fit a linear mixed model with fixed effects for a 3 period crossover 
design and participant as a random effect. A significance level of 5% was adopted. Where the repeated 
measures model showed significant differences, pairwise comparisons between the interventions 
were performed using post hoc analysis (Bonferroni adjustment). The graphs were generated with 














4.4.1 Baseline characteristics of study population and tolerance of intervention 
 
Baseline characteristics of 28 pre-hypertensive and stage 1 hypertensive, mixed gender individuals 
were measured. (Table 4.2). The intervention and control products were well tolerated by all subjects 
and no adverse events were reported. 
Table 4.2 Baseline clinical characteristics of the study population at screening 
 
Baseline Characteristics Mean ± SEM 
Age (y) 49.6 ± 2.3 
BMI (kg/m2) 26.7 ± 0.7 
Systolic blood pressure (mm Hg) 129.7 ± 1.9 
Diastolic blood pressure (mm Hg) 80.1 ± 1.2 
Heart rate (bpm) 71.1 ± 2.3 
Plasma glucose (mmol/L) 5.6 ± 0.1 
Plasma total cholesterol (mmol/L) 5.3 ± 0.1 
Haemoglobin (g/L) 145.5±2.1 
 




4.4.2 Twenty-four Hour Ambulatory Blood Pressure (AMBP) 
 
There were statistically significant mean changes in 24 SBP (p<0.05) and night time SBP (p<0.01) and 
DBP (p<0.05) following the intake of high phenolic oat relative to moderate phenolic or control 
interventions in relation to baseline measurements (Figure 4.5 and Table 4.3). A significant decrease 
was observed in 24 SBP following the intake of high phenolic oats (126.23± 1.53 mm Hg) relative to 
baseline (127.39± 1.67 mm Hg) over the timeframe of the intervention. Significant reductions in night 
time SBP  and DBP  were also observed following the consumption of high phenolic oat intervention 
(110.58 ± 2.05 mm Hg and 66.42 ± 1.51 mm Hg, respectively), compared to baseline (115.68 ± 1.68 



























Changes from baseline in 24 hour, day-time and night-time systolic (A) and diastolic (B) 
ambulatory blood pressure (BP) (mm Hg)  measured at baseline and following to  4 week 
consumption of control (filled bar), moderate (dotted bar) or high phenolic (lined bar) oats . 
Values are expressed as means ± SEMs from Table 4.3. A linear mixed model analysis  fixed 
effects of 3 period crossover design and participant as a random effect was performed, n 
= 28, followed by Bonferroni ‘s correction to adjust for multiple testing. *p<0.05, **p<0.01 



















Control Moderate Phenolic Oats Intervention High Phenolic Oats Intervention   
Baseline Post Baseline Post Baseline Post p-value 
24 h SBP 125.8 ± 1.8 129.3 ± 2.4 126.2 ± 2.3 128.8 ± 2.8 127.4 ± 1.7 126.2 ± 1.5* 0.050 
Day SBP 129.7 ± 1.9 134.9 ± 2.4 129.5 ± 2.2 134.0 ± 3.0 131.7 ± 1.8 131.6 ± 1.9 0.234 
Night SBP 113.2 ± 2.2 114.5 ± 2.3 114.2 ± 2.7 113.7 ± 2.4 115.7 ± 1.7 110.6 ± 2.1** 0.011 
24 h DBP 76.8 ± 1.2 77.9 ± 1.3 77.5± 1.3 79.1 ± 1.5 77.7 ± 0.9 78.4 ± 0.9 0.816 
Day DBP 79.9 ± 1.1 81.5 ± 1.3 80.4 ± 1.4 83.2 ± 1.6 80.9 ± 0.9 81.9 ± 1.2 0.676 
Night DBP 68.4 ± 1.7 67.5 ± 1.3 68.8 ± 1.6 67.8 ± 1.5 68.7 ± 1.1 66.4 ± 1.5* 0.054 
 
Twenty-four-hour ambulatory blood pressure (n=28), systolic blood pressure (SBP) and diastolic blood pressure (DBP). a Values are presented 
as mean measurement ± SEM. Data were analysed using linear mixed model with fixed effects of 3 period crossover design and participant as 




Table 4.3 Twenty-four hour ambulatory blood pressure measurements of participants at baseline and following to 4 week consumption of 
control, moderate or high dose phenolicsa. 
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4.4.3 Vascular function 
 
There was no significant changes in endothelium dependent brachial artery vasodilation, measured by 
FMD following consumption of control, moderate- or high phenolic oat interventions when compared 
to baseline. There was, however non-significant, dose-dependent increases from baseline 
measurements by 0.43, 0.50 and 1.09 % respectively (Figure 4.6, calculated from Table 4.4) after 28-
days of chronic consumption (p=0.91).  
Similarly, microvascular reactivity, assessed by LDI was not significantly different following the 
consumption of control, moderate- or high phenolic oat interventions in relation to baseline (Figure 
4.7 and Table 4.4). However, there were, small but measurable increases following the consumption 
of high phenolic oat intake, AUC (146.6 PU/h-1) and iAUC (43.7 PU/h-1) of endothelium-dependent 
vasodilation, facilitated by Ach (p=0.96 and p=0.76 , respectively). Non-significant increases were also 
found following the high phenolic oat intake, AUC (150.6 PU/h-1 ) and  iAUC (380.1 PU/h-1),  and 
moderate phenolic oat intake, AUC( 285 PU/h-1) and iAUC (552.1 PU/h-1) of endothelium-independent 
vasodilation facilitated by SNP (p=0.31 and p=0.5, respectively). 
No significant changes were found for arterial stiffness measured by PWA and expressed as AIx (%) 






Figure 4.6 Changes in FMD. 
 
 
Changes in % FMD from baseline after 4 week consumption of control (filled bar), moderate (dotted bar) or 
high phenolic (lined bar) oats. Values are expressed as means ± SEMs, n=28 from Table 4.4. Data were 
analysed using linear mixed model with fixed effects of 3 period crossover design and participant as a 












Control Moderate Phenolic Oats Intervention High Phenolic Oats Intervention   
Baseline Post Baseline Post Baseline Post p-value 
FMD (%) 5.7 ± 0.47 6.1 ± 0.5 5.6 ± 0.4 6.1 ± 0.4 5.8 ± 0.4 6.9 ± 0.4 0.911 
LDI-AchAUC  1188.7 ± 233.2 1156.5 ± 233.4 1312.8 ± 171.5 1290.9 ± 236 1569.6 ± 227.1 1716.3 ± 292.9 0.967 
LDI-SNP AUC 1171.8 ± 200.8 1233.3 ± 150.7 1127.8 ± 127.3 1412.8 ± 256.8 1459.4 ± 241.6 2011.5 ± 386 0.314 
LDI-Ach iAUC 320.7 ± 163.4 298.2 ± 137.6 378.1 ± 135.6 344.5 ± 207.2 611.3 ± 220.4 655.0 ± 207.7 0.760 
LDI-SNP iAUC 407.2 ± 172.4 353.1 ± 114.4 255.6 ± 65.1 406.2 ± 161.2 492.0 ± 206.3 872.1 ± 286.6 0.500 
PWA, Alx (%) 28.0 ± 1.7 28.1±1.7 27.8±2.1 26.8±2.1 27.3±1.8 27.7±1.8 0.325 
PWA, AIxHR75 (%) 21.5±1.4 21.4±1.4 21.3±1.8 20.8±1.7 21.2±1.5 20.7±1.5 0.819 
 
Flow-mediated dilatation (FMD) (n=28); Laser Doppler Iontophoresis (LDI); endothelial-dependent vasodilation (Ach) (n=28) and 
endothelial-independent vasodilation (SNP) (n=28), expressed as both area under curve (AUC) and incremental area under curve 
(iAUC); Pulse wave analysis (PWA); AIx (n=26); Augmentation index, AIxHR75 (n=25); Augmentation index when corrected for a HR of 
75 mm Hg. a Values are presented as mean measurement ± SEM, for units see the text. Data were analysed using linear mixed model 
with fixed effects of 3 period crossover design and participant as a random effect followed by Bonferroni’s correction to adjust for 





        Figure 4.7 Changes in LDI. 
 Changes from baseline in microvascular function measured with LDI at baseline and following to 4 
week consumption of control (filled bar), moderate (dotted bar) or high phenolic (lined bar) oats: 
(A) endothelium-dependent vasodilation (Ach) represented by  area under the curve  (AUC) and 
incremental area under the curve (Ach iAUC) (perfusion units per hour, PU/h-1) and (B) 
endothelium-independent vasodilation (SNP), represented by area under the curve (AUC) and 
incremental area under the curve (SNP iAUC) (perfusion units per hour, PU/h-1).Values are 
expressed as means ± SEMs from Table 4.4. A linear mixed model analysis  fixed effects of 3 period 
crossover design and participant as a random effect was performed, n = 28, followed by 
Bonferroni ‘s correction to adjust for multiple testing where there was a significant finding.  
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4.4.4 Lipid Profile  
 
There were no significant changes in TC (p=0.42), LDL-cholesterol( p=0.24), HDL-cholesterol(p=0.85) 
and triglycerides(p=0.95) following to consumption of high phenolic, moderate phenolic or control 
interventions in relation to baseline measurements (Table 4.5). However, small, non-significant and 
therefore only indicative reductions were observed in the following:  TC was decreased by -0.2 mmol/L 
and -0.16 mmol/L in moderate and high phenolic oat interventions respectively between the baseline 
and post-intervention measurements, compared to a slight increase in the control group. LDL-
cholesterol was reduced by -0.07 mmol/L and -0.26 mmol/L respectively, compared to -0.05 mmol/L 
in the control. HDL-cholesterol also decreased by -0.14 mmol/L and -0.04 mmol/L respectively, 
compared to -0.02 mmol/L in the control. In contrast, triglycerides increased only slightly by 0.17 
mmol/L and 0.05 mmol/L respectively, compared to 0.06 mmol/L in the control. 
4.4.5 Enumeration of Circulating Extracellular Vesicles 
 
No significant decreases were found in the numbers of circulating EVs analysed with flow cytometry 
as PS+ EVs (p=0.19), PS+ CD41+ , PDEVs (p=0.77) and PS+ CD105+, EDEVs (p=0.07) following to 
consumption of high, moderate phenolic or control interventions (Figure 4.8 and Table 4.5). 
Although, there was a very slight reduction observed in  PS+ EVs following the consumption of high or 
moderate phenolic oats relative to baseline measurements, this effect did not reflect to the numbers 
of PS+ CD41+ , PDEVs and PS+ CD105+, EDEVs. Additionally, increases in the number of PS+ CD105+, 




Table 4.5 Fasting lipid profile and number of circulating EVs at baseline and following to 4 week consumption of control, moderate or high phenolic                                       
oat  interventionsa
Lipids and EVs Control Moderate Phenolic Oats Intervention High Phenolic Oats Intervention  
Baseline Post Baseline Post Baseline Post p-values 
Total cholesterol (mmol/L) 5.2 ± 0.2 5.3 ± 0.2 5.4 ± 0.2 5.2 ± 0.2 5.2 ± 0.2 5.1 ± 0.2 0.426 
LDL cholesterol (mmol/L) 3.2 ± 0.2 3.1 ± 0.2 2.9 ± 0.3 2.9 ± 0.2 3.2 ± 0.1 2.9 ± 0.2 0.241 
HDL cholesterol (mmol/L) 1.5 ± 0.1 1.5 ± 0.1 1.6 ± 0.1 1.5± 0.1 1.5 ± 0.1 1.5 ± 0.1 0.849 
Triglycerides (mmol/L) 1.2 ± 0.1 1.3 ± 0.1 1.0 ± 0.1 1.2 ± 0.1 1.2 ± 0.1 1.2 ± 0.1 0.953 
PS+ EVs 2.7x107±2.7x106 2.9x107±5.7x106 2.7 x107±2.6x106 2.6 x107±2.4x106 2.9 x107±2.7x106 2.8x107±4x106 0.195 
PS+ CD41+ PDEVs 1.5x107±1.7x106 1.3x107±1.3x106 1.4 x107±1.5x106 1.4 x107±1.5x106 1.5x107±1.2x106 1.5x107±1.5x106 0.776 
PS+ CD105+ EDEVs 8.3x106±1.7x106 7.6x106±1.7x106 8.3x106±1.8x106 8.9x106±1.9x106 7.3x106±1.2x106 8.9x106±1.6x106 0.074 
        
 
Fasting lipid profile (n=28) measured as total cholesterol (mmol/L), low-density lipoprotein (LDL)-cholesterol (mmol/L), high density lipoprotein 
(HDL)-cholesterol (mmol/L) and triglycerides (mmol/L). Extracellular vesicles (EVs) (n=23) measured with flow cytometry as phosphatidylserine 
positive EVs (PS+ EVs), phosphatidylserine and CD41 double positive platelet derived EVs (PS+CD41+PDEVs), phosphatidylserine and CD105 double 
positive endothelial derived EVs (PS+ CD105+ EDEVs). a Values are presented as mean measurement ± SEM. Data were analysed using linear mixed 
model with fixed effects of 3 period crossover design and participant as a random effect followed by  Bonferroni’s correction to adjust for multiple 






   Figure 4.8 Changes in circulating EVs. 
 
Effects of control (black bars), moderate (dotted bars) or high (lined bars) phenolics oat intervention on numbers of 
circulating EVs measured by flow cytometry pre and post treatment: (A) PS+ EVs , (B) PS+ CD41+ PDEVs , (C) PS+ CD105+ 
EDEVs. Values are expressed as means ± SEMs from Table 4.5. A linear mixed model analysis  fixed effects of 3 period 
crossover design and participant as a random effect was performed, n = 23, followed by Bonferroni ‘s correction to 
adjust for multiple testing where there was a significant finding. 
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4.4.6 Nutrient Intake Summary 
 
There were differences in the dietary intake of carbohydrate, fat and MUFA. However, no statistically 
significant differences observed between the groups for these nutrients (P ˃ 0.05) (Table 4.6). 
Table 4.6 Daily consumption of the principal dietary nutrients is shown for the control, moderate 
and high phenolic oats interventionsa. 





















High Phenolic Oats 
Intervention 
Range  
Energy (kcal) 2338± 120 2328± 133 2456± 165 2195 - 2621 
Carbohydrate 311 ± 18 305± 19 287± 16 271 - 329 
Fibre 33 ± 2 29± 2 33 ± 2 27 - 35 
Protein 95 ± 5 99 ± 6 107± 7 90 - 114 
Total Fat 75 ± 4 76 ± 6 92 ± 9 71 - 101 
Saturated Fat 28 ± 2 28 ± 3 31 ± 3 25 - 34 
MUFA 24 ± 2 24 ± 2 31 ± 3 22 - 33 
PUFA 10 ± 1 11 ± 1 14 ± 1 9 - 15 
Sodium 3.1 ± 0.2 2.9± 0.3 3.4± 0.3 2.6 - 3.7 





In this chronic intervention study, we examined the vasoactive potential of the intake of moderate and 
high phenolic containing oats in pre or stage 1 hypertensive adults, over a 4-week intake period, 
relative to iso-caloric low phenolic containing control. Our results indicate that the consumption of 
oats at our highest dosage of phenolic acids (48.8 mg phenolic acids and 19.3 mg avenanthramides) 
significantly reduced 24 h SBP (p<0.05), night time SBP (p<0.01) and DBP (p<0.05) relative to baseline 
and in comparison to moderate phenolic containing oats 38.4mg of phenolic acids and 0.5 mg of 
avenanthramides) and control (13.8 mg phenolic acids). Similarly, although not significant, 
consumption of high or moderate containing phenolic oats also improved FMD of the brachial artery 
and microvascular blood. 
Measurement of 24h ambulatory blood pressure demonstrated significant decreases in 24h SBP (-1.2 
mm Hg), night time SBP (-5.1 mm Hg) and DBP (-2.3 mm Hg) following the consumption of high phenolic 
oats relative to baseline measurements and moderate phenolics or control interventions. No changes 
were observed in day time BP following any of the interventions, which may be due to the confounding 
impact of daily activity levels (362).  In agreement with our findings, consumption of whole grain oats 
in a similar pre or stage 1 hypertensive study group showed a significant 6 mm Hg reduction in SBP 
after a 6-week intervention (353) and reductions of 7.5 mm Hg SBP and 5.5 DBP following wholegrain 
oats consumption in hypertensive subjects (354). It must be noted that these studies used single blood 
pressure measurements, which is considered inferior to 24h-BP assessment in providing robust data 
(363). Conversely to our study, it has been reported that ambulatory 24-h BP was not significantly 
changed in hypertensive men following oat intake over a 12-week period (355). This inconsistency is 
reflected across other studies with polyphenol interventions, with long-term flavanol-rich cocoa (> 2 
weeks, 500-700mg of flavanols) and tea (< 6 months, 58-500mg polyphenols) consumption found to 
reduce both SBP and DBP by 2 mmHg and 1-3 mmHg, respectively (194, 195), similarly studies with 
anthocyanin-rich foods such as berries resulted in reduced BP in overweight or hypertensive men (199, 
200).  With respect to other phenolic acid rich foods, studies testing coffee consumption reported no 
changes in blood pressure following 1 week of intake (400 mg chlorogenic acids), whereas acute 
consumption of coffee with the same dose showed -2.4 and -1.4 mm Hg reduction in SBP and DBP, 
respectively in healthy individuals (202, 364). Chronic consumption of phenolic rich olive leaf extract 
were also reported to lower day time (-3.9 mmHg) and 24h-SBP, ( -3.3 mmHg) and day time(-3 mmHg) 
and 24h- DBP(-2.42 mmHg) in pre-hypertensive men(365). While the previous evidence is inconsistent, 
our results provide further evidence that oats high in phenolics may reduce BP, particularly night time 
BP which is reported to be a better predictor of cardiovascular events (366, 367). Importantly, -5.1 
mmHg and -2.3 mmHg decrease seen in our night time SBP and DBP can be considered as medically 
relevant improvements as observational studies suggest that a 2 mm Hg decrease in both SBP and DBP 
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are associated with 6% and 7% decreases in CHD risk and 10% and 15% decreases in heart attack and 
stroke, respectively(368, 369). 
Our primary outcome, FMD, showed small, but non-significant improvements: 0.43, 0.50 and 1.09 % 
in response to control, moderate and high phenolic oats interventions, respectively. Previous data 
focusing on the effects of wholegrain oat intake on vascular health has predominantly focussed on the 
impact of fibre, in particular β-glucan, and have not been controlled for phenolic content (276-280). 
Despite this, in agreement with our data, studies testing the vascular effects of oat based interventions 
in healthy subjects for 4 or 6 weeks, also report no significant improvements in endothelial function 
(276, 277) and this is also true in hypercholesterolemic patients over a similar timeframe (278, 279).  
In contrast, significant increases in % FMD (1.80 ± 0.50%) have been reported following the 
consumption of a wild green oat extract (1500 mg/day) for 12 weeks in healthy older adults (280). Wild 
green oat extract was reported to be rich in bioactives such as avenanthramides, saponin, vitexin and 
isovitexin but this study did not analyse the nutritional content of the intervention product(280). With 
respect to other polyphenol-containing foods/beverages, there is extensive evidence to suggest foods 
rich in flavanols, for example cocoa (370) and tea(349) might be effective to improve vascular function.  
A meta-analysis of chronic cocoa/chocolate trials, reported improvements in FMD by 1.45 %, on 
average, at flavanol intake levels of 100-200 mg/day (371). Other studies testing a variety of 
polyphenol rich foods reported mixed results, for example a study using wild blueberry drink providing 
375 mg of anthocyanins and 127 mg of chlorogenic acid for 6 weeks did not show any improvements 
in FMD in subjects with CVD risk factors (218). However, olive oil polyphenols (30mg/day for 8 weeks) 
have been reported to benefit vascular system with improving endothelial function and increasing NO 
levels in pre-hypertensive women (203). Although these studies were not examining the vascular 
benefits of phenolic acids similar to those present in oats, it is known that the metabolism of flavonoids 
in the colon leads to the formation of phenolic acids which have structurally similarity to those found 
in oats, and it may be these same components that underpin the vascular activity of such flavonoid 
interventions in humans (22). 
Consistent with our findings, a study providing flavonoid-rich fruit and vegetable puree drink for 6 
weeks (296 mg anthocyanins per day) showed non-significant improvements in endothelial dependent 
microvascular function in healthy subjects(372). However, another study similarly investigating 
flavonoid rich fruit and vegetable intake for 6 weeks reported significant increase in endothelial 
dependent micro vascular function in healthy men (373). In the current study, no changes were found 
in arterial stiffness determined by PWA and represented as AIx and AIx@75 following the consumption 
of either treatments.  Existing data related to oat consumption and arterial stiffness is limited, an acute 
study reportedly failed to show any changes in AIx@75 following the consumption of 60 g 
oatmeal(374). Furthermore, long term studies focusing on polyphenols and arterial stiffness showed 
inconsistent findings with most promising evidence coming from consumption of cocoa flavanols and 
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cranberry polyphenols showing a positive effect (212, 375). Taken together, despite the non-
significance of our findings on FMD, LDI and PWA and individual measures being relatively variable in 
our trial population making statistical significance hard to achieve, our results tentatively show that 
the intake of oats with highest phenolics tends to benefit the vascular system the most. 
No significant changes in blood lipid profile including total (TC), LDL and HDL cholesterol and 
triglycerides were found in this current study following any of the interventions. While there is a well-
established effect of oat consumption on TC and LDL cholesterol mostly in hypercholesteraemic 
subjects (25, 345), our results are consistent with some other studies which have concluded that oat 
or polyphenol consumption led to no significant difference in plasma lipid profiles of healthy, 
overweight or pre hypertensive subjects (201, 376-378).  However, it must be noted that our power 
calculations were calculated based on FMD, the primary study outcome, rather than lipid markers and 
so our results may be due to lack of statistical power. Circulating EVs as emerging CVD risk factors 
majorly expose phosphatidylserine (PS) as a sign of early cell activation process and EV shedding (379-
383), in this current study, we tested the effect of chronic phenolic rich oat consumption on the 
number of these PS+ circulating vesicles in pre or stage 1 hypertensive subjects. Our results did not 
show any significant differences in the numbers of PS+EVs, PS+ platelet derived extracellular vesicles 
(PDEVs)  and PS+ endothelial derived extracellular vesicles (EDEVs) following the consumption of high 
phenolic, moderate phenolic oats and control. While there is no evidence regarding to the effect of 
wholegrains or oat consumption on the number of circulating EVs, there are few studies examining the 
effect of polyphenols, particularly cocoa flavanols on this outcome and reporting reductions in the 
numbers of PDEVs and EDEVs (99, 219, 221, 222). Different phenotyping techniques and gating 
strategies between these studies and our study need to be considered when comparing the findings. 
Moreover, the threshold of the flow cytometer was set as >300nm to detect EVs in the current study 
whereas some of the previous studies reported threshold values as high as < 3µm which indicates the 
possibility of reporting platelets and apoptotic bodies as EVs as well (219, 222). While the existing 
evidence shows that cocoa flavanols might reduce the number of circulating EVs particularly, EDEVs 
and these results are shown to be paralleled with improvements in FMD and circulating nitric oxide 
species suggesting that flavanols may improve endothelial integrity in subjects with CVD(99), our study 
showed that oat phenolics do not affect the numbers of circulating EVs. This could be because of oat 
phenolics not being as biologically active as flavanols on EVs or the dose provided in the current study, 
which was at a realistic dietary intake level, was not sufficient to induce an effect.  
A number of limitations of the current study are worth noting. The relatively short duration, along with 
the sample size, which was too small to have enough power to draw conclusions across all the 
outcomes tested, are likely the principal limitations. Although we reported significant changes in blood 
pressure following the intake of high phenolic oats, our study was powered for the primary outcome, 
FMD, therefore, we are cautious with our conclusions. Lack of compliance with the intervention diet 
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can be another potential factor influencing our lack of statistically relevant findings.  We used strict 
controls over dietary intake of oats but, as with the majority of dietary intervention studies, we relied 
on self-reporting of diet by individuals. Our diet dairy analysis of the study participants showed no 
significant differences in the dietary intake of carbohydrate and fat (384), fibre (385) and MUFA (386, 
387), or any other dietary components that could influence specific outcomes such as cholesterol and 
lipid profiles. However, it must be noted that our high phenolic intervention contained higher levels of 
PUFA and MUFA when compared to moderate phenolics and control. This could be considered as a 
limitation of our study as intake of MUFA and PUFA may also beneficially influence the blood pressure 
and vascular function (362, 388). Finally, the findings from the study population, which consisted of 
pre or stage-1 hypertensive adults, cannot be extended to the general population, and further work is 
necessary to observe whether, for example, elderly or CVD patients experience similar benefits. 
Therefore, further studies with more sample size, and for a longer intervention period are necessary 
for the effects to become better resolved and statistically significant. 
In conclusion, the present study has strengthened the existing body of evidence that oat consumption 
may beneficially influence the cardiovascular health. Our data suggest that at normal dietary intake 
levels, chronic consumption of oats may reduce blood pressure at a medically relevant levels and 
beneficially effect human vascular system.  These effects may be mediated, in part, by phenolic acids 
and avenanthramides contained within oats. Additional long-term studies are required to examine 
potential mechanisms of action behind these findings and to understand the exact contribution of 
















5.1 General Discussion 
 
CVD accounts for one third of the mortality in the UK and a diet rich in vegetable, fruit and 
wholegrains may help to maintain a healthy cardiovascular function (3, 10). Wholegrain intake is 
associated with reduced risk of CVD and dietary fibre content of cereals has been reported to play an 
important role in cardiovascular health (15, 281). Evidence suggest that oats are effective in lowering 
blood cholesterol and improving post-prandial glycaemia, via a mechanism partly related to their 
high β-glucan soluble fibre (25, 275). Oats are also a rich source of phenolic acids and 
avenanthramides, although the degree to which these compounds contribute to cardiovascular 
health benefits of these cereals has not been investigated in humans (115). Recent dietary 
interventions using phenolic acid-rich foods/beverages (blueberry, coffee and champagne) are 
capable of improving vascular function (29-31). These studies reported improvements in 
microvascular blood flow and large artery function which shown to be driven by small phenolic acids 
including ferulic acid, caffeic acid and p-coumaric acid with mainly modulating endothelial function 
by increasing NO bioavailability. Oats which may promote healthy cardiovascular aging, have a 
similar phenolic acid profile and are sustainable, relatively cheap product that offers an alternative to 
more expensive and less sustainable foods/beverages such as blueberries and champagne. 
Therefore, main scope of this thesis was to investigate whether consumption of phenolic acids and 
avenanthramides found within oat-based diets may promote vascular function particularly via their 
potential to enhance NO bioavailability to the vascular endothelium in an acute and chronic manner 
in humans. The main findings of this thesis include; 
 Phenolic acid and avenanthramide concentrations and compositions of commercial oat 
products are broadly similar and oats are an important source of dietary phenolics to the 
consumer providing 15.8-25.1 mg in a portion. 
 Consumption of 50 mg of phenolics resulted in acute improvements in microvascular 
function and correlated with circulating phenolic acid metabolites in blood in pre- and stage 
1 hypertensive men. Large variability observed in phenolic absorption between study 
volunteers. 
 Daily consumption of an oat based diet for 4 weeks providing 68.1 mg of phenolics 
significantly decreased 24 hour SBP, night time SBP and DBP and resulted in non –significant, 




Initially, phenolic acid and avenanthramide composition and amounts of a variety of commercial oats 
including oat bran, oat bran concentrate, rolled, flaked oats and oat cakes were aimed to be 
determined. Analysis of commercial oat products showed that fibre rich oat bran concentrate has the 
highest total concentrations of phenolics whereas other oat products contained lower but similar 
amounts. In agreement with previous studies, bound fraction of phenolic acids formed the majority 
of the total content whereas free+conjugated fraction were lower and similar in all products 
including oat bran concentrate(295, 296). High amounts of bound phenolic acids quantified in this 
study demonstrated the importance of gut microbiota that may assist the release of colonic phenolic 
acid metabolites to enhance the health benefits of oats (149). On the other hand, similar amounts of 
more bioaccesible free+conjugated fraction of phenolic acids and avenanthramides which may be 
absorbed from the small intestine showed that potential health benefits could be delivered by all 
products analyzed regardless of type (333). Based on our sample range that included the most 
available products to the consumer, we concluded that oats, a popular breakfast cereal in the UK can 
provide 15.8-25.1 mg of phenolic acids and avenanthramides in a 40g portion whereas oat bran 
concentrate provides 16.7 mg in 11 g portion. This analysis mainly provided data about the average 
dietary intake of phenolics from oats and informed our following clinical work to use a realistic dose 
to test the vascular effects of these compounds in humans. 
 
Secondly, an acute randomized controlled trial was performed to test the ability of oat phenolic acids 
and avenanthramides to produce improvements in circulatory function over 24 h in pre and stage 1 
hypertensive men using established, gold standard, clinical measures of blood flow in the body. Our 
findings suggested small non-significant improvements in vascular function, measured by FMD, at 1h 
and 24h following to a single intake of oats (90g, containing 50mg of total phenolics) relative to 
macro- , micronutrient and fibre matched cream of rice control. Lack of effect observed in our FMD 
results broadly disagrees with other acute human intervention trials tested higher doses of flavonoid 
and/or phenolic acid containing foods/beverages such as cocoa, blueberries, cranberries and coffee 
and reported changes as early as 1 h after consumption(29, 30, 283, 389). As a proposed underlying 
mechanism, inhibitory effects of oat phenolics on NADPH oxidase activity was tested but no changes 
were observed in this current acute trial whereas a blueberry dose response study providing >766mg 
of polyphenols reported improvements in FMD and also correlated phenolic acids including vanillic 
acid, homovanillic acid and hippuric acid with a decreased NADPH oxidase activity between 1- 2h and 
6h (29).   
On the other hand, we reported significant changes in endothelium dependent and independent 
microvascular function at 2h following the consumption of oats. These results were in agreement 
with a study that showed improvements in endothelium independent microvascular function at 4h 
and 8h with higher total excretion levels of phenolic acids following the consumption of 
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champagne(31). Changes in endothelial independent microvascular function in our study were 
positively correlated with blood concentrations of phenolic acid metabolites including ferulic acid 
sulfate, ferulic acid glucuronide and p-coumaric acid. However, we observed large variations in 
phenolic acid absorption between study participant’s, 2 h after intake, some participants were 
classified as absorbers with a greater change in microvascular response and others low/non 
absorbers with small or no improvements of microvascular function. In agreement with the 
variability of microvascular response we observed, a very recent review systematically analyzing the 
data from published studies stated that there are number of factors such as individual’s gut 
microbiota composition and function, genetic make- up, age, sex, ethnicity, BMI and 
pathophysiological status which could be responsible for variability in absorption, biological 
responsiveness to polyphenols and these may influence the cardiometabolic response (390).  
 
Finally, a chronic human study was conducted to test the effect of high and moderate dose of oat 
phenolic acids and avenanthramides on vascular health. Consumption of high phenolic oats that 
consisted of  66.8 g of oatmeal and 60 g of oatcake (providing 68.1 mg of phenolics) for 4 weeks led 
to a significant improvement in 24-hour SBP, night time SBP and night time DBP. In agreement with 
our findings, few other studies reported a decrease in blood pressure following the consumption of 
oats in pre and stage 1 hypertensive men (353, 354). While these studies did not distinguish the 
phenolic content of oats and mainly attributed the observed effects to oat based diets or fibre 
content of oats, our study provides a clearer evidence that the decrease observed in blood pressure 
may also partly be mediated by oat phenolics. Additionally, there is a body of evidence suggests that 
chronic consumption of polyphenols in various foods may reduce BP. While the studies on cocoa and 
tea flavanols are being more consistent, there are some studies examining flavanoids in berries and 
phenolics in coffee and olive oil and showing a reduction in BP (194, 195, 199, 202, 364, 365). It must 
be noted that structurally bigger polyphenols such as flavonoids can be metabolized into smaller 
phenolics which may exert health benefits in humans, therefore findings of these studies might be 
relevant to our findings. We also observed dose dependent changes in vascular, microvascular 
response and LDL cholesterol following the consumption of high and moderate dose of phenolics, 
however these results were not significant and high variability of responsiveness was observed 
between the participants. There is a valuable amount of evidence  that shows the potential beneficial 
effects of polyphenol rich foods including  cocoa , tea ,berries and olive oil on endothelial function 
whereas oat intake was generally shown to fail to induce any improvements in FMD but extensively 
reported to reduce total cholesterol and LDL-cholesterol , particularly in subjects with 
hypercholesterolemia (22, 25, 203, 277-279, 349). Because of these conflicting findings between our 
study and others, also the dose-response improvement we observed in our measures, we suggest 
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that a bigger sample size is necessary to understand the long-term effects of oat phenolics on 
vascular and microvascular function and cholesterol. 
In summary, our results suggest that acute consumption of structurally smaller oat phenolic acids 
and avenanthramides at provided doses might be effective on microvascular function whereas higher 
doses of phenolic acids or consumption of these compounds together with other classes of 
polyphenols such as flavonoids might be required to exert biological actions on vascular function. We 
can suggest that free+conjugated phenolics that are likely to be absorbed from small intestine after 
consumption might be responsible for the significant effect that we observed in microvascular 
function at 2h. Inter-individual variability that we observed in phenolic absorption shows that every 
individual may not equally benefit from these compounds and this should be considered in future 
strategies of personalized nutrition for a better prevention of CVDs. In comparison to the acute 
study, our chronic study demonstrated stronger evidence that the intake of oat phenolics may 
reduce blood pressure that are in terms of magnitude, possibly medically relevant. Variability 
observed in the measures of chronic study further supported the variability to the responsiveness to 
the intervention, although we did not measure phenolic acid metabolite levels chronically to define 
this. Overall, this study adds further evidence that consumption of oats, containing phenolic acids 
and avenanthramides may help to maintain a healthy cardiovascular system. 
 
5.2 Future Perspectives 
 
In this thesis, we addressed a number of research questions while highlighting some gaps for further 
studies. We showed that the acute improvement in microvascular function might be mediated by 
phenolic acid metabolites quantified in blood. However, our chronic study lacked similar type of 
pharmacokinetic analysis. Therefore, further studies are required to measure the blood and urinary 
levels of phenolic acid metabolites in order to understand the accumulation over long-term intake. 
Based on a previous bioavailability study performed in our group, we showed elevated total urinary 
excretion levels of phenolics between 0-2h and 4-8h following the consumption of oatbran (See 
Appendix). Therefore, we could suggest that a collection time of blood and urine samples in a chronic 
study could start from 8h after consumption and extend beyond this time point to examine whether 
bound phenolics are absorbed to the bloodstream and also to see if phenolics accumulate over time 
to exert beneficial effects on vascular function. On the other hand, variabilities in individual’s gut 
microbiota composition may limit the action of colonic metabolites, therefore, enzymatic treatments 
of oat products to release the bound phenolics into free forms to increase the bio accessible phenolic 
content might be help to increase health benefits of oats. Together with circulating metabolites, in 
order to examine the mechanisms of action, the inhibitory effects of oat phenolics on NADPH oxidase 
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activity and circulating levels of NO might be measured in a chronic manner to understand the 
effects of phenolic acid exposure on cells following repeated ingestion. 
Finally, conducting similar types of studies for longer intervention periods, in other populations 
including elderly or people with other cardiovascular disease factors may help to better define the 
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Scope: Wholegrain has been associated with reduced chronic disease mortality, with oat intake 
particularly notable for lowering blood cholesterol and glycemia. To better understand the complex 
nutrient profile of oats, we studied urinary excretion of phenolic acids and avenanthramides after 
ingestion of oat bran in humans. 
Methods and results: After a 2d (poly)phenol-low diet, 7 healthy men provided urine 12h before, and 
48h after, consuming 60g oat bran (7.8µmol avenanthramides, 139.2µmol phenolic acids) or a 
phenolic-low (traces of phenolics) control in a crossover design. Analysis by UPLC-MS/MS showed that 
oat bran intake resulted in an elevation in urinary excretion of 30 phenolics relative to the control, 
suggesting that they are oat bran-derived. Mean excretion levels were elevated between 0-2 and 4-
8h, following oat bran intake, and amounted to a total of 33.7±7.3µmol total excretion (mean recovery: 
22.9±5.0%), relative to control. The predominant metabolites included : vanillic acid, 4- and 3-
hydroxyhippuric acids and sulfate-conjugates of benzoic and ferulic acids, which accounted collectively 
for two thirds of total excretion. 
Conclusion: Oat bran phenolics follow a relatively rapid urinary excretion, with 30 metabolites 
excreted within 8h of intake. These levels of excretion suggest that bound phenolics are, in part, rapidly 




Increasing the daily intake of wholegrain cereals by 90g has been associated with reduction in 
mortality from cardiovascular disease by 27%, total cancer by 15%, respiratory disease by 22%, 
diabetes by 51% and infectious diseases by 26%, as indicated by recent meta-analysis of 45 prospective 
studies (15). Human intervention studies have to date largely focused on wholegrain oats (Avena 
sativa L.), with meta-analyses establishing that regular oat intake lowers blood cholesterol (391, 392) 
and improves insulin sensitivity and post-prandial glycemic control (275). Although oats only account 
for 1% of world grain production, they, unlike more widely consumed grains, are almost exclusively 
consumed as wholegrains and therefore a rich dietary source of high quality proteins, minerals, 
vitamins, soluble β-glucan fiber and phenolic compounds (i.e. phenolic acids and avenanthramides), 
all of which are concentrated in the outer bran layers (393). 
β-glucan is, at least in part, responsible for the health benefits of oats (275, 391, 392), while there is 
limited in vitro evidence that avenanthramides (394) and phenolic acids (28) may also promote 
beneficial cardiovascular physiology. Phenolic acid intake in Europe is on average 605 mg/d, with the 
main dietary sources being coffee (75%), fruits (5.6%) and wholegrain products (5.5%) (395). 
Wholegrain is the richest dietary source of ferulic acid, which has a mean intake of 38 mg/d in Europe 
(395), although a number of other phenolic acids and phenolic alkaloids, notably the avananthramides, 
are present in oats, either in the ‘free form’, as soluble conjugates, or as insoluble bound forms 
(including ester-linked to fiber) (396). Understanding the urinary excretion (an indirect measure of 
absorption) of oat phenolic compounds following the dietary intake of whole oats or oat bran is a key 
prerequisite for determining which phenolic metabolites may mediate the health benefits of oats.  
Previous data using oat phenolic extracts or wheat have indicated that phenolics transfer to the 
circulation following intake (123, 150), whilst limited data exist for the urinary excretion of phenolics 
and other bioactive components from whole oats or oat bran at a dietary level. Notably, the intake of 
150 mg of avananthramides (highly concentrated oat extract), led to detection of avenanthramides 
2c, 2f and 2p at nanomolar concentrations in plasma between 0.25 and 5h, peaking at 2h (123). While 
this study did not examine metabolism, data from studies in animals suggest that avenanthramide 2c 
is metabolized to avenanthramide 2f, dihydroavenanthramide 2f and 2c, four hydroxycinnamic acids, 
and 5-hydroxyanthranilic acid following oral intake (313). Furthermore, intake of 94 g wholegrain 
wheat bread, containing 87 mg of ferulic acid or aleurone-enriched white bread led to the appearance 
of ferulic acid-sulfate, dihydroferulic-sulfate, hippuric acid and two hydroxyhippuric acids in plasma, 
with the former two reaching peak plasma concentrations of 84 nM and 9 nM at 1 and 7 h after intake, 
respectively (150), along with 12 other phenolic acid metabolites in 48h urine, suggesting that ferulic 
acid is subject to extensive metabolism and that some fiber-linked ferulic acid is released later during 
transit through the gastrointestinal track through action of the microbiota (150). 
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The aim of our study was to examine the urinary excretion of avenanthramides and phenolic acids 
following intake of 60g oat bran. Specifically, the study focused on three objectives; 1) to establish 
peak urinary excretion intervals of phenolic acids and avenanthramides; 2) to determine the temporal 
nature of oat phenolic release from the bound state in the gastrointestinal tract; and 3), to identify 
and quantify the range of phenolic metabolites derived from the oat phenolics using comprehensive 
UPLC-MS/MS methods. 
 
Materials and Methods 
 
Chemicals and reagents 
 
Avenanthramide 2c, avenanthramide 2f, avenanthramide 2p, 2,4-dihydroxy benzoic acid, p-coumaric 
acid, caffeic acid, isoferulic acid, syringic acid, salicylic acid, o-coumaric acid, vanillic acid, 
syringaldehyde, ferulic acid, sinapic acid, 4-hydroxybenzaldehyde, 4-hydroxybenzoic acid, vanillin, 
protocatechuic acid, isovanillic acid, gallic acid, homovanillic acid, hippuric acid, dihydroferulic acid, 
dihydrocaffeic acid, 4-hydroxyphenylacetic acid and 2-hydroxyhippuric acid were obtained from 
Sigma-Aldrich (see Supporting Information Table 1 for IUPAC names). Dihydroferulic acid-4-O-
glucuronide, isoferulic acid-3-O-sulfate, ferulic acid-4-O-glucuronide, dihydroxybenzoic acid-3-O-
glucuronide and 5-hydroxyanthranilic acid were obtained from Toronto Research Chemicals Inc. 4-
hydroxyhippuric acid and 3-hydroxyhippuric acid were purchased from Enamine (see Supporting 
Information Table 1 for IUPAC names). All solvents were HPLC grade and were obtained from Sigma-
Aldrich or Fisher Scientific. While we acknowledge that avenanthramides are phenolic alkaloids, the 
terms phenolics is used throughout the paper to include both avenanthramides and phenolic acids. 
 
Extraction and analysis of oat bran phenolics 
 
Soluble and bound phenolic fractions were extracted from oats using an established method (294), 
with addition of hexane defatting steps adapted from (397) and preservation of phenolics during alkali 
hydrolysis using ascorbate and EDTA adapted from (398). Phenolic acids and avenanthramides were 
separated using an Agilent 1100 series HPLC equipped with a Kinetex biphenyl column (100 Å 250x4.6 
mm, 5µm; Phenomenex) with a Security Guard ultra biphenyl cartridge (Phenomenex). Sample 
injection volume was 20 μL, the flow rate 1 mL/min and mobile phases consisted of 0.1% formic acid 
(v/v) in water (solvent A) and 0.1% formic acid (v/v) in methanol (solvent B). The solvent gradient 
consisted of 5% B at 0 min, 25% B at 20 min, 26% B at 25 min, 35% B at 30 min, 36% B at 40 min, 70% 
B at 53 min, 95% B at 56 min, 95% B at 61 min, 5% B at 62 min, 5% B at 65 min. The absorbance was 
recorded at 254, 280 and 320nm and quantification was based on 12 point linear calibration curves 
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(mean R2 > 0.994) and as a ratio to the internal standard (i.e. 3,5-dichloro-4-hydroxybenzoic acid) to 
account for losses during extraction. 
Study design 
 
Seven healthy men aged 25-62 years were recruited from the local community. Exclusion criteria were 
as follows: recent (last 3 months) use of antibiotics, flu vaccination or dietary supplements. All 
participants gave written informed consent prior to study commencement and the study was 
performed at the Hugh Sinclair Unit of Human Nutrition, University of Reading (UK) between July 2014 
and September 2014. The study was approved by the University of Reading Research Ethics Committee 
(Reference number: 31/15), followed the principles of the Declaration of Helsinki and was registered 
on ClinicalTrials.gov under NCT02574039. 
The study was designed as a non-blinded, randomized, controlled trial, where participants attended 
two experimental visits that were identical with the exception of the two study meals: 1) Test 
intervention consisting of 60 g oat bran porridge, 200 ml semi-skimmed milk and 100 ml water, 
microwaved (2min); or 2) a control consisting of 100g white bread, 14g butter, golden syrup, one boiled 
egg and 200 ml semi-skimmed milk; given in random order. Participants arrived at the Nutrition Unit 
at 8am or 9am to consume the study meal within 10 min. Urine was collected at 11 specific intervals 
relative to study meal consumption: -12h to 0h (i.e. baseline), 0h to 2h, 2h to 4h, 4h to 6h, 6h to 8h, 
8h to 12h, 12h to 24h, 24h to 28h, 28h to 32h, 32h to 36h and 36h to 48h (see Figure 1). Collected 
urine was kept on ice packs, the excretion volume measured and aliquots were stored at -80°C with 
and without 5% formic acid acidification. During the 48h urine collection period, participants 
consumed a low-phenolic meals provided to them (lunch: a white bread cheese sandwich and toffee 
yoghurt; dinner: macaroni cheese pasta, white bread roll and crème brulée; breakfast: white toast with 
butter and golden syrup, a boiled egg and glass of milk), whilst drinking water ad libitum. Prior to each 
experimental visit, participants followed a diet low in (poly)phenols for 48h (i.e. no fruits, vegetables, 
wholegrains, pulses, spices, herbs, nuts, seeds, chocolate, tea and coffee), and attended an overnight 
fast after having consumed a low-(poly)phenol dinner (a cheese pasta bake, white bread roll and crème 
brulée). Compliance to the dietary restrictions was assessed using food intake diaries and 
questionnaires. One volunteer was excluded from the final dataset, due to non-compliance to the 
dietary restrictions (i.e. volunteer reported intake of (poly)phenol-rich foods and baseline and post-





Figure 1: Study Design Overview. 
 
Solid phase extraction 
 
Phenolic acids were extracted from urine using a validated method (399) with minor modifications. 
Briefly, 1 mL of urine was spiked with an internal standard (i.e. 3,5-dichloro-4-hydroxybenzoic acid) 
and subsequently extracted using solid phase extraction cartridges (Strata-X columns 500mg/6mL; 
Phenomenex). These were washed with 12 mL of 0.1/99.9 v/v hydrochloric acid/water, dried for 30 
min under vacuum, soaked in 0.1/99.9 v/v hydrochloric acid/methanol for 10 min and eluted into glass 
vials with 7 mL 0.1/99.9 v/v hydrochloric acid/methanol. Samples were evaporated to complete 
dryness under speedvac at room temperature. The dried samples were resuspended in 250 μL of 
mobile phase (0.1/5/94.9, v/v/v, formic acid/methanol/water) by 30s vortexing, 15min ultrasound 
sonicating and 1h shaking. Samples were stored at -80°C until analysis. For phenolic acids and 
metabolites the method has a mean ± SD extraction efficiency of 88.3 ± 17.8% as previously reported 





The UPLC-electrospray ionisation-MS/MS system consisted of an Aquity UPLC Hclass (Waters) coupled 
to a Xevo TQ-S micro electrospray ionisation mass spectrometer (Waters) operated using MassLynx 
software (V4.1, Waters Inc, USA). Compound separation was achieved using an Aquity UPLC HSS T3 
1.8µm column (2.1 x 100mm) attached to a Van guard pre-column of the same material and pore size, 
maintained at 45°C with a flow of 0.65 mL/min and a sample injection volume of 2 μL. The mobile 
phase consisted of 0.1/99.9 v/v formic acid/water (A) and 0.1/99.9 v/v formic acid/acetonitrile (B); and 
a mobile phase gradient consisting of: 1% B at 0 min, 1% B at 1 min, 30 % B at 10 min, 95 % B at 12 
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min, 95% B at 13 min, 1% B at 13.10 min, 1% B at 16 min. A scheduled multiple reaction monitoring 
(sMRM) method was developed by syringe infusion of 34 analytical standards (see section Chemicals 
and Reagents and Supporting Information Table 1) to determine sMRM transitions, optimal sMRM 
modes (i.e. negative or positive) and collision energies (Supporting Information Table 2). 
Regarding phase II metabolites, while four authentic standards were used for the sMRM method (i.e. 
dihydroferulic acid-4-O-glucuronide, isoferulic acid-3-O-sulfate, ferulic acid-4-O-glucuronide and 
dihydroxybenzoic acid-3-O-glucuronide), further putative glucuronide or sulfate conjugated phenolic 
acid metabolites and feruloyl glycine were added to the sMRM method, even though analytical 
standards were not commercially available. For these, retention times and sMRM transitions were 
tentatively identified by injecting a pooled extract of urine (i.e. using urine collected after oat bran 
intake from all n=7 participants and during all 10 post-intake time intervals). sMRM transitions were 
taken from the literature (151, 326, 400, 401) or derived from the fragmentation pattern of the 
phenolic acid aglycones by adding the m/z of glucuronide (i.e. 176) or sulfate (i.e. 80) to the precursor 
ion and including the appropriate MS/MS fragment. Furthermore, 113 m/z, a common fragment of 
glucuronic acid, was added as an MS/MS fragment for glucuronide conjugates (326). Collision energies 
were optimized to a limited extent by injecting the pooled urine extract three times at collision 
energies -11, -17 and -21 and the best one was selected for each sMRM transition. In the final sMRM, 
a total of 74 potential compounds were targeted and statistical comparison between the oat and 
control intervention was used to identify those which are oat bran-derived phenolics. Identification of 
the phenolic metabolites for which standards were available was based on their retention times and 
the major sMRM ion transitions of the standards, while the tentative identification of phenolic 
metabolites for which analytical standards were not available was based on 3-6 sMRM ion transitions 
(except for benzoic acid-sulfate which only has 2 sMRM ion transitions as reported in the literature 
(401) ) (Supporting Information Table 2). 
Quantification was established using the most intense sMRM transition and 11-14 point calibration 
curves of analytical standards (Supporting Information Table 2). Where pure standards were not 
available, quantification was conducted relative to standard curves of compounds with similar 
structures (e.g. the calibration curve of isoferulic acid-3-O-sulfate was used to quantify all tentatively 
identified sulfate metabolites). The limit of detection and quantification were established for each 
compound as the concentrations of peaks with signal to noise ratios of 3 and 10, respectively, and 
were lowest for avenanthramide 2p ( 0.8nM and 2.7nM, respectively) and highest for vanillin or 
hydroxyphenylacetic acid-O-glucuronide (35.0nM and 116.7nM, respectively; Supporting Information 
Table 2). Blanks and quality controls were run every 10 injections. Validation parameters indicate that 
the method had good precision and repeatability (inter-day variability: 9.1%; inter-day variability: 
13.7%) and good linearity (linear regression coefficient range: 0.990 to 1.000; Supporting Information 
Table 2) 
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Sample acidification using 5% formic acid did not significantly affect phenolic compound peak areas 
(established in n=3 volunteers; data not shown) and therefore non-acidified urine was used for the 
complete analysis. 
 
Table 1: Content and composition of phenolics in 60g oat bran a) 
  
 Fraction 
  Conjugated and free Bound % Conjugated and free 
Avenanthramides    
Avenanthramide 2c 0.8mg (2.5µmol) ND 100% 
Avenanthramide 2f 1.0mg (3.1µmol) ND 100% 
Avenanthramide 2p 0.7mg (2.2µmol) ND 100% 
Hydroxycinnamic acids    
Ferulic acid 2.0mg (10.1µmol) 14.8mg (76.4µmol) 12% 
p-Coumaric acid 0.4mg (2.3µmol) 3.0mg (18.1µmol) 11% 
Caffeic acid 0.1mg (0.4µmol) 1.3mg (7.0µmol) 5% 
Sinapic acid 0.9mg (3.8µmol) 1.2mg (5.5µmol) 41% 
Hydroxybenzoic acids    
4-Hydroxybenzoic acid 0.2mg (1.8µmol) 0.3mg (1.9µmol) 48% 
Vanillic acid 0.4mg (2.4µmol) 0.4mg (2.2µmol) 53% 
Syringic acid 0.4mg (2.1µmol) 0.3mg (1.5µmol) 57% 
Benzaldehydes    
4-Hydroxybenzaldehyde 0.2mg (1.4µmol) 0.1mg (1.1µmol) 56% 
Vanillin ND 0.2mg (1.3µmol) 0% 
Total 7.0mg (32.1µmol) 21.6mg (115.0µmol) 24% 









A two-factor repeated-measurement linear mixed model was fitted to analyze hourly urinary excretion 
data. The model included participants nested within time as a random effect and baseline hourly 
urinary excretion, intervention, time and interaction as fixed effects. When the model showed a 
significant interaction effect, post-hoc analysis with Tukey-Kramer adjustment was performed. Data 
are presented as means ± SEMs. P-values of <0.05 were considered statistically significant, and 
statistical analysis was performed by using R programming language version 3.1.2 (R Development 





Phenolic composition of the oat bran intervention 
 
Twelve phenolic compounds were detected in the oat bran used for the trial, with eight phenolic acids 
being present in both soluble and bound fractions, three avenanthramides only present in the soluble 
fraction and vanillin only in the bound fraction (Table 1). The intervention diet (60g oat bran) contained 
28.6mg total phenolics (24% in the soluble fraction), with ferulic acid being the predominant phenolic 
acid (16.8mg) followed by p-coumaric acid (3.3mg) and the three avenanthramides collectively 
amounting to 2.5mg. Although the control meal and all other meals consumed during the 48h study 
periods were not analyzed, they consisted of white wheat bread and pasta and would therefore be 
expected to contain only low amounts of phenolic acids (402). 
Identification of oat bran-derived phenolic compounds in urine 
 
A wide range of phenolic compounds were detected in urine at baseline and after the control meal 
intake (Supporting Information Table 3). However, the hourly excretion of 30 individual phenolic 
compounds was elevated following intake of oat bran compared to the control intervention (significant 
mixed model P-value of intervention and/or time*intervention; Supporting Information Table 3), 
suggesting that they are derived from the ingested oat bran. These phenolics were identified as 
avenanthramides 2f and 29 phenolic acids (nine aglycones, four glycine conjugates, ten sulfate 
conjugates and seven glucuronide conjugates; Supporting Information Table 2). Excretion of hippuric 
acid, the dominant phenolic acid in human urine,  was not statistically higher after the oat bran 
intervention relative to the control and was thus not identified as an oat bran-derived metabolites 
(mixed model time*intervention interaction P-values: 0.36; Supporting Information Table 4). In total, 
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44 targeted phenolic compounds were statistically similar between interventions (Supporting 
Information Table 4). 
 
 
Figure 2: Urinary excretion rate of total 30 oat bran-derived phenolic compounds after intake of 60g 
oat bran or a control meal in healthy men (µmol/h). Data are reported as mean ± SEM and were 
analyzed by two-factor repeated measurement linear mixed model with time and intervention as the 
two factors [significant effect of intervention (P = 0.005), time (P = 3*10-13), and time and intervention 
interaction (P = 5*10-6)]. Post-hoc analysis with Tukey-Kramer adjustment was performed and P-values 




Hourly urinary excretion of oat phenolic compounds 
 
At baseline, the mean hourly excretion of the total excretion of 30 phenolic compounds prior to oat 
bran and control interventions was 2.4±0.6 µmol/h and 1.9±0.4 µmol/h, respectively (Figure 2). 
Following intervention, the total hourly phenolic excretion significantly increased at 0-2h (oat: 9.3±1.9 
µmol/h, control: 3.1±0.7 µmol/h; post-hoc P-value <0.0001), returned to a similar level as control at 2-
4h (oat: 4.7±0.9 µmol/h, control: 4.0±1.2µmol/h; post-hoc P-value >0.05) and peaked again between 
the 4-6 h period (oat: 8.7±1.9µmol/h, control: 4.0±0.7µmol/h; post-hoc P-value < 0.05) and 6-8h (oat: 
13.7±1.2µmol/h, control: 7.5±0.6µmol/h; post-hoc P-value < 0.01) before returning to a similar level 
to the control intervention from 8 to 48h (post-hoc P-value >0.05; Figure 2). Figure 3 shows the oat 
bran induced increase in excretion of the individual 30 oat bran-derived phenolics proportional to the 
total excretion at 0-2h, 4-6h and 6-8h, relative to control. Vanillic acid, 3-hydroxyhippuric acid, 4-
hydroxyhippuric acid, benzoic acid-O-sulfate and ferulic acid- O-sulfate were the predominant oat 
bran-derived phenolics excreted, accounting collectively for more than two thirds of the total excretion 
(i.e. 20.3%, 16.3%, 16.1%, 9.8% and 7.3%, respectively). (Iso)ferulic acid-O-sulfate was predominant 
134 
during the early 0-2h peak, vanillic acid was almost exclusively excreted during the late 4-8h period, 
whilst excretion of hydroxyhippuric acids and benzoic acid-O-sulfate was biphasic, with early and late 
peaks (Figure 3). Ferulic acid, p-coumaric acid and avenanthramides 2p (i.e. the most abundant 
phenolic compounds in oats) accounted only for small percentages of the total excreted phenolics (i.e. 
0.21%, 0.04% and 0.02%, respectively; Figure 3) and avenanthramide 2f and 2c were not detected, 
suggesting that these dietary forms are subject to extensive metabolism. 
The mean absolute urinary excretion of the 30 oat bran-derived phenolics from 0-8h was 70.7±8.1µmol 
after consumption of oat bran and 37.1±4.4µmol after the control intervention (Table 2). Hence, on 
average 22.9±5.0% of the ingested dose (i.e. 147µmol phenolics in 60g oat bran; Table 1) was 
recovered in the 0-8h urine and there was large inter-individual variability in absorption that ranged 
from 3.7% to 41.2% (Table 2). The mean percentage recovery of metabolites was lowest for the 
avenanthramide 2p (0.3%), intermediate for hydroxycinnamic acids (6.8-10.7%) and highest for 






Table 2: 0-8h absolute urinary excretion (µmol) of oat bran-derived phenolics and recovery of ingested dose (%) 
  Mean±SEM urinary excretion 0-8h (µmol)   Recovery of ingested dose (%) 
 
Excreted phenolics Control Oat bran Difference 
 
Mean±SEM Lowest/highest absorber Oat parent compounds (Ingested dose) 
Avenanthramide 2p 0.006±0.001 0.012±0.003 0.006±0.003 0.3 ± 0.1% 0% /0.7% Avenanthramide 2p (2.2µmol) 
Hydroxycinnamic acids        
Ferulic acid metabolitesa) 4.1±0.4 10±0.8 5.9±0.7 
 
6.8 ± 0.8% 4.9% /9.3% Ferulic acid (86.5µmol) 
Caffeic acid-O-sulfate 0.4±0.2 1.2±0.4 0.8±0.5 
 
10.7 ± 7% -15.6% /34.9% Caffeic acid (7.4µmol) 
Sinapic acid-O-sulfate 0.5±0.1 1.5±0.2 1±0.2 
 
10.6 ± 1.6% 4.9% /15% Sinapic acid (9.3µmol) 
Hydroxybenzoic acids        
(Iso)vanillic acid 6.1±2.5 13.5±3.1 7.3±2.5 
 
159.2 ± 53.8% -80.5% /308.3% Vanillic acid (4.6µmol) 
Benzoic acid-O-sulfate/glucuronide 7.1±2 10.3±2.7 3.2±1 
 
85.2 ± 26% 8.1% /176.1% 4-hydroxybenzoic acid (3.7µmol) 
Syringic acid-O-sulfate 0.4±0.1 0.9±0.2 0.5±0.1 
 
14.5 ± 4.1% 1.5% /30.5% Syringic acid (3.6µmol) 
Total 30 phenolics 37.1±4.4 70.7±8.1 33.7±7.3   22.9 ± 5% 3.7% /41.2% Total 12 phenolics (147.1µmol) 










Figure 3: Proportions of individual oat bran-derived phenolics relative to total excretion levels at 0-
2h, 4-6h and 6-8h. Excretion level differences between the oat and control interventions were used to 




The present randomized controlled trial is, to our knowledge, the first to have examined the excretion 
of phenolic metabolites following intake of dietary amounts of oat bran as a whole food over a 48h 
timeframe and complements previous studies that examined the metabolism and bioavailability of 
phenolics following intake of an oat avenanthramide extract at a high-dose (123) or following intake 
of wheat (150). Oat bran intake resulted in elevated urinary excretion of 30 phenolic compounds at 0-
2h and 4-8h, with sulfate or glycine conjugated benzoic acids being the major metabolites together 
with ferulic acid-O-sulfate, and the total amounts of phenolic compounds recovered in urine 
amounting to 22.9±5.0% of the ingested phenolic dose. These results suggest that a high proportion 
of oat phenolics are bioavailable as a wide range of metabolites with absorption occurring both in the 
small intestine and then in the large intestine within eight hours of consumption. 
Analysis of the utilized oat bran detected nine phenolic acids amounting to 434 µg/g and three 
avenanthramides amounting to 41 µg/g (Table 1). These levels are comparable to four previous studies 
that analyzed wholegrain oats or oat bran, identifying up to 10 phenolic acids at levels ranging from 
273 to 874 µg/g and three avenanthramides at levels ranging from 13 to 116 µg/g (296, 301, 396, 403). 
The relatively wide range in the reported contents and compositions of phenolics can be explained by 
the different oat products analyzed (i.e. commercial or non-commercial varieties, bran or wholegrain, 
and hulled or de-hulled), and by the different extraction and analytical methods used for their analysis. 
Although other cereals may be richer sources of phenolic compounds (for example, Mattila et al. found 
6.8-fold and 6.3-fold more total phenolic compounds in wheat and rye bran, respectively, than in oat 
bran (301)), oats are particularly interesting because of the relatively high proportions of phenolics in 
free and conjugated forms (24% in our oat bran and from 34 to 62% in non-commercial hulled 
wholegrain oats (396), whereas wheat has less than 18% (402) and wheat bran cereals only 8% (151)) 
and thus phenolic components from oats may have a higher bio-accessibility in comparison to other 
cereals. 
We observed high background excretion of all 30 oat bran-derived phenolic compounds at baseline 
and in the control arm (Supporting Information Table 3; Figure 2), even though volunteers followed a 
48h low-phenolic diet. A high background phenolic excretion has previously been described in the 
control groups of other studies of (poly)phenol bioavailability after following 2d (404) or 7d (405) low 
phenolic dietary restrictions. These phenolic compounds may originate from the relatively low 
amounts of phenolics consumed in white bread and pasta during the dietary restrictions (402) and 
from the metabolism of other dietary components such as aromatic amino acids (406). Despite this 
high background excretion, our data indicate that intake of oat bran leads to urinary excretion of 30 
phenolic acid compounds which peak early at 0-2h, and again later between 4-8h (Figure 2). The early 
appearance of metabolites suggests that the absorption of free phenolics from the oat bran occurs in 
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the upper gastrointestinal tract with esterified conjugates being hydrolyzed by esterase activity in the 
intestinal mucosa (407), followed by the transfer of free phenolics across the intestinal epithelium 
through passive diffusion or via transporters (408). Although we hypothesized that phenolics in the 
bound fraction would appear late in the urine, due to a requirement for gut microbiota to cleave 
covalent linkages between phenolic and fibre, the second peak of excretion was complete by 8 h, 
suggesting that the release and absorption occurred more rapidly (Figure 2). This agrees with previous 
studies, showing that bound phenolics may reach the colon and undergo microbial fermentation within 
4 hours of oat bran intake. Indeed, in fasted volunteers (which was true in our study) a mean mouth-
to-cecum transit time can be as rapid as 2.3h (409) and in vitro fermentation of wheat bran with human 
microbiota shows that digestion by microbial esterase and xylanase starts within 2h resulting in most 
fiber-bound phenolics being released within 6h (410). 
The urinary recovery of ingested phenolics was on average 22.9±5.0% in the first 8 h after the oat bran 
intake, relative to the control (Table 2). Previous non-controlled studies reported lower mean 
recoveries in 24h urine of 4 ± 1%, 8 ± 2% and 3 ± 1% following ingestion of phenolics in wholegrain 
wheat bread (150), aleurone-enriched wheat bread (150) or wheat bran cereals (151), respectively, 
but a higher mean recovery of 29 ± 4% following ingestion of phenolics in instant coffee (400). This 
wide variation in phenolic bioavailability may partly be explained by differences in the bioaccessibility 
of phenolics within the food matrix. While phenolic acids in coffee are conjugated to quinic acids and 
are relatively water soluble (400), the oat bran used here had 24% soluble phenolic acids (Table A1) 
and wheat bran cereals only 9% (151). However, such direct comparisons of recoveries between 
studies may be of limited value due to the non-controlled design of previous studies (150, 151, 400), 
and differences in the methods used to analyze phenolic acids in the urine and food samples including 
the number of metabolites targeted with the LC-MS/MS methods. 
Free forms of vanillic and isovanillic acids were the highest and 7th most highly excreted phenolics, 
respectively being mainly excreted in the late peak between 4-8h after oat bran intake (Figure 3) and 
at levels totaling more than the total amount of vanillic acid that was ingested (mean ± SEM recovery: 
159.2 ± 53.8%; Table 2). These data suggest that whilst only a limited amount of vanillic acid is 
absorbed directly in the small intestine, a larger proportion is absorbed following release by 
fermentation by the colonic microbiota with previous studies suggesting that it originated partly from 
the metabolism of avenanthramides and hydroxycinnamic acids (404, 411-413). Vanillic acid may be 
formed by β-oxidation of ferulic acid in the liver, and isovanillic acid from methylation of caffeic acid 
to isoferulic acid followed by liver β-oxidation (404, 411-413). 4-, 3- and 2-hydroxyhippuric acids were 
also highly excreted, with their excretion following a biphasic pattern (early 0-2h and late 4-8h) after 
oat bran intake (Figure 3). While hydroxyhippuric acids are common flavonoid metabolites detected, 
for example, following intake of orange juice (414) and cocoa (415), results from this oat trial and a 
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recent wheat trial (150) suggest that hydroxyhippuric acids are also important metabolites derived 
from wholegrain. 
A study feeding 75-150mg avenanthramides in an oat extract to humans detected nanomolar 
concentrations of circulating avenanthramides (123), while the present study detected only traces of 
the ingested 2.5mg avenanthramides in urine. This may indicate that avenanthramides are bioavailable 
when ingested at a relatively high dose and that avenanthramides are mostly metabolized particularly 
to hydroxycinnamic acids during their passage through the GI tract and into the circulation (Table 2). 
Hydroxycinnamic acids, in turn, undergo reduction, methylation, sulfation or glucuronidation, and are 
also metabolized to smaller hydroxybenzoic acids (Table 2). Chlorogenic acid and caffeic acid aglycones 
in coffee have a similar metabolic fate to avenanthramides and hydroxycinnamic acids in cereals. A 
study in ileostomy patients showed that although 33% of chlorogenic acid and 95% of caffeic acid were 
absorbed in the small intestine, only traces of chlorogenic acid and 11% of caffeic acid of the ingested 
dose were excreted in the urine (416). Avenanthramides were also metabolize to hydroxyanthralinic 
acid and dihydroavenanthramides as reported in a study feeding in mice with a high dose of 200mg/kg 
avenanthramide 2c (313); however, the present study did determine these two compounds because 
of poor ionization of the former and unavailability of sMRM parameters for the latter. 
In conclusion, oats are a popular health food and to our knowledge the present study is the first to 
study the metabolic fate of oat avenanthramides and phenolic acids when ingested at a dietary dose 
and as a whole food. Our data suggest that oat bran phenolics are more bioavailable than previous 
studies reported (150, 151, 400) with 22.9±5.0% of the ingested dose being excreted in urine during 
8h following intake in the form of 30 different phenolics or their metabolites. The data showed that 
benzoic acid derivatives, and in particular (iso)vanillic acid, and three isoforms of hydroxyhippuric 
acids, accounted for a high proportion of the excreted compounds, together with ferulic acid-O-sulfate. 
While the present study is an important contribution to the existing literature, future work is required 
to verify tentatively identified phenolic metabolites against analytical standards, to establish the 
detailed pharmacokinetics and circulating concentrations of these oat bran-derived phenolic 
compounds, and to determine their biological activities and contributions to the health benefits of a 





Supporting Information Table 1 – Common and IUPAC names of phenolic compounds 
  
Common Name IUPAC Name 
List of available analytical standards 
2,4-dihydroxy benzoic acid 2,4-dihydroxybenzoic acid 
2,5-dihydroxy benzoic acid 2,5-dihydroxy benzoic acid 
2-hydroxyhippuric acid 2-[(2-hydroxybenzoyl)amino]acetic acid 
3-hydroxyhippuric acid 2-[(3-hydroxybenzoyl)amino]acetic acid 
4-hydroxybenzaldehyde 4-hydroxybenzaldehyde 
4-hydroxybenzoic acid 4-hydroxybenzoic acid 
4-hydroxyhippuric acid 2-[(4-hydroxybenzoyl)amino]acetic acid 
4-hydroxyphenylacetic acid 2-(4-hydroxyphenyl)acetic acid 
5-hydroxyanthranilic acid 2-amino-5-hydroxybenzoic acid 
Avenanthramide 2c 2-[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]amino]-5-hydroxybenzoic acid 
Avenanthramide 2f 5-hydroxy-2-[[(E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]amino]benzoic acid 
Avenanthramide 2p 5-hydroxy-2-[[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]amino]benzoic acid 
Caffeic acid (E)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid 
Dihydrocaffeic acid 3-(3,4-dihydroxyphenyl)propanoic acid 
Dihydroferulic acid 3-(4-hydroxy-3-methoxyphenyl)propanoic acid 
Dihydroferulic acid-4-O-glucuronide (2S,3S,4S,5R,6S)-6-[4-(2-carboxyethyl)-2-methoxyphenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid 
Dihydroxybenzoic acid-3-O-glucuronide (2S,3S,4S,5R,6S)-6-(5-carboxy-2-hydroxyphenoxy)-3,4,5-trihydroxyoxane-2-carboxylic acid 
Ferulic acid (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoic acid 
Ferulic acid-4-O-glucuronide (2S,3S,4S,5R,6S)-6-[4-[(E)-2-carboxyethenyl]-2-methoxyphenoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid 
Gallic acid 3,4,5-trihydroxybenzoic acid 
Hippuric acid 2-benzamidoacetic acid 
Homovanillic acid 2-(4-hydroxy-3-methoxyphenyl)acetic acid 
Isoferulic acid (E)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoic acid 
Isoferulic acid-3-O-sulfate (E)-3-[3-sulfooxy-4-(methoxy)phenyl]prop-2-enoic acid 
Isovanillic acid 3-hydroxy-4-methoxybenzoic acid 
o-coumaric acid (E)-3-(2-hydroxyphenyl)prop-2-enoic acid 
p-coumaric acid (E)-3-(4-hydroxyphenyl)prop-2-enoic acid 
Protocatechuic acid 3,4-dihydroxybenzoic acid 
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Salicylic acid 2-hydroxybenzoic acid 
Sinapic acid (E)-3-(4-hydroxy-3,5-dimethoxyphenyl)prop-2-enoic acid 
Syringaldehyde 4-hydroxy-3,5-dimethoxybenzaldehyde 
Syringic acid 4-hydroxy-3,5-dimethoxybenzoic acid 
Vanillic acid 4-hydroxy-3-methoxybenzoic acid 
Vanillin 4-hydroxy-3-methoxybenzaldehyde 
Tentatively identified oat-derived phenolics 
3,4-dihydroxyhydrocinamic acid-O-glucuronide (2S,3S,4R,5R,6S)-3-(5-(2-carboxyethyl)-2-hydroxyphenoxy)-4,5,6-trihydroxytetrahydro-2H-pyran-2-carboxylic acid 
4-hydroxyphenylacetic acid-O-glucuronide (2S,4R,5R,6S)-3-(4-(carboxymethyl)phenoxy)-4,5,6-trihydroxytetrahydro-2H-pyran-2-carboxylic acid 
Benzoic acid-O-glucuronide (2S,3S,4R,5R,6S)-3-(4-carboxyphenoxy)-4,5,6-trihydroxytetrahydro-2H-pyran-2-carboxylic acid 
Benzoic acid-O-sulfate 4-carboxyphenyl sulfate 
Caffeic acid-O-sulfate (E)-4-(2-carboxyvinyl)-2-hydroxyphenyl sulfate 
Dihydroferulic acid-O-glucuronide (2S,3S,4R,5R,6S)-3-(4-(2-carboxyethyl)-2-methoxyphenoxy)-4,5,6-trihydroxytetrahydro-2H-pyran-2-carboxylic acid 
Dihydroxybenzoic acid-O-sulfate 4-carboxy-2-hydroxyphenyl sulfate 
Feruloylglycine 2-[[(E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]amino]acetic acid 
Homovanillic acid-O-glucuronide (2S,3S,4S,5R)-6-(4-(carboxymethyl)-2-methoxyphenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid 
Hydroxyphenylacetic acid-O-sulfate 4-(carboxymethyl)phenyl sulfate 
(Iso)ferulic acid-O-glucuronide (2S,3S,4R,5R,6S)-3-(4-((E)-2-carboxyvinyl)-2-methoxyphenoxy)-4,5,6-trihydroxytetrahydro-2H-pyran-2-carboxylic acid 
(Iso)ferulic acid-O-sulfate 4-(2-carboxyethyl)-2-methoxyphenyl sulfate 
Sinapic acid-O-sulfate (E)-4-(2-carboxyvinyl)-2,6-dimethoxyphenyl sulfate 
Syringaldehyde-O-glucuronide (2S,3S,4R,5R,6S)-3-(4-formyl-2,6-dimethoxyphenoxy)-4,5,6-trihydroxytetrahydro-2H-pyran-2-carboxylic acid 
Syringaldehyde-O-sulfate 4-formyl-2-hydroxy-6-methoxyphenyl sulfate 
Syringic acid-O-sulfate 4-carboxy-2,6-dimethoxyphenyl sulfate 
Vanillin-O-glucuronide (2S,3S,4R,5R,6S)-3-(4-formyl-2-methoxyphenoxy)-4,5,6-trihydroxytetrahydro-2H-pyran-2-carboxylic acid 
Vanillin-O-sulfate 4-formyl-2-methoxyphenyl sulfate 
Non oat-derived phenolics  
3,4-dihydrocaffeic acid 3-(3,4-dihydroxyphenyl)propanoic acid 
4-hydroxybenzaldehyde 4-hydroxybenzaldehyde 
4-hydroxyphenylacetic acid 2-(4-hydroxyphenyl)acetic acid 
3-hydroxyphenylacetic acid 2-(3-hydroxyphenyl)acetic acid 
Dihydroisoferulic acid 3-(3-hydroxy-4-methoxyphenyl)propanoic acid 
Isoferulic acid (E)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoic acid 
o-coumaric acid (E)-3-(2-hydroxyphenyl)prop-2-enoic acid 
Salicylic acid 2-hydroxybenzoic acid 
Syringaldehyde 4-hydroxy-3,5-dimethoxybenzaldehyde 
Vanillin 4-hydroxy-3-methoxybenzaldehyde 
4-hydroxybenzoic acid 4-hydroxybenzoic acid 
Caffeic acid (E)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid 
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Gallic acid 3,4,5-trihydroxybenzoic acid 
Hippuric acid 2-benzamidoacetic acid 
Homovanillic acid 2-(4-hydroxy-3-methoxyphenyl)acetic acid 
Protocatechuic acid OR acid 3,4-dihydroxybenzoic acid 
3,5-dihydroxybenzoic 3,5-dihydroxybenzoic 
Salicylic acid-O-sulfate 2-sulfooxybenzoic acid 
Dihydroxybenzoic acid-O-sulfate 3-carboxy-2-hydroxyphenyl sulfate 
Coumaric acid-O-sulfate (E)-3-(4-sulfonatooxyphenyl)prop-2-enoate 
(iso)vanillic acid-O-sulfate 4-carboxy-2-methoxyphenyl sulfate 
Hippuric acid-O-sulfate (2-(sulfooxy)benzoyl)glycine 
Homovanillic acid-O-sulfate 2-(3-methoxy-4-(sulfooxy)phenyl)acetic acid 
Dihydroxyhydroycinamic acid-O-sulfate 3-(2-carboxy-2,2-dihydroxyethyl)phenyl sulfate 
Hydroxybenzaledhyde-O-glucuronide (2S,3S,4S,5R)-6-(2-formyl-6-hydroxyphenyl)-3,4,5,6-tetrahydroxytetrahydro-2H-pyran-2-carboxylic acid 
Benzoic acid-O-glucuronide (2S,3S,4S,5R)-6-(2-carboxyphenyl)-3,4,5,6-tetrahydroxytetrahydro-2H-pyran-2-carboxylic acid 
Vanillin-O-glucuronide (2S,3S,4S,5R)-6-(4-formyl-2-methoxyphenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid 
Hydroxyphenylacetic acid-O-glucuronide (2S,3S,4S,5R)-6-(carboxy(phenyl)methoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid 
Coumaric acid-O-glucuronide (2S,3S,4S,5R)-6-(4-((E)-2-carboxyvinyl)phenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid 
(iso)vanillic acid-O-glucuronide (2S,3S,4S,5R)-6-(4-carboxy-2-methoxyphenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid 
Hippuric acid-O-glucuronide (2S,3S,4S,5R)-6-(2-((carboxymethyl)carbamoyl)phenyl)-3,4,5,6-tetrahydroxytetrahydro-2H-pyran-2-carboxylic acid 
Caffeic acid-O-glucuronide (2S,3S,4S,5R)-6-(5-((E)-2-carboxyvinyl)-2-hydroxyphenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid 
Homovanillic acid-O-glucuronide (2S,3S,4S,5R)-6-(4-(carboxymethyl)-2-methoxyphenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid 
Syringaldehyde-O-glucuronide (2S,3S,4S,5R)-6-(4-formyl-2,6-dimethoxyphenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid 
Dihydroxycaffeic acid-O-glucuronide (2S,3S,4S,5R)-6-(4-(2-carboxy-2,2-dihydroxyethyl)phenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid 
Dihydroferulic acid-O-glucuronide (2S,3S,4S,5R)-6-(4-(2-carboxyethyl)-2-methoxyphenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid 
Syringic acid-O-glucuronide (2S,3S,4S,5R)-6-(4-carboxy-2,6-dimethoxyphenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid 
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Supporting Information Table 2 – sMRM transitions, parameters and detection limits of 30 identified oat bran-derived phenolics 
        
Metabolite RT MW sMRM ion transitions (m/z) Collision energy (V) LOD (nM) LOQ (nM) R2 
Aglycones      
 
 
2,5-dihydroxybenzoic acid 4.8 154.1 153 / 109 -11 4.7 15.8 0.999 
2,4-dihydroxybenzoic acid 5.5 154.1 153 / 109 -11 7.3 24.3 0.999 
Vanillic acid 5.6 168.2 169 / 93 12 9.8 32.7 0.994 
Isovanillic acid 6.0 168.2 169 / 93 12 7.3 24.4 0.999 
Syringic acid 6.5 198.2 197 / 182 -13 14.9 49.6 0.999 
Dihydroferulic acid 7.1 196.2 195 / 136 -15 21.5 71.8 1.000 
p-coumaric acid 7.3 164.2 163 / 119 -13 4.2 9.5 0.997 
Ferulic acid 7.7 194.2 193 / 178 -10 8.2 27.4 1.000 
Avenanthramide 2p 9.9 299.3 298 / 254 -17 0.8 2.7 0.994 
Glycines        
4-hydroxyhippuric acid 4.4 195.2 194 / 100 -11 4.3 14.2 0.997 
3-hydroxyhippuric acid 4.7 195.2 194 / 100 -11 24.5 81.7 0.999 
2-hydroxyhippuric acid 7.0 195.2 194 / 100 -11 2.9 9.7 0.998 
Feruloylglycine 6.4 251.2 250 / 100*, 206, 191, 177, 149 -11 2.2 7.2 no standard 
Glucuronides        
Syringaldehyde OR Homovanillic acid OR  
3,4-dihydroxyhydrocinamic acid-O-glucuronidea,b) 4.2 358.2 357 / 113* , 59 , 137 , 175 , 181 -17, -23, -23, -11, -17 20.7 
68.9 
no standard 
Benzoic acid-O-glucuronidea) 5.1 314 313 / 113* , 175 , 137 , 93 -17, -17, -17, -23 15.7 52.2 no standard 
Ferulic Acid-4-O-Glucuronide 5.3 370.3 369 / 193* , 178 , 113 , 175 -19, -23, -19, -10 21.4 71.3 0.997 
Vanillin OR 4-hydroxyphenylacetic acid-O-glucuronidea,b) 5.3 328.1 327 / 113* , 107 , 175 , 151 -17, -23, -11, -11 35.0 116.7 no standard 
Dihydroferulic acid-4-O-glucuronide 5.8 372.3 371 / 113* , 195 , 85 , 175 -17, -20, -23, -17 11.7 39.1 0.990 
Isoferulic acid-O-glucuronidea) 6.1 370 369 / 193* , 178 , 113 , 175 -19, -23, -19, -10 11.2 37.5 no standard 
Dihydroferulic acid-O-glucuronidea) 6.2 372.3 371 / 113* , 195 , 85 , 175 -17, -20, -23, -17 8.0 26.5 no standard 
Sulfates        
Dihydroxybenzoic acid-O-sulfatea) 3.0 234 233 / 109* , 189, 153, 97 -23, -11, -23, -23 3.6 12.1 no standard 
Benzoic acid-O-sulfatea) 3.3 218 217 / 137*, 173 -11, -11 5.7 19.3 no standard 
Syringaldehyde-O-sulfatea) 4.1 262.2 261 / 166* , 123 , 181 -23, -23, -11 3.1 10.2 no standard 
Syringic acid-O-sulfatea) 4.1 278.2 277 / 197* , 182 , 153 , 123 -11, -23, -23, -23 2.6 8.8 no standard 
Caffeic acid-O-sulfatea) 5.4 260.2 259 / 179* , 135 , 107 -17, -23, -23 7.7 25.8 no standard 
Sinapic acid-O-sulfatea) 5.6 304.2 303 / 223* , 208 , 164 , 120 -11, -23, -23, -23 1.6 5.3 no standard 
(Iso)ferulic acid-O-sulfatea) 5.7 274.2 273 / 178* , 192 , 134 -20, -16, -25 1.6 5.3 no standard 
(Iso)ferulic acid-O-sulfatea) 5.9 274.2 273 / 178* , 192 , 134 -20, -16, -25 1.5 5.0 no standard 
Isoferulic acid 3-O-sulfate 6.1 274.2 273 / 178* , 192 , 134 -20, -16, -25 1.4 4.7 1.000 
Vanillin or hydroxyphenylacetic acid-O-sulfatea) 6.4 232.1 231.1 / 151*, 136, 92 -17, -23, -23 2.7 8.9 no standard 
*sMRM transition used for quantification; a) site of conjugation could not be ascertained as identification was based on known transitions where pure standards for isomers were not available or separation of 
isomers was chromatographically not possible; b)tentatively identified compound which could have different isomeric configuration. Abbreviations: LOD, limit of detection (Signal/Noise = 3); LOQ, limit of 
quantification (Signal/Noise = 10); MW, molecular weight; RT, Retention time; sMRM, scheduled multiple reaction monitoring; R2, linear regression coefficient of standard curve; no standard, no analytical 
standard was available to make standard curve 
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Supporting Information Table 3 – Urinary excretion rate per hour of oat bran-derived phenolic compounds after intake of 60g oat bran or a control meal in six healthy 
men (nmol/h) 
 
                
             Model P value 
Metabolite 





  µmol/h 
Avenanthramide A Oats 1 ± 0 3 ± 0**** 1 ± 0 2 ± 0* 2 ± 0 1 ± 0 1 ± 0 2 ± 0 1 ± 0 1 ± 0 1 ± 0 *** *** *** 
 CON 1 ± 0 1 ± 0 1 ± 0 1 ± 0 1 ± 0 1 ± 0 2 ± 0 1 ± 0 1 ± 0 1 ± 0 1 ± 0    
Ferulic acid Oats 9 ± 4 61 ± 15* 29 ± 6 21 ± 3 41 ± 9 15 ± 5 15 ± 8 15 ± 3 24 ± 8 12 ± 4 13 ± 3 0.3 **** * 
 CON 7 ± 1 21 ± 4 13 ± 4 18 ± 6 48 ± 23 25 ± 13 24 ± 13 14 ± 3 26 ± 5 23 ± 9 8 ± 3    
p-coumaric acid Oats 1 ± 0 7 ± 1** 3 ± 0 3 ± 1 5 ± 0 2 ± 1 2 ± 0 2 ± 1 2 ± 0 2 ± 1 1 ± 0 0.1 *** * 
 CON 2 ± 1 3 ± 1 2 ± 1 2 ± 0 3 ± 0 3 ± 2 3 ± 1 1 ± 0 2 ± 0 2 ± 1 1 ± 0    
Dihydroferulic acid Oats 34 ± 16 90 ± 42 34 ± 12 60 ± 17 378 ± 135**** 109 ± 68 35 ± 17 23 ± 5 78 ± 22 60 ± 19 23 ± 6 0.1 **** *** 
 CON 14 ± 5 56 ± 28 26 ± 8 26 ± 15 102 ± 38 38 ± 24 32 ± 10 24 ± 5 101 ± 66 84 ± 55 18 ± 5    
Isovanillic acid Oats 6 ± 5 24 ± 22 44 ± 5 69 ± 18 744 ± 470*** 54 ± 51 22 ± 20 16 ± 3 188 ± 136 54 ± 44 31 ± 15 0.1 * * 
 CON 7 ± 6 18 ± 17 30 ± NA 62 ± 14 87 ± 39 4 ± 1 1 ± 0 ND 59 ± 17 4 ± 1 1 ± 0    
Syringic acid Oats 6 ± 2 29 ± 5 12 ± 3 18 ± 5 65 ± 20**** 23 ± 10 6 ± 2 12 ± 2 14 ± 3 8 ± 4 6 ± 1 * **** *** 
 CON 2 ± 1 13 ± 3 12 ± 3 9 ± 1 16 ± 3 9 ± 2 8 ± 1 19 ± 7 14 ± 3 13 ± 4 4 ± 1    
2,4-dihydroxybenzoic acid Oats 4 ± 1 15 ± 1 10 ± 3 54 ± 26* 62 ± 18*** 13 ± 5 23 ± 15 12 ± 2 43 ± 22 10 ± 3 8 ± 2 ** ** *** 
 CON 4 ± 1 11 ± 3 16 ± 6 6 ± 2 16 ± 5 6 ± 2 5 ± 2 18 ± 8 6 ± 2 6 ± 2 4 ± 2    
2,5-dihydroxybenzoic acid Oats 51 ± 17 209 ± 58** 78 ± 9 87 ± 15 97 ± 13 41 ± 11 27 ± 9 32 ± 10 28 ± 6 17 ± 6 27 ± 11 0.3 **** * 
 CON 47 ± 9 88 ± 23 70 ± 24 63 ± 21 73 ± 15 34 ± 11 29 ± 16 40 ± 24 34 ± 19 43 ± 31 20 ± 8    
Vanillic acid Oats 29 ± 14 175 ± 36 80 ± 8 3352 ± 743** 2918 ± 624* 201 ± 98 58 ± 22 39 ± 12 1600 ± 600 168 ± 71 56 ± 21 * **** * 
 CON 13 ± 8 13 ± 7 41 ± 14 1281 ± 624 1594 ± 702 45 ± 33 15 ± 11 28 ± 5 1162 ± 513 128 ± 37 30 ± 20    
2-hydroxyhippuric acid Oats 111 ± 35 371 ± 173* 133 ± 35 294 ± 112 525 ± 82*** 228 ± 75 137 ± 28 198 ± 107 133 ± 37 81 ± 21 117 ± 27 ** **** ** 
 CON 101 ± 21 113 ± 29 121 ± 32 84 ± 17 195 ± 20 101 ± 21 70 ± 24 54 ± 20 99 ± 41 158 ± 55 58 ± 20    
3-hydroxyhippuric acid Oats 443 ± 148 2068 ± 536** 958 ± 278 1142 ± 409 1643 ± 302 414 ± 124 452 ± 98 599 ± 209 650 ± 329 288 ± 75 557 ± 98 * **** ** 
 CON 395 ± 89 617 ± 203 729 ± 226 405 ± 140 981 ± 271 364 ± 97 541 ± 298 344 ± 223 297 ± 111 820 ± 325 355 ± 126    
4-hydroxyhippuric acid Oats 553 ± 133 2262 ± 551** 1289 ± 289 1566 ± 457 2479 ± 79 939 ± 348 748 ± 187 1108 ± 274 1302 ± 298 885 ± 228 899 ± 105 0.1 **** ** 
 CON 430 ± 71 809 ± 232 1133 ± 342 807 ± 195 1875 ± 246 820 ± 105 628 ± 221 650 ± 247 1020 ± 334 1314 ± 307 528 ± 167    
Feruloylglycine Oats 11 ± 5 39 ± 12 11 ± 2 28 ± 8 56 ± 18** 22 ± 10 13 ± 3 8 ± 2 15 ± 5 11 ± 4 12 ± 3 0.1 **** *** 
 CON 9 ± 3 12 ± 3 9 ± 3 8 ± 1 24 ± 6 14 ± 3 14 ± 4 9 ± 3 19 ± 5 28 ± 10 8 ± 2    
Caffeic acid-sulfate Oats 68 ± 31 298 ± 127*** 90 ± 38 128 ± 41 103 ± 25 23 ± 10 18 ± 7 13 ± 4 34 ± 15 17 ± 5 12 ± 4 0.6 0.1 *** 
 CON 65 ± 27 28 ± 8 15 ± 5 30 ± 12 137 ± 98 110 ± 84 47 ± 19 18 ± 6 76 ± 51 103 ± 62 22 ± 9    
(Iso)ferulic acid-O-sulfate Oats 78 ± 25 879 ± 142**** 560 ± 104 474 ± 57 661 ± 119 245 ± 82 101 ± 36 170 ± 39 359 ± 76 219 ± 71 118 ± 29 **** **** **** 
 CON 48 ± 14 71 ± 20 282 ± 63 210 ± 51 454 ± 87 135 ± 31 79 ± 22 121 ± 54 235 ± 74 131 ± 58 70 ± 25    
(Iso)ferulic acid-O-sulfate Oats 6 ± 1 43 ± 7**** 29 ± 8** 20 ± 4 28 ± 6 12 ± 5 8 ± 1 8 ± 1 16 ± 3 10 ± 3 7 ± 1 ** **** **** 
 CON 5 ± 2 5 ± 1 13 ± 3 9 ± 1 25 ± 4 9 ± 2 6 ± 1 7 ± 2 15 ± 4 14 ± 4 5 ± 1    
Isoferulic acid-3-O-sulfate Oats 2 ± 0 23 ± 3**** 16 ± 5 12 ± 1 7 ± 1 11 ± 6 3 ± 1 1 ± 0 4 ± 1 4 ± 2 3 ± 2 0.1 *** **** 
 CON 1 ± 0 3 ± 1 9 ± 4 6 ± 2 12 ± 7 4 ± 2 2 ± 1 6 ± 3 7 ± 4 6 ± 3 3 ± 1    
Syringic acid-O-sulfate Oats 19 ± 8 99 ± 20*** 54 ± 9 51 ± 10 165 ± 54**** 76 ± 29 33 ± 11 41 ± 8 47 ± 9 32 ± 7 23 ± 4 ** **** **** 
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 CON 15 ± 6 22 ± 9 58 ± 15 20 ± 4 68 ± 16 26 ± 9 22 ± 8 35 ± 12 51 ± 16 52 ± 16 13 ± 3    
Sinapic acid-O-sulfate Oats 40 ± 15 249 ± 55**** 108 ± 14 144 ± 21 252 ± 75** 66 ± 23 51 ± 17 55 ± 13 103 ± 20 49 ± 11 34 ± 6 ** **** **** 
 CON 28 ± 15 31 ± 13 59 ± 12 41 ± 8 130 ± 17 57 ± 25 45 ± 15 40 ± 11 101 ± 33 78 ± 27 32 ± 10    
Dihydroxybenzoic acid-O-
sulfate Oats 24 ± 6 53 ± 13* 27 ± 7 51 ± 12*** 35 ± 7 16 ± 4 22 ± 6 16 ± 1 18 ± 4 18 ± 5 25 ± 4 0.2 0.1 **** 
 CON 16 ± 5 18 ± 2 14 ± 5 9 ± 2 28 ± 6 23 ± 8 26 ± 8 11 ± 2 18 ± 6 37 ± 18 17 ± 6    
Benzoic acid-O-sulfate Oats 596 ± 209 1697 ± 494 720 ± 219 1230 ± 451 1283 ± 274 1062 ± 359 863 ± 351 1034 ± 274 1125 ± 368 580 ± 236 852 ± 270 0.5 * * 
 CON 506 ± 194 842 ± 251 935 ± 446 668 ± 213 988 ± 207 707 ± 162 819 ± 149 1073 ± 295 1146 ± 444 1066 ± 464 461 ± 143    
Vanillin or hydroxyphenylacetic 
acid-O-sulfate Oats 13 ± 9 81 ± 50*** 22 ± 12 40 ± 23 29 ± 15 12 ± 7 14 ± 6 20 ± 11 13 ± 6 9 ± 3 9 ± 3 0.3 * * 
 CON 4 ± 1 11 ± 7 6 ± 3 6 ± 3 9 ± 4 6 ± 3 7 ± 3 9 ± 5 7 ± 3 6 ± 2 7 ± 4    
Syringaldehyde OR homovanillic 
acid OR dihydroxyhydrocinamic 
acid sulfate Oats 13 ± 3 38 ± 9* 21 ± 6 33 ± 9 46 ± 10 21 ± 8 15 ± 4 19 ± 2 32 ± 6 19 ± 4 14 ± 2 0.1 **** * 
 CON 12 ± 3 17 ± 3 29 ± 8 20 ± 3 40 ± 11 15 ± 2 13 ± 2 18 ± 4 32 ± 9 27 ± 9 9 ± 1    
Ferulic Acid-4-O-glucuronide Oats 49 ± 20 265 ± 65**** 205 ± 36 170 ± 27 214 ± 33 62 ± 23 61 ± 22 57 ± 14 128 ± 30 80 ± 28 52 ± 11 **** **** **** 
 CON 45 ± 12 44 ± 10 85 ± 20 67 ± 12 171 ± 21 75 ± 19 58 ± 9 45 ± 16 123 ± 25 101 ± 40 38 ± 8    
Isoferulic acid-O-glucuronide Oats 22 ± 6 142 ± 34**** 94 ± 29 78 ± 14 104 ± 23 36 ± 32 23 ± 5 29 ± 7 58 ± 11 43 ± 15 25 ± 4 * **** *** 
 CON 17 ± 4 21 ± 5 39 ± 9 29 ± 5 67 ± 8 33 ± 6 20 ± 3 20 ± 6 57 ± 7 41 ± 9 15 ± 4    
Dihydroferulic acid-4-O-
glucuronide Oats 3 ± 1 16 ± 5 11 ± 3 16 ± 5 49 ± 22**** 27 ± 11 8 ± 4 8 ± 3 10 ± 2 10 ± 3 8 ± 3 ** *** * 
 CON 3 ± 1 6 ± 3 6 ± 1 8 ± 3 18 ± 6 7 ± 4 5 ± 2 5 ± 1 12 ± 7 13 ± 8 7 ± 2    
Dihydro(iso)ferulic acid-O-
glucuronide Oats 31 ± 10 64 ± 16 21 ± 5 73 ± 20 189 ± 64**** 69 ± 30 42 ± 12 29 ± 8 45 ± 10 53 ± 13 36 ± 9 * **** ** 
 CON 27 ± 8 29 ± 6 14 ± 3 17 ± 5 68 ± 25 46 ± 15 35 ± 7 21 ± 4 39 ± 18 92 ± 44 27 ± 12    
Benzoic acid-O-glucuornide Oats 23 ± 8 83 ± 26 28 ± 5 45 ± 15 78 ± 15** 36 ± 11 34 ± 7 37 ± 14 29 ± 6 19 ± 4 23 ± 5 *** **** * 
 CON 27 ± 8 43 ± 10 31 ± 7 22 ± 4 36 ± 5 19 ± 3 23 ± 5 24 ± 9 25 ± 3 30 ± 12 19 ± 9    
Syringaldehyde OR 
Homovanillic acid OR 3,4-
dihydroxyhydrocinamic acid-O-
glucuronide Oats 128 ± 30 528 ± 146** 205 ± 37 176 ± 53 273 ± 67 155 ± 31 167 ± 30 267 ± 60 142 ± 40 179 ± 47 203 ± 29 0.8 *** ** 
 CON 68 ± 27 201 ± 66 208 ± 61 95 ± 15 203 ± 40 141 ± 37 177 ± 34 179 ± 37 131 ± 32 211 ± 46 131 ± 32    
Vanillin OR 4-
hydroxyphenylacetic acid-O-
glucuronide Oats 14 ± 7 39 ± 16 48 ± 18 134 ± 36**** 212 ± 27**** 60 ± 22 26 ± 8 19 ± 3 20 ± 6 16 ± 3 14 ± 3 *** **** **** 
 CON 10 ± 6 15 ± 7 22 ± 20 15 ± 5 36 ± 8 15 ± 2 17 ± 2 12 ± 2 19 ± 3 20 ± 4 11 ± 4    
Data are reported as mean ± SEM and were analysed by two-factor repeated measurement linear mixed model with time and treatment as the two factors. When the interaction effect was significant, post-hoc analyses with Tukey-Kramer adjustment were performed. 
If excretion was ND, the concentration was replaced with the limit of detection for statistical analysis. Model P values in the three far right columns and post-hoc P values next to the excretion rates are indicated as follow: * P < 0.05; ** P <0.01; *** P<0.001; **** 




Supporting Information Table 4 – sMRM transitions, parameters and detection limits of non oat bran-derived phenolics 
        












122.12 121.12 / 92 
-20 
31.7 105.8 0.995 
4-hydroxyphenylacetic acid 6.5 152.15 151.14 / 107 -10 56.3 187.8 0.997 
3-hydroxyphenylacetic acid 6.3 152.15 151.14 / 107 -10 64.8 215.9 0.996 
Dihydroisoferulic acid 7.5 196.2 195 / 136 -15 35.2 117.5 1.000 
Isoferulic acid 8.0 195.2 194.2 / 136 -15 16.1 53.8 1.000 
o-coumaric acid 8.4 164.2 163 / 119 -13 44.8 149.4 0.997 
Salicylic acid 8.1 138.1 137.12 / 93 -23 41.0 136.6 0.999 
Syringaldehyde 7.5 182.2 181.17 / 151 -18 0.3 1.0 0.993 
Vanillin 6.9 152.1 151.15 / 136 -12 42.8 142.8 0.999 
4-hydroxybenzoic acid 4.9 138.1 137.12 / 93 -13 64.8 216.1 0.998 
Caffeic acid 6.0 180.2 179.16 / 135 -15 124.1 413.7 0.988 
Gallic acid 1.7 170.1 169.12 / 125 -13 6.5 21.7 0.998 
Hippuric acid 5.7 179.2 178.17 / 134 -11 211.6 705.5 0.995 
Homovanillic acid 6.2 182.2 181.17 / 137 -10 44.4 148.0 0.999 
Protocatechuic acid OR 3,5-dihydroxybenzoic acida) 3.7 154.1 153.12 / 109 -13 64.1 213.7 0.998 
Salicylic acid-O-sulfate a,b) 3.2 218.1 217 / 137* , 93 , 79 -11, -23, -17 75.5 251.6 no standard 
Dihydroxybenzoic acid-O-sulfate a,b) 2.7 234.0 233 / 153* , 189 , 109 -23, -11, -23 76.8 255.9 no standard 
Coumaric acid-O-sulfate a,b) 9.0 244.2 243 / 163* , 93 , 79 -17, -23, -23 38.0 126.6 no standard 
(iso)vanillic acid-O-sulfate a,b) 4.2 248.0 247 / 167* , 152 , 123, 108 -23, -17, -17, -23 80.4 267.9 no standard 
Hippuric acid-O-sulfate a,b) 3.4 259.2 258 / 178* , 79 , 134 -17, -23, -23 77.2 257.3 no standard 
Hippuric acid-O-sulfate a,b) 3.1 259.2 258 / 178* , 79 , 134 -17, -23, -23 59.4 198.1 no standard 
Hippuric acid-O-sulfate a,b) 3.8 259.2 258 / 178* , 79 , 134 -17, -23, -23 38.4 127.9 no standard 
Homovanillic acid OR dihydrocaffeic acid-O-sulfate 
a,b) 
4.6 
262.2 261 / 181* , 121 , 79, 137 -17, -23, -23, -23 121.1 403.6 
no standard 
Homovanillic acid OR dihydrocaffeic-O-sulfate a,b) 4.9 262.2 261 / 181* , 121 , 79, 137 -17, -23, -23, -23 155.5 518.2 no standard 
Hydroxybenzaledhyde-O-glucuronide a,b) 8.3 298.1 297 / 113* , 175 , 121 -11, -11, -23 50.8 169.2 no standard 
Benzoic acid-O-glucuronide a,b) 2.7 314.0 313 / 137* , 175 , 113, 93 -17, -11, -11, -23 48.9 162.9 no standard 
Benzoic acid-O-glucuronide a,b) 3.8 314.0 313 / 137* , 175 , 113, 93 -17, -11, -11, -23 55.9 186.3 no standard 
Benzoic acid-O-glucuronide a,b) 4.6 314.0 313 / 137* , 175 , 113, 93 -17, -11, -11, -23 93.7 312.5 no standard 
Benzoic acid-O-glucuronide a,b) 4.8 314.0 313 / 137* , 175 , 113, 93 -17, -11, -11, -23 44.9 149.6 no standard 
Salicylic acid-O-glucuronide a,b) 7.8 314.1 313 / 137* , 93 , 75, 175, 113 -11, -23, -11, -11, -11 41.2 137.2 no standard 
Salicylic acid-O-glucuronide a,b) 7.7 314.1 313 / 137* , 93 , 75, 175, 113 -11, -23, -11, -11, -11 46.5 155.0 no standard 
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Vanillin OR hydroxyphenylacetic acid-O-glucuronide 
a,b) 
4.5 
328.1 327 / 113* , 136 , 175, 151 -11, -23, -11, -23 111.6 372.1 
no standard 
Coumaric acid-O-glucuronide a,b) 9.1 328.1 327 / 113* , 107 , 175, 151 -17, -23, -11, -11 131.5 438.3 no standard 
Coumaric acid-O-glucuronide a,b) 10.3 340.2 339 / 113* , 117 , 175, 163 -11, -23, -11, -17 62.9 209.7 no standard 
(iso)vanillic acid-O-glucuronide a,b) 4.0 344.0 339 / 113* , 117 , 175, 163 -11, -23, -11, -17 85.4 284.6 no standard 
(iso)vanillic acid-O-glucuronide a,b) 4.5 344.0 343 / 113* , 175 , 167, 152, 108 -17, -17, -17, -23, -23 102.6 341.9 no standard 
Hippuric acid-O-glucuronide a,b) 4.9 355.2 354 / 113* , 134 , 175, 178 -11, -23, -11, -17 56.5 188.3 no standard 
Caffeic acid-O-glucuronide a,b) 6.1 356.2 355 / 113* , 135 , 175, 179 -17, -23, -11, -17 109.2 364.2 no standard 
Syringaldehyde OR Homovanillic acid OR 
dihydrocaffeic-O-glucuronide a,b) 
5.1 
358.2 357 / 113* , 175 , 181, 166, 123 -11, -11, -17, -23, -23 84.1 280.2 
no standard 
Syringaldehyde OR Homovanillic acid OR 
dihydroxycaffeic acid-O-glucuronide a,b) 
3.9 
358.2 357 / 113* , 175 , 181, 166, 123 -11, -11, -17, -23, -23 70.5 235.0 
no standard 
Dihydroferulic acid-O-glucuronide a,b) 5.1 372.3 371 / 113* , 195 , 85, 175 -17, -20, -23, -17 78.1 260.5 0.990 
Syringic acid-O-glucuronide a,b) 7.5 374.2 373 / 113* , 175 , 197, 153 -17, -11, -11, -17 74.8 249.4 no standard 
Syringic acid-O-glucuronide a,b) 9.0 374.2 373 / 113* , 175 , 197, 153 -17, -11, -11, -17 77.6 258.6 no standard 
*sMRM transition used for quantification; a) site of conjugation could not be ascertained as identification was based on known transitions where pure standards for isomers were not available or separation of 
isomers was chromatographically not possible; b)tentatively identified compound which could have different isomeric configuration. Abbreviations: LOD, limit of detection (Signal/Noise = 3); LOQ, limit of 
quantification (Signal/Noise = 10); MW, molecular weight; RT, Retention time; sMRM, scheduled multiple reaction monitoring; R2, linear regression coefficient of standard curve; no standard, no analytical 
standard was available to make standard curve 
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Supporting Information Table 5 – Urinary excretion rate per hour of non oat bran-derived phenolic compounds after intake of 60g oat bran or a control meal in six 
healthy men (nmol/h) 
                 
Non-metabolite 
RT 





   (nmol/h)    
3,4-dihydrocaffeic acid 6.4 Oats 8±5 11±2 ND 54±11 164±31 60±28 15±4 6±1 81±20 63±26 18±5 0.2 **** 0.7 
  CON 10±3 10±4 9±4 50±11 138±23 47±16 20±5 6±3 100±17 44±13 13±4    
4-hydroxybenzaldehyde 5.9 Oats 9±3 43±12 29±6 37±11 48±9 23±8 8±3 24±7 30±9 18±6 12±3 0.5 **** 0.2 
  CON 4±2 11±4 24±9 17±6 35±6 16±5 12±5 15±7 30±10 21±5 8±3    
4-hydroxyphenylacetic acid 6.5 Oats 2944±997 7303±888 3598±538 4737±1289 9307±1394 3870±1227 2667±686 3229±754 4045±1013 3609±1237 3379±533 0.2 **** 0.5 
  CON 2658±622 5407±884 5961±2151 4948±859 9741±1885 4846±1390 3459±1119 4297±1125 4778±1278 6608±3173 2256±698    
3-hydroxyphenylacetic acid 6.3 Oats 21867±6765 63086±16587 29542±6008 39413±11293 72562±8932 26418±7768 23593±7204 39232±10190 39862±8965 26007±8449 30693±5066 0.3 **** 0.1 
  CON 20461±4935 44887±8620 47366±13805 27549±6555 63817±5442 23306±2171 27629±7689 25976±8532 33403±10462 38274±13067 15391±4559    
Dihydroisoferulic acid 7.5 Oats 15±7 36±23 23±8 22±11 42±4 7±3 20±5 28±18 25±12 16±7 19±6 0.2 * 0.6 
  CON 7±3 10±3 18±16 53± 27±18 7±2 9±2 18±7 16±6 13±7 6±2    
Isoferulic acid 8.0 Oats 17±5 99±59 96±29 58±12 148±46 22± 7±1 13±7 61±20 47±22 9±2 0.2 *** 0.5 
  CON 15±3 20±7 24±16 24± 130±22 41±12 20±1 23±1 41±19 36±12 6±    
o-coumaric acid 8.4 Oats 2± ND ND 11± 17±10 ND 1±0 1±0 26±14 3± 0± 0.6 * 0.4 
  CON 0± 4±3 3±3 9±6 39±3 5± 1±0 1± 22±9 2±1 0±    
Salicylic acid 8.1 Oats 67±59 171±64 143±54 77±21 222±120 39±19 17±5 95±66 103±36 109±82 30±14 ** 0.1 0.2 
  CON 6±2 17±7 39±17 32±12 43±7 24±11 11±5 20±9 27±8 24±8 9±3    
Syringaldehyde 7.5 Oats 0±0 0±0 0±0 1±0 0±0 ND 0± 0± 0±0 ND 0±0 0.2 ** 0.4 
  CON 0±0 0±0 0± 0± 0±0 0±0 0±0 0± 0± 1± 0±0    
Vanillin 6.9 Oats 3±1 11±3 13±3 18±2 24±2 9±4 4±1 8±3 17±3 8±2 4±1 0.2 **** 0.3 
  CON 2±0 3±1 10±3 18±6 19±2 4±1 4±1 5±1 20±2 7±1 3±1    
4-hydroxybenzoic acid 4.9 Oats 75±22 337±83 182±40 224±31 340±41 164±50 146±67 208±45 226±56 147±44 185±58 0.5 **** 0.7 
  CON 53±10 256±123 211±86 204±99 343±118 182±64 208±113 165±64 162±55 171±49 85±42    
Caffeic acid 6.0 Oats 34±8 119±29 91±26 111±19 161±18 80±35 53±13 73±18 81±18 62±20 62±9 0.1 **** 0.4 
  CON 30±4 61±16 87±24 67±15 128±21 60±7 47±15 46±18 78±30 80±23 33±10    
Gallic acid 1.7 Oats 1±1 1±0 2±1 2±1 2±1 3±2 1±1 2±1 1±0 2±1 1±1 0.8 0.8 0.8 
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  CON 0±0 1±1 2±2 2±1 1±0 0±0 0±0 1±0 1±0 5±4 0±0    
Hippuric acid 5.7 Oats 2772±703 9454±2193 7027±2028 7653±2036 12773±1494 5060±2449 4158±1001 5857±1432 6817±1545 5006±1627 4930±683 0.1 **** 0.4 
  CON 2403±339 5052±1396 7131±1944 5439±1199 10688±1668 4905±592 3905±1209 3593±1437 6311±2403 6525±1869 2696±853    
Homovanillic acid 6.2 Oats 251±64 894±261 584±76 726±164 1600±698 437±132 284±47 535±97 553±104 320±78 399±80 0.5 **** 0.8 
  CON 357±102 995±393 1116±189 1098±599 1616±309 657±316 352±81 959±384 1409±771 943±475 361±145    
Protocatechuic acid OR 3,5-
dihydroxybenzoic acid 3.7 Oats 8±2 24±5 11±2 14±5 22±3 10±3 12±4 16±3 21±6 14±4 13±2 0.7 0.5 0.1 
  CON 7±2 14±3 14±3 13±2 26±3 13±2 14±4 18±3 26±2 20±4 9±2    
Salicylic acid-O-sulfate 3.2 Oats 574±202 1619±473 689±213 1180±435 1224±269 1005±343 828±336 999±263 1094±362 563±231 802±281 0.5 * * 
  CON 488±190 804±242 903±434 640±208 944±207 675±156 775±147 1041±296 1107±435 1029±451 442±141    
Dihydroxybenzoic acid-O-
sulfate 2.7 Oats 11±4 19±7 5±1 15±8 14±3 7±2 19±7 8±1 10±3 6±1** 14±4 0.1 0.3 ** 
  CON 9±2 13±3 9±4 7±2 18±5 21±8 14±3 8±2 13±4 26±13 7±2    
Coumaric acid-O-sulfate 9.0 Oats 27±6 30±10 11±2 21±5 35±10 20±4 22±7 14±4 18±8 11±4 13±2 0.3 0.5 0.2 
  CON 8±1 17±7 17±6 13±2 26±4 128±110 11±2 18±6 29±18 70±34 59±39    
(iso)vanillic acid-O-sulfate 4.2 Oats 27±9 153±35 61±13 2956±767 3392±823 245±90 65±25 36±4 2658±490 168±45 61±11 0.7 **** 0.9 
  CON 32±9 27±7 42±13 2623±448 3272±883 217±53 65±19 28±7 2979±684 240±65 70±22    
Hippuric acid-O-sulfate 3.4 Oats 120±55 310±109 89±29 139±70 160±29 61±13 72±20 105±26 73±20 52±12 101±28 0.9 *** 0.1 
  CON 106±38 180±51 137±53 68±19 109±28 54±16 93±37 90±38 68±29 182±128 69±20    
Hippuric acid-O-sulfate 3.1 Oats 4±1 9±3 3±1 5±2 6±1 3±1 6±3 5±1 4±2 3±1 5±2 0.4 0.5 0.6 
  CON 12±9 9±3 4±2 5±2 7±3 5±2 6±2 5±1 4±1 7±3 3±1    
Hippuric acid-O-sulfate 3.8 Oats 91±44 216±94 147±76 171±78 213±93 179±98 143±64 174±70 215±94 86±55 183±89 * 0.1 0.3 
  CON 59±37 156±104 141±78 127±85 166±92 128±82 112±58 185±102 173±87 202±103 118±78    
Homovanillic acid OR 
dihydroxyhydroycinamic 
acid-O-sulfate 4.6 Oats 168±19 350±68 113±22 179±49 260±40 161±35 184±52 236±18 212±39 162±25 206±37 0.3 ** 0.2 
  CON 158±35 278±38 218±63 154±25 281±40 185±28 231±48 199±29 216±60 322±163 128±27    
Homovanillic 
acid34dihydrocaffeic-O-
sulfate 4.9 Oats 115±35 152±49 32±9 117±29 171±45 172±88 88±25 60±11 101±31 191±81 172±20 ** *** 0.3 
  CON 165±43 101±31 41±11 56±20 91±23 115±40 125±31 37±4 43±14 190±65 74±34    
Hydroxybenzaledhyde-O-
glucuronide 8.3 Oats 65±52 186±137 151±134 137±102 156±95 168±154 74±39 103±36 143±84 70±31 211±136 0.5 0.8 0.5 
  CON 48±33 116±78 194±166 151±79 104±71 68±37 104±44 127±36 142±31 145±79 56±13    
Benzoic acid-O-glucuronide 2.7 Oats 11±3 35±10 12±5 18±8 18±4 12±3 23±10 21±9 19±7 13±4 17±6 0.3 * 0.5 
  CON 9±5 18±8 18±12 13±6 20±10 11±6 15±6 17±6 17±6 16±8 6±2    
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Benzoic acid-O-glucuronide 3.8 Oats 11±2 35±7 15±3 18±7 24±5 11±3 14±5 15±4 14±4 13±3 13±3 0.8 **** 0.1 
  CON 7±2 16±4 15±5 10±2 19±3 12±2 13±2 11±3 12±3 16±7 8±2    
Benzoic acid-O-glucuronide 4.6 Oats 3±1 7±2 6±1 8±3 14±5 3±1 3±1 4±1 5±1 4±1 3±0 0.3 **** 0.3 
  CON 2±1 5±1 6±2 ND 7±1 3±1 3±0 3±0 4±1 5±2 3±1    
Benzoic acid-O-glucuronide 4.8 Oats 2±1 ND** ND ND ND ND 1± ND ND ND 2±1 0.1 **** ** 
  CON 2±0 2±1 ND ND ND 3±0 2±0 2±1 ND 6±2 1±1    
Salicylic acid-O-
glucuronide 7.8 Oats 2±1 5±1 ND 5±3 12± 2±1 3±1 2±1 2± 1± 3±1 0.4 *** 0.8 
  CON 3±1 7±3 7±6 6±2 11±5 5±2 3±1 4±0 7±3 4±2 2±1    
Salicylic acid-O-
glucuronide 7.7 Oats 2±1 7±1 ND 11± 5±2 2±1 3±2 3±1 3± 1± 3±2 0.9 *** 0.9 
  CON 3±2 8±4 13±13 7±3 14±10 5±2 3±1 4±1 5±1 5±2 2±1    
Vanillin OR 
hydroxyphenylacetic acid-
O-glucuronide 4.5 Oats 26±9 68±14 32±6 44±14 71±11 27±7 30±8 34±7 37±8 32±10 34±7 0.3 *** 0.2 
  CON 18±3 39±5 49±12 31±4 65±12 35±5 39±5 27±6 32±6 58±38 17±7    
Coumaric acid-O-
glucuronide 9.1 Oats 19±8 55±24 22±2 29±8 35±3 26±11 24±5 17±5 21±1 17±9 15±3 * 0.5 0.2 
  CON 14±4 37±18 33±17 24±7 29±4 96±70 46±32 23±6 36±23 120±80 60±43    
Coumaric acid-O-
glucuronide 10.3 Oats 43±32 58±21 17±5 21±9 23±6 8±3 11±3 10±4 8±2 11±4 15±3 1 0.2 0.5 
  CON 150±137 29±12 23±5 23±11 35±16 47±36 115±102 17±10 20±11 18±8 9±3    
(iso)vanillic acid-O-
glucuronide 4.0 Oats 35±12 127±38 93±12 1720±453 3518±501 672±248 143±38 44±8 1811±500 676±222 149±31 * **** 0.9 
  CON 49±14 46±11 52±13 1466±284 3110±367 591±152 150±25 32±8 1628±449 528±114 163±62    
(iso)vanillic acid-O-
glucuronide 4.5 Oats 165±52 677±159 367±54 7116±1491 10045±1653 1591±596 382±118 214±30 6104±1656 1568±521 478±96 0.2 **** 1 
  CON 187±44 237±68 219±52 6227±994 9168±1313 1512±396 450±63 147±33 5892±1604 1459±320 424±130    
Hippuric acid-O-
glucuronide 4.9 Oats 54±21 144±48 58±20 84±38 103±25 47±20 50±22 65±24 84±30 64±22 50±19 0.8 *** 0.2 
  CON 31±14 54±27 71±43 38±20 96±40 44±20 38±14 48±18 63±22 56±30 30±14    
Caffeic acid-O-glucuronide 6.1 Oats 16±7 57±17 19± 21±3 25±9 5±2 8±2 13±3 7±0 12±4 23±2 0.7 0.2 0.1 
  CON 33±24 25±4 13±1 16±5 24±5 19±7 40±22 11±5 22±16 18±7 20±9    
Syringaldehyde OR 
Homovanillic acid OR 
dihydrocaffeic-O-
glucuronide 5.1 Oats 13±3 45±11 22±4 31±6 47±7 23±6 24±5 32±7 30±5 24±6 26±4 0.1 **** 0.4 
  CON 16±4 29±5 29±7 24±4 42±4 25±4 28±4 26±4 30±4 34±13 17±5    
Syringaldehyde OR 
Homovanillic acid OR 
dihydroxycaffeic acid-O-
glucuronide 3.9 Oats 7±1 21±2 12±2 14±3 21±3 12±4 9±2 12±2 14±3 11±3 9±2 0.1 **** 0.4 
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  CON 5±1 11±3 13±3 10±2 17±1 9±2 8±1 8±2 13±2 12±3 6±1    
Dihydroferulic acid-O-
glucuronide 5.1 Oats 6±2 17±4 8±2 10±4 21±5 5±1 7±2 7±2 16±5 9±2 7±2 0.5 *** 0.4 
  CON 5±1 7±1 8±3 17±7 38±19 11±3 7±1 6±1 15±5 11±3 5±1    
Syringic acid-O-
glucuronide 7.5 Oats 249±66 700±75 268±41 399±60 535±77 276±79 357±55 407±72 327±80 319±101 415±56 0.5 *** 0.1 
  CON 258±38 426±44 333±67 276±28 498±46 294±25 390±37 316±49 400±73 479±157 258±65    
Syringic acid-O-
glucuronide 9.0 Oats 56±29 183±47 126±66 194±71 277±77 175±82 132±31 178±53 146±55 141±54 145±20 * **** 0.4 
  CON 88±31 171±54 140±34 150±47 259±60 175±59 138±31 144±44 213±67 197±55 112±44    
Data are reported as mean ± SEM and were analysed by two-factor repeated measurement linear mixed model with time and treatment as the two factors. When the interaction effect was significant, post-hoc analyses with Tukey-Kramer adjustment were performed. If excretion was ND, 
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